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Protein based vaccine antigens and adjuvants offer several advantages over inactivated or live 
attenuated viruses and bacteria including ease to manufacture and improved safety. Due to the 
structural complexity and inherent marginal stability of protein based antigens and adjuvants, 
however, extensive analytical characterization and robust formulation development approaches 
are required to develop a stable, potent and safe vaccine dosage form for use in patients. In 
addition, the elucidation of physical and chemical instability pathways of protein antigens plays a 
key role in their formulation design, and are generally studied using numerous biophysical and 
analytical techniques, during forced degradation as well as accelerated and real-time stability 
studies. Furthermore, analytical comparability assessments form a cornerstone for assessing 
vaccine quality (including stability) between pre-change versus post-change drug products 
during development and scale-up of manufacturing processes. This Ph.D. thesis research work is 
aimed to better understand vaccine stability from three different pharmaceutical development 
aspects including analytical characterization, formulation development and comparability 
assessments. In addition, this work contributes towards the ongoing efforts to discern 
interrelationships of a protein antigen’s physicochemical properties to critical quality attributes 
of various vaccine candidates.  
As a part of this work, we developed and utilized improved analytical tools for formulation 
development and comparability assessments. For example, a scaled down micro-polyethylene 
glycol (PEG) induced precipitation assay was developed to determine apparent solubility of 
proteins using less than a milligram of material (as described in Chapter 2). This assay will be 
helpful in apparent solubility measurements during pharmaceutical development of proteins, 




characterization of three different protein virus-like particle antigens (equine encephalitis virus-
like particles, EEV) and a protein adjuvant (double mutant heat labile toxin, dmLT) by various 
biophysical and biochemical techniques was performed. The analytical characterization of the 
physical stability profile of the VLPs and physicochemical stability profile of dmLT, along with 
the role of pharmaceutical excipients in stabilizing their respective formulations, was evaluated. 
Lastly, an analytical comparability assessment involving five CRM197 carrier protein molecules 
was performed to better understand the effect of different manufacturing processes on the 
physicochemical and in vitro antigenic properties of the carrier protein.  
Currently, the protein adjuvant dmLT is an oral vaccine candidate for enterotoxigenic E.coli 
(ETEC) and is under clinical development. For this project, the primary and higher-order 
structures, physicochemical and conformational stability profiles of dmLT were assessed as 
described in Chapter 3. The physicochemical degradation pathways of dmLT included protein 
aggregation, glycation and oxidation. By identifying the physicochemical degradation pathways 
of dmLT using newly developed stability-indicating analytical methods, a more stable candidate 
bulk formulation of dmLT was developed that protected dmLT against conformational 
destabilization, freeze-thaw stress, aggregation/particle formation and chemical degradation.  
As described in Chapter 4, this work contributed to ongoing efforts to develop a vaccine against 
three strains of equine encephalitis (Eastern, Western and Venezuelan). Here, analytical 
characterization of three different monovalent VLPs was performed to identify structural 
alterations induced by thermal and pH stress. A candidate formulation mitigating thermal and 
aggregation instabilities of the VLPs was also developed. The candidate formulation showed a 
good maintenance of stability at all storage temperatures (40 to -80
o
C), with the exception of a 




interaction of both monovalent and trivalent VLP formulation with aluminum salt adjuvants was 
also studied to better understand the binding interactions of the VLPs with the adjuvant and its 
implications on future drug product development are discussed.  
Lastly, a comprehensive and detailed analytical characterization of CRM197 molecules from 
different manufacturers and expression hosts was executed as described in Chapter 5. This work 
provides an initial basis to eventually develop global manufacturing specifications to ensure the 
quality of the bulk CRM197 proteins from a variety of manufacturers. Furthermore, the high 
similarities between five different recombinant CRM197 expressed in the native host 
(C.diptheriae) vs. alternative hosts (E.coli or P.fluorescens), as demonstrated in this work, is a 
first step that will help facilitate lower cost CRM197 bulk production, with the long term goal to 
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Vaccines are considered as one of the greatest inventions of mankind in controlling, and in 
some cases, eliminating infectious diseases. The historic innovations of both Edward Jenner and 
Louis Pasteur are widely recognized in the field of vaccinology
1
. Their original methods of 
vaccination with alternative or attenuated versions of virulent viruses have undergone medical 
and technological advances in the past century, and have resulted in development of numerous 
successful vaccines. The implementation of these vaccines along with public health efforts have 
been successful in both reducing the prevalence of many diseases such as measles, mumps, 
rubella etc., as well as completely eradicating small pox
2
 and eliminating polio by 99 % 
globally
3
. This remarkable achievement has been made possible due to the massive efforts of 
several entities such as academic and industrial scientists, pharmaceutical companies, public 
health officials, World Health Organization (WHO), non-profit organizations such as Bill and 
Melinda Gates Foundation, Global Alliance for Vaccines and Immunization (GAVI) and 
governments of various countries worldwide.  
With the advent of recombinant DNA technology and whole genome sequencing, the field 
of vaccinology has greatly advanced in the past 50 years, and has resulted in effective vaccines 
for the prevention cervical cancer caused by human papilloma virus, liver infections including 
hepatitis A and B viruses as well as bacterial infections such as meningitis. These new 
technological advances have also resulted in increased efforts to develop novel vaccine 
candidates against fighting many diseases such as malaria, Ebola, AIDS, cancer and enteric 
diseases causing diarrhea. However, the development of a vaccine from early discovery to 
regulatory approval for use in humans is very challenging since vaccines are the most complex 
products of the pharmaceutical industry
4




the components of a vaccine, different types of vaccines, and some aspects of the pharmaceutical 
development of a vaccine by treating them as molecules with well-defined physical and chemical 
properties
5
. This work contributes towards better understanding of the inter-relationships 
between vaccine’s structural integrity, pharmaceutical stability and critical quality attributes 
including immunological activity. 
1.2 Components of Vaccines 
There are three major components of a vaccine dosage form namely, an antigen, an 
adjuvant and various pharmaceutical excipients. 
1) Antigen (active ingredient): An antigen is a weakened version or subcomponent of a foreign 
disease causing microorganism such as a virus or bacteria. By being modified from the original 
infectious form, it no longer causes a disease but still elicits an immune response in the body
6
. 
The antigen is often made from weakened or killed forms of the entire microbe, or from 
components such as its toxins or one of its surface proteins or polysaccharides. 
2) Adjuvant: Vaccine adjuvants include any substance that primarily enhances the immune 
response of the antigen or helps shape antigen-specific immune responses
7,8
. Currently, the 
licensed adjuvants include aluminum salts, adjuvant systems (AS03, AS04), virosomes, a TLR9 
agonist and the oil in water emulsion MF-59®
9
. Numerous novel adjuvants such as CpG 
oligonucleotides, labile toxin from entertoxigenic E.coli (LT) and its mutants are currently in 
development to enhance the efficacy of vaccines
7,10
. 
3) Stabilizers (inactive ingredient): Apart from the antigen and adjuvant, excipients or inactive 
ingredients such as stabilizers or preservatives are often added to a vaccine either during its 




acids, buffering agents, etc. are added to ensure that the various components remain stable and 
effective and to ensure appropriate tonicity for parenteral administration
11
. Preservatives such as 
thiomersal and phenolic compounds prevent contamination and enable multi-dose vaccine 
formulations.  
1.3 Types of Vaccines 
The design of a vaccine depends on several factors including type of microbe, pathology of 
disease, desired immune responses for protection, and geographical location of the world. There 
are several kinds of vaccines
12-14
 which are currently approved or in developmental phases and 
can be grouped into three main categories as described below: 
1) First generation or Traditional Vaccines: 
The first generation vaccines consist of whole cell microorganisms (viruses and bacteria) either 
killed or live, attenuated, forms. These vaccines are still widely in use as outlined below. 
a) Killed or Inactivated whole-cell vaccines: Inactivated vaccines are produced by killing the 
pathogen with chemicals, heat, or radiation. Majority of inactivated vaccines elicit a weaker 
immune response than live vaccines and usually require adjuvants and booster doses. However, 
they are considered safer than live vaccines since they do not contain live viruses or bacteria.  
Examples include whole-cell pertussis (wP), inactivated polio virus (IPV), hepatitis A, influenza 
(flu), and rabies vaccines. 
b) Live attenuated vaccines (LAV): These vaccines contain the weakened form of the live 
pathogen (virus or bacteria), elicit strong cellular and antibody immune responses and often 




disease-causing form. Examples include measles, mumps, rubella (MMR vaccine), oral polio 
vaccine (OPV), rotavirus, shingles, tuberculosis (BCG) and yellow fever vaccines. 
2) Second generation or Modern Vaccines: 
The modern vaccines do not contain the whole pathogen and in general exhibit a higher level of 
safety than the traditional vaccines described above. These vaccines are based on subunit design, 
and consist of only a part of pathogen such as toxins from bacteria or certain 
proteins/components of pathogens. Modern vaccines can be grouped into three main categories 
as described below. 
a) Toxoid vaccines: These vaccines contain an inactivated or detoxified bacterial protein toxin 
isolated from the microorganism and are capable of eliciting a neutralizing immune response. 
They are considered safer because they neither can cause the disease nor revert back to virulent 
form. Examples include tetanus toxoid (TT) and diphtheria toxoid (DT) vaccines. 
b) Subunit vaccines: These contain a define component (antigenic part) from a pathogen such as 
a protein or a polysaccharide capsule, that elicits a specific immune response that is capable of 
neutralizing the pathogen so as to prevent actual infection. They are safer than live and 
inactivated vaccines but elicit a weaker immune response and usually require an adjuvant. 
Subunit vaccines can be further categorized into:  
 Protein-based subunit vaccines: Acellular pertussis (aP), hepatitis B (HepB), human 
papillomavirus (HPV), influenza 
 Polysaccharide vaccines: Pneumococcal and meningococcal  




3) Third generation or Novel Vaccines:                                                                                                
They comprise of approaches to identify and develop vaccine candidates against difficult targets 
and unmet medical needs for diseases such as HIV/AIDS, cancer, malaria and they attempt to 
improve the ways of antigen presentation and vaccine delivery
15
.  Some of the research and 
development activities also include structure-based antigen design, synthetic vaccine candidates, 
genomic analysis, novel nanoparticle delivery systems and novel routes of administration. The 
main categories of novel vaccines are as follows: 
a) Nucleic acid (DNA and mRNA) vaccines: Naked viral or bacterial DNA (plasmids) or 
mRNA encoding immunogens can be taken up human cells and translated into protein. mRNA 
represents a promising platform for developing prophylactic and therapeutic vaccines
16
. Some of 
these vaccines against influenza, zika
17
 etc. are still in experimental stages. Recently, an mRNA-
based cancer vaccine has entered into Phase I clinical trial
18
. 
b) Recombinant Vector: The vaccine components (DNA for a surface protein) are introduced 
into a recombinant vector (usually a virus or bacteria) and then injected into the body. 
Experimental vaccines include the use of vectors (e.g., adenovirus, CMV, etc.) for vaccine 
targets against HIV, rabies and measles. 
c) Synthetic peptide vaccines: These comprise of peptide sequences of antigen as the vaccine 
component and are produced using chemical synthetic approaches. Again, these vaccines are 
under experimental or early clinical development and will need to overcome many challenges
19
. 
1.4 Pharmaceutical Development of Vaccines 
The journey of a vaccine from lab to clinic is long, complex and costly with a high rate of 




stages of vaccine development
20
 is shown in Figure 1.1.  The exploratory stage involves a basic 
understanding of the disease, its epidemiological data and protective antigen and host responses. 
The preclinical stage assesses antigen efficacy and safety by conducting animal studies for 
selection of the best vaccine candidate. As the vaccine candidate moves into human clinical trials 
the process gets more complex. The clinical stage has three phases (phase I, II and III) and is the 
longest development phase for a vaccine candidate. Phase I or safety studies are performed by 
testing the vaccine candidate on a small group of people, Phase II involves larger group of 
people to assess immune responses and Phase III includes the largest groups of people to 
evaluate both safety and efficacy. Phase III also involves production of clinical and industrial 
batches of the vaccine candidate for compliance and regulatory approval. The results from all the 
preceding stages are collected and submitted to regulatory authorities to obtain an approval for 
use in humans (regulatory stage). If the vaccine candidate is approved, Phase IV or post-
licensure studies continue to gather additional information on the efficacy and safety of the 
vaccine in various populations. Finally, after the regulatory approval manufacturing process 
begins; which may take up to 24 months to produce, release and ship a single batch of vaccine. 
The majority of the production time is spent not only in manufacturing the bulk and drug 
product, but also on checking the quality of the final vaccine product. This whole process of 
bringing a vaccine candidate from basic lab research to an approved product for use in humans 
typically takes on an average 12-15 years
20,21
.  
In the field of vaccine development, the final product is frequently strictly defined by the 
manufacturing process
22,23
. The process of manufacturing a vaccine comprises of a diverse 
production, purification and fill-finish platforms. Traditionally, the manufacturing process of a 




sometimes inactivating it, and then vialing (and sometimes lyophilizing) allowing for injecting 
the pathogen or pathogen component
24
. MMR, diphtheria and tetanus toxoid vaccines are still 
produced using this technology. Modern vaccine manufacturing as shown in Figure 1.2 consists 
of recombinant expression of the antigen and viral vectors in cell lines followed by harvesting, 
purification, and inactivation, addition of other components (adjuvants, stabilizers, etc), 
formulation, fill-finish, packaging, lot release and distribution
24
. These manufacturing steps 
present challenges and complexity as vaccines are manufactured from living organisms such as 
virus, bacteria or cell culture. The complexity is due to the diversity of the complex set of 
vaccine antigens (live organisms, proteins, etc.) coupled with different production platforms (egg 
based, cell culture, cell free, VLP etc.). Additionally, since vaccines are administered in healthy 
population rather than patients, the vaccine must meet an increased number of quality checks 
throughout the entire manufacturing cycle as well as those of its country of destination. This 
additional complexity further adds to the manufacturing challenges for vaccines. Thus, due to the 
complexity of all the different stages of manufacturing a vaccine product, it becomes utmost 
important to have a thorough knowledge of the vaccine components, the final drug product and 
process development activities as the vaccine candidate moves from discovery into clinical 
development phase. This is achieved through a combination of analytical characterization and 
quality control tests. Furthermore, understanding the critical quality attributes (CQA’s) of 
vaccine antigens and adjuvants is crucial not only for eliciting optimal vaccine immune response 
but also for reproducibility of vaccine manufacturability, potency and safety
25
. The failure to 
understand the factors that can affect structural integrity and stability of either the vaccine 
antigen or adjuvant which in turn can affect its potency and safety, and is one of the primary 




Therefore, there is a need to better characterize and evaluate vaccine antigens and adjuvants to 
understand the interrelationship of physicochemical properties to critical functional attributes of 
the molecule.  
The focus of this work was to better understand vaccine stability from three different 
aspects of pharmaceutical development namely, analytical characterization, formulation 
development and comparability assessments (Figure 1.3) by treating vaccine candidates as well-
defined physicochemical entities from an analytical point of view. It is critical that the vaccine 
maintains stability during all stages of development to ensure the safety and potency of the final 
vaccine drug product. Analytical methods are needed to monitor vaccine stability at all stages of 
preclinical and clinical development. Additionally, developing analytical methods that can 
successfully characterize and discriminate between all the components (multiple antigens, 
adjuvant, and stabilizers) of a vaccine is essential and is a challenge.  An optimized formulation 
is required to ensure the final vaccine remains stable and potent throughout its desired shelf life. 
Apart from this, comparability studies are needed during the clinical development and post 
approval lifecycle management of a vaccine product in order to evaluate the impact of both 
product and process related changes to the manufacturing process that occur during clinical 
development that can potentially affect the quality of the final vaccine drug product. 
1.5 Vaccine Stability 
Protein based vaccine antigens and novel protein adjuvants such as bacterial enterotoxins, 
like any other therapeutic protein drug, consist of complex, heterogeneous, fragile primary and 
higher order structures with marginal stability. As a result, structures of these proteins are very 




manufacturing, formulation, storage, transport and administration. These degradation pathways 
can lead to changes in the both primary and higher order structures of proteins that in turn can 
affect the stability, potency and safety profile of the vaccine drug product during storage. The 
two main types of degradation pathways observed for protein vaccine antigens are physical and 
chemical instability. 
1.5.1 Physical Instability 
Physical instabilities refers to structural changes of the proteins without any changes to 
their chemical composition
26
. This primarily includes structural alterations, undesirable 
adsorption to surfaces, and aggregation. The exposure of vaccine antigens to stresses such as pH 
changes, temperature fluctuations, agitation and light exposure can negatively affect their 
physical stability and potency
27,28
. Due to the temperature sensitive nature (heat and freezing) of 
vaccines, cold chain (2-8 
o
C) is required during the storage, distribution and administration of the 
vaccine in various parts of the world. The lack of efficient vaccine cold chain systems, or 
accidental exposure to freezing or elevated temperatures in both the developed and developing 
countries, can expose the vaccine to excessive heat or freezing conditions
27,29-31
. These 
temperature excursions are known to decrease the potency of many vaccines
27,30,32
. For example, 
HBV vaccine containing hepatitis B surface antigen (HbsAg) is formulated with aluminum salt 
adjuvant. Freezing of the vaccine causes aggregation of aluminum salt that alters the 
conformation of antigen, agglomerates the aluminum adjuvants particles and reduces potency
33
. 
Changes in the structure/conformation of the vaccine antigen could either result in loss of 
key epitopes or lead to the exposure of additional epitopes potentially causing a competition 
between neutralizing and non-neutralizing antibody responses.
34-36
 Additionally, the exposure of 






. Protein aggregation has been shown to affect potency and reduce the yields of 
number of vaccine antigens
38-41
.  
1.5.2 Chemical Instability 
Chemical instabilities involve either breaking or formation of covalent bonds in a protein 
leading to formation of new chemical species
26
. There can be a number of chemical degradation 
reactions that a protein vaccine can undergo such as deamidation, oxidation, glycation, disulfide 
scrambling, hydrolysis, fragmentation/proteolysis, racemization, etc. These modified molecules 
can potentially affect antigen and or adjuvant conformation, stability, efficacy and 
immunogenicity. For example, deamidation reaction involves conversion of asparagine or 
glutamine residues to their corresponding acids. Typically, asparagine (Asn) residue is converted 
into an aspartic or isoaspartic acid under both acidic (pH <3) and basic conditions (pH >6) by 
direct hydrolysis or via formation of a succinimide intermediate, respectively. Previous studies 
have shown that Asn deamidation in critical epitopes of the recombinant protective antigen lead 
to a change in the conformation of epitopes which caused reduction in potency and 
immunogenicity of a recombinant anthrax vaccine
42,43
.  
Another major chemical degradation pathway for protein vaccines is oxidation of Met, 
His, Cys, Trp and Tyr amino acids. Oxidation can be caused by peroxides, light, metal impurities 
from aluminum adjuvants or excipients such as polysorbates which are frequently used in 
vaccines. Recently, one study showed that an inactivated Japanese encephalitis vaccine 
(IXIARO®) adsorbed to aluminum hydroxide adjuvant degraded via a oxidation pathway 
involving residual metal impurity Cu from aluminum hydroxide
44
. Another study by Estey et.al
45
 
identified both Met and Trp oxidation (+16 m/z) in rBoNT(Hc) antigens bound to aluminum 








Hydrolysis mediated degradation of carbohydrate monomers in polysaccharide based 
vaccines over time has also been reported
46-48
. The hydrolysis may result in reduction of the 
molecular size of both the saccharide component and the conjugate, and cause increase in 
unbound saccharide content. Further, aluminum hydroxide used as an adjuvant in haemophilus 
influenza type B polysaccharide vaccine was reported to catalyze the depolymerization of 
polysaccharides and release of oligomers from the conjugate vaccine
46
. 
1.6 Analytical Characterization of Vaccines 
Vaccines are considered as a heterogeneous product of the biopharmaceutical industry, and 
require extensive clinical testing for market approval
49-51
. The heterogeneity is related to the type 
of vaccine antigen (e.g., viral or bacterial vaccine versus a subunit protein vaccine) and different 
components of a vaccine (single or multiple antigens, adjuvants, stabilizers, etc.). In addition, the 
protective effect of the immune response triggered by a vaccine is not well understood, which in 
turn makes it difficult to link the in vivo potency of vaccine to its quality attributes that can be 
tested in vitro. Therefore it is challenging to develop relevant analytical tests to characterize the 
vaccine and each vaccine requires product specific set of analytical techniques to monitor 
product quality at release and during storage. For example, in the case of a live-attenuated viral 
vaccine, it is critical to measure the degree and stability of infectivity along with the number of 
infectious particles
52
. For a subunit protein vaccine, analytical techniques may be needed to 
monitor the physical and chemical stability of the protein antigen. Moreover, an extensive set of 
analytical tools comprising both physicochemical and potency assays are needed during the 
development of a vaccine in order to ensure that the vaccines remain stable during storage and 




Physicochemical assays comprise of techniques that can monitor the purity, quantity, 
identity, size, stability and structural integrity of the protein antigen
53
. These techniques are not 
only used to monitor and quantify both the active components, but to evaluate the level of 
impurities as well. Potency assays measure a surrogate of the biological immunological activity 
of the vaccine including immunological binding assays, infectivity assays or animal studies. 
Potency assays are considered a key vaccine release/stability assay and are frequently a predictor 
of clinical outcome
24
. The selection of analytical methods and extent of characterization for a 
particular vaccine depends on several factors including the physicochemical properties of antigen 
and adjuvant, formulation conditions, degradation pathways and the stage of development
54
. It is 
possible that sufficient resources and materials may not be available for an extensive analytical 
characterization during early stages of development. However, it is expected by the regulatory 
authorities that a recombinant protein antigen containing vaccine should be well characterized 
before a Biologics Licensing Application (BLA) is filed
55
. An overview of physicochemical and 
potency assays that can be useful to assess the properties of protein based vaccines (focus of this 
work) is summarized in Table 1. 
The structural complexity and marginal stability of protein-based antigens and adjuvants 
require extensive analytical characterization to monitor the physical, chemical and biological 
properties of the molecule and link these properties to critical quality attributes of the vaccine 
(e.g., ability to generate the appropriate immune response).  Analytical methods are needed 
throughout entire vaccine product lifecycle including preclinical, clinical and commercialization 
phases. During preclinical development, regulatory compliant analytical tools are needed for cell 




must be able to identify and quantify the active species, structurally related molecules (product 
related variants) and impurities
24
.  
Analytical methods are needed to assess protein antigen degradation during 
preclinical/clinical and commercialization phases. Orthogonal methods are often needed during 
most stages of vaccine development to evaluate different types of protein degradations (structural 
changes, charge variants and chemical changes). The stability indicating methods are also 
essential for monitoring the accelerated and long-term stability testing in order to establish the 
expiration dating of the vaccine. Further, in comparability studies, analytical tools are required to 
monitor the vaccine’s key structural and functional properties to demonstrate product 
consistency as a result of both process and product related manufacturing changes,
56
 such as 
changes in fermentation conditions or changes in final vaccine dosage form (e.g., lyophilized to 
liquid formulation), that may occur during clinical development. 
The characterization and quality assessment of the final vaccine drug product requires 
specialized analytical tools. The quantification of the antigen amounts in the final vaccine 
formulation may cause some problems since their amounts tend to be relatively low and are 
adsorbed to adjuvants. Aluminum salts such as aluminum hydroxide and aluminum phosphate 
are the most commonly used adjuvants in protein based subunit vaccines. It is important to 
understand antigen-adjuvant interactions to design a stable and efficacious vaccine drug 
product
57
. The characterization of a protein antigen in presence of aluminum is challenging since 
aluminum particulates can interfere with common analytical assays such as chromatographic 
techniques. Therefore, the antigen needs to be desorbed to better characterize the final vaccine 
drug product for total antigen content, amount of antigen adsorbed, conformational integrity and 




often assessed by in vivo potency assays in animals
53
. It is now possible to characterize the 
antigen-adjuvant samples using biophysical techniques such front-face fluorescence, attenuated 
total reflection fourier transform infrared (ATR-FTIR) and raman spectroscopies, however, often 
the vaccine dose is low and near the sensitivity limit of such methods. 
 Historically, the development of vaccines has solely relied on testing in animal models. 
However, recent advances in analytical techniques have now made it possible to more rapidly 
monitor the key structural attributes of vaccines and evaluate the effect of process and 
formulation changes without relying solely on extensive biological testing such as animal 
potency assays.  Many of the analytical techniques mentioned in Table 1 can be used to develop, 
characterize, and manufacture protein based vaccines. In addition, high resolution techniques 
such as X-ray crystallography and hydrogen-deuterium exchange mass spectrometry (HX-MS) 
can aid in development of epitope-based vaccines which may in the long term reduce the cost, 
complexity, and time of development of new vaccines
58,59
. HX-MS could potentially be an 
effective and faster way to obtain complete information about epitope structure and relate to 
functional properties
60
. Various groups have probed the binding between antibodies and antigens 
using HX-MS and found the results to correlate well with high resolution techniques such as 
crystallography and electron microscopy
61-64
. 
1.7 Formulation Development of Vaccines 
Traditionally, vaccine formulation development for live and attenuated bacterial and viral 
vaccines has been an empirical process and focused on studying the temperature stability of the 
different formulations for various periods of time using in vitro antigenicity measurements 
and/or in vivo animal studies
28,65




pathogens and their relationship to generating protective immune responses. On the other hand, 
recombinant protein vaccines can take advantage of the tremendous improvements in 
stabilization and formulation of recombinant protein therapeutics to consider more rational 
formulation design strategies
66
. However, the need for systematic formulation development 
studies, which can be used to minimize instability and maintain/augment the potency of vaccine, 
is often poorly recognized in the field of vaccinology 
67
. For example, in vivo animal studies are 
often used to monitor antigen-adjuvant structural integrity, while, sensitive biophysical and 
analytical assays can often help to better understand the structural characteristics and the 




Further, recombinant protein vaccine antigens such as proteins and virus-like particles, as 
well as whole, inactivated viruses, are often inherently marginally stable and are sensitive to 
external conditions such as changes in pH and temperature, surface interactions and agitation, 
light exposure, and even the presence of impurities from excipients
68
. For example, vaccines may 
be exposed to temperature fluctuations during manufacturing, storage, and transport from the 
manufacturer to the end user (e.g., clinic site)
69
. The fill finish process can induce mechanical 
stress on the protein antigen or adjuvant causing aggregation and structural alterations. In 
addition, the lack of a robust cold chain in developing countries
70
, and even in developing 
countries, can expose vaccines to elevated temperatures, as well as freeze thaw effects, causing 
degradation and loss of potency. Further, these vaccine dosage forms are multicomponent and 
inherently complex in nature (e.g., biological antigens, adjuvants, excipients). Hence, it becomes 
essential as part of their formulation development to study the factors that can affect their 




To design a stable and efficacious vaccine for clinical use, formulation development 
activities include preformulation characterization of the antigen including forced degradation 
studies to identify stability indicating assays, formulation design and excipient screening to 
define stabilizing solution conditions, and accelerated and real time stability studies as well as 
freeze-thaw and potency studies
54,71,72
 to ensure that the candidate formulations remain stable 
and maintain potency over a defined shelf life. Pharmaceutical excipients are added not only to 
stabilize the vaccine antigen, but also to ensure appropriate interaction with the adjuvant (e.g., 
binding of antigen to aluminum adjuvant) as well as to maintain appropriate solubility, tonicity, 
and compatibility with containers and administration procedures
65,71,73
. 
Another major component of vaccines includes the use of adjuvants such as aluminum 
salts, oil in water emulsions (e.g., MF-59
®
), or immunostimulatory molecules (e.g., MPL) in 
order to boost the immune response. Similar to antigens, adjuvants may also be susceptible to 
degradation under certain stress conditions. For example, aluminum salts used in recombinant 
protein vaccines are known to undergo freeze-thaw induced aggregation
74-76
 leading to a loss of 
adjuvant activity
33,77
. It is also well established in literature that certain antigens when adsorbed 
to aluminum undergo conformational destabilization that may alter the thermal stability of 
vaccine
45,78,79
. Hence, vaccine formulation should also involve studying the stability of antigen, 
adjuvant and antigen-adjuvant complex during all stages of vaccine formulation development. 
Vaccine formulation also involves identification and testing of suitable container-closure 
system. The selection of container-closure depends on variety of factors such as product 
compatibility, route of administration, potential market and regulatory guidelines
28,80
. Injectable 
vaccines (subQ and IM) are typically formulated in glass vials or prefilled syringes while oral 






. The incompatibility of vaccine components with the container 
material can cause product instability, loss of potency, loss of market share and safety risks to 
patients. Lastly, validation of the scale-up of formulation process for commercial manufacturing 
is also essential in order to ensure that the all the quality attributes of the vaccine product are 
optimized and do not change at a large scale. Hence, it is critical to have a robust formulation 
with consideration of scale-up and technology transfer effects. 
1.8 Comparability Assessments of Vaccines 
During the clinical development and post approval manufacturing of a vaccine, both 
product and process related changes
56
 can occur that may affect the structural and functional 
properties of protein antigens and adjuvants. For example, alterations in the manufacturing 
process to increase the yields, scale-up, and introduce new facilities and new manufacturing 
technologies, as well as changes in formulation or in the final vaccine dosage form (e.g., 
lyophilized to liquid formulation) may be necessary to meet market demands. These types of 
process and product changes can potentially affect the identity, strength, purity, quality, and 
potency of the drug substance (antigen/adjuvant) or the final vaccine drug product. Hence, it 
becomes essential to have an adequate understanding of both the manufacturing process and the 
product to design comparability studies to assess the impact of such changes on any critical 
quality attributes of the vaccine and in turn their impact on safety and potency
82,83
. 
Comparability assessments requiring an extensive combination of analytical and biological 
tests
56,84,85
, and in some cases, nonclinical and clinical studies are performed to evaluate the 




 Comparability does not necessarily mean that the quality attributes of the pre-change and 
post-change product are identical, but that they are highly similar and sufficient knowledge is 
available on the drug product development (early research, stability studies, manufacturing 
process and validation, early clinical trials etc.) to ensure that any differences in quality attributes 
have no adverse impact on safety or efficacy of drug product (ICH Q5E Guideline). The key 
components of a comparability exercise may include impact of manufacturing process changes, 
physicochemical characterization, impurity profiles, stability profile assessments, and potency 
assays
84
. Many changes can take place during the manufacturing stages including changes in 
expression system (prokaryotic vs eukaryotic) and changes in process (raw materials, equipment, 
downstream processing steps). In such cases, it is essential to have a thorough understanding of 
how these changes can impact the final vaccine drug product and its potential impact on safety, 
purity, and efficacy. Furthermore, comparability also needs to be demonstrated to ensure the 
consistency of production of a vaccine. This means that, each lot of the vaccine is of the same 
quality and within the same specifications as a lot which has been shown to be safe and 
efficacious in animal or human trials. 
An assessment of the physicochemical properties of the protein antigen including its 
primary structure, higher-order structure (HOS), post-translational modifications, content, 
impurity profiles, and biological activity is a critical part of comparability studies
86
. Another 
important of aspect of comparability studies is to compare product and process related impurity 
profiles
87
 between the pre change and post change product. The impurities in vaccines may 
include host cell DNA, host cell proteins, cell culture components, endotoxins, adventitious 
agents and viral contamination. In order to demonstrate comparability, the impurity profiles of 






. It is also necessary to conduct forced degradation (elevated temperatures, freeze-thaw, 
oxidation etc.) and stability studies to assess the impact of process changes on product quality 
and potency. A comparison between the degradation profiles of pre-change versus post change 
product using various analytical and functional assays can help to assess comparability and 
potentially estimate shelf-life, based on the pre-change product
88-90
.  
A wide set of analytical techniques and bioassays that can be used to characterize the 
impact of both process and product related changes on the different structural aspects of a protein 
antigen, impurity profiles, elucidate the degradation mechanisms on both physical and chemical 
stresses and determine bioactivity using in vitro and in vivo assessments are summarized in Table 
1. High resolution techniques such as HX-MS, NMR and X-ray crystallography can potentially 
be used to monitor subtle changes in HOS of proteins and vaccines
91-94
, however, some of these 
techniques may not be routinely available, expensive and are time consuming. Therefore, lower 
resolution biophysical and biochemical techniques such as circular dichroism, fluorescence 
spectroscopy, differential scanning calorimetry etc. coupled with new data visualization tools 
such as empirical phase diagram (EPD) and radar plots may be useful in examining the structural 
alterations in proteins under stress conditions. In fact, the use of both the above-mentioned data 
visualization tools has been reported to be potentially useful in analytical comparability 
assessments for proteins
84,95,96
. Although there are many analytical tools available for assessing 
comparability, however, the major question during any comparability evaluation is the extent of 
testing needed to answer how the changes affect the safety and efficacy of the drug product. 
Hence, scientifically sound comparability design and assessment is needed based on target 
profile of the protein antigen and structure/function relationship
56
, leading to reduced testing and 




 In this Ph.D. thesis work, we utilized state-of-the-art analytical techniques to assess and 
compare numerous physicochemical properties of different vaccine candidates including (a) a 
virus-like particle (VLP) antigen  against equine encephalitis, (b) double mutant heat labile toxin, 
dmLT (a protein-based adjuvant), and (c) five CRM197 molecules (a carrier protein used in 
conjugate-polysaccharide vaccines). The VLP candidates and CRM197 molecules were 
extensively characterized in terms of higher order structure (HOS) and physical stability profiles 
while, for dmLT, apart from the above mentioned studies, chemical stability studies were also 
executed. In addition, the data from the various biophysical techniques were incorporated into 
EPD’s and radar plots to better understand the stability profiles of these proteins under stress 
conditions (pH and temperature). We also developed separate candidate formulations for VLPs 
and dmLT. Additionally, we developed a miniaturized version of polyethylene glycol (PEG) 
induced solubility assay to determine the apparent solubility of various broadly neutralizing 
monoclonal antibodies (mAbs) against HIV-1 which are considered as potential candidates for 
the development of a passive HIV-1 vaccine. The PEG precipitation assay was also utilized to 
compare the apparent solubility profiles of CRM197 molecules as part of the analytical 
comparability assessment. 
 The analytical comparability assessment between five CRM197 molecules produced by 
different manufacturer’s and expression systems (E. coli, P. fluorescens and C. diptheriae) was 
performed. Using various analytical techniques, the physicochemical and in vitro antigenic 
properties of the CRM197 molecules were compared. Additionally, the readouts from biophysical 
techniques combined with EPDs and radar plots helped to probe the changes in higher order 
structure (HOS) and the stability profiles of the CRM197 molecules under stress conditions such 




conditions is important part of comparability studies. This study contributes towards the 
importance of in-depth analytical characterization during comparability assessments. It also 
provides an initial analytical dataset to eventually develop manufacturing specifications and 
ensuring the quality of the purified carrier protein produced by different manufacturers. 
1.9 Chapter Reviews 
1.9.1  A Micro-PEG Precipitation Assay as a Relative Solubility Screening Tool for 
Monoclonal Antibody Design and Formulation Development (Chapter 2) 
Adequate protein solubility is an important prerequisite for development and manufacture 
of protein based drugs and vaccines, and for administration of biotherapeutic drug candidates in 
high-concentration protein formulations. A previously established method for determining the 
relative apparent solubility (thermodynamic activity) of proteins using polyethylene glycol 
(PEG) precipitation is adapted for screening and comparing monoclonal antibody (mAb) 
candidates where only limited quantities (≤1 mg) are available. This micro-PEG assay is used to 
evaluate various broadly neutralizing mAb candidates to HIV-1 viral spike (gp120 and gp41 
glycoproteins) for potential clinical use as a passive immunization strategy. Using ∼1 mg of 
VRC01-WT mAb per assay, the precision of the micro-PEG assay was established. A series of 7 
different broadly neutralizing mAbs to the HIV-1 viral spike proteins were compared by curve 
shape (%PEG vs. protein concentration), %PEGmidpoint determinations, and extrapolated apparent 
solubility values. Numerous formulation conditions were then evaluated for their relative effects 
on the VRC01-WT mAb. The PEGmidpt and apparent solubility values of VRC01-WT mAb 
decreased as the solution pH increased and increased as NaCl and arginine were added. A final 




Thus, the micro-PEG assay has significant potential as a relative solubility screening tool during 
candidate selection and early formulation development. 
1.9.2 Structural Characterization, Physicochemcial Stability Profile and Formulation 
Development of a Double Mutant heat Labile Toxin (dmLT)- A Novel Protein Based 
Adjuvant Candidate (Chapter 3) 
A novel protein adjuvant, a double-mutant Escherichia coli heat-labile toxin 
(R192G/L211A), called dmLT, is in preclinical and early clinical development with various 
vaccine candidates. Structural characterization and formulation development of dmLT will play a 
key role in its successful process development, and eventual scale-up/transfer and commercial 
manufacturing. This work describes extensive analytical characterization of structural integrity 
and physicochemical stability profile of dmLT from a lyophilized formulation from an early 
phase clinical lot. Reconstituted dmLT contained a heterogeneous mixture of intact holotoxin 
(AB5, ∼75%) and free B5 subunit (∼25%) as assessed by analytical ultracentrifugation and 
hydrophobic interaction chromatography. Intact mass spectrometry (MS) and LC-MS peptide 
mapping analysis revealed presence of Lys
84
 glycation near the native sugar-binding site 
in dmLT. Forced degradation studies using LC-MS peptide mapping also demonstrated specific 
Asn deamidation and Met oxidation sites in dmLT. Using multiple biophysical 
measurements, dmLT was found most conformationally stable between pH 6.5 and 7.5 and at 
temperatures ≤50°C. Upon shake stress, soluble aggregates and particle formation were observed 
with the reconstituted dmLT solution. By identifying the physicochemical degradation pathways 
of dmLT using newly developed stability-indicating analytical methods, a more stable candidate 
bulk formulation of dmLT was developed. The new candidate formulation containing phosphate, 




conformational destabilization, freeze-thaw stress, aggregation/particle formation and chemical 
degradation (e.g., Met oxidation and Lys glycation). In addition, the new bulk formulation of the 
dmLT adjuvant also provides flexibility for future use in combination with a variety of different 
vaccine dosage forms with different antigens. 
1.9.3 Structural Characterization and Formulation Development of a Trivalent Equine 
Encephalitis Virus-Like Particle Vaccine Candidate (Chapter 4) 
The zoonotic equine encephalitis viruses (EEV) can cause debilitating and life-
threatening disease, leading to ongoing vaccine development efforts for an effective virus-like 
particle (VLP) vaccine based on three strains of EEV (Eastern, Western and Venezuelan or EEE, 
WEE and VEE VLPs, respectively).  In this work, TEM and light scattering studies showed 
enveloped, spherical, and ~70 nm sized VLPs.  Biophysical studies demonstrated optimal VLP 
physical stability in the pH range of 7.5-8.5 and at temperatures below ~50
o
C.  Interestingly, the 
individual stability profiles differed notably between the three VLPs. Numerous pharmaceutical 
excipients were screened for their VLP stabilizing effects against thermal stress.  Sucrose, 
sorbitol, sodium chloride and pluronic F-68 were identified as promising stabilizers and the 
concentrations and combinations of these additives were optimized.  Candidate monovalent VLP 




C to establish 
freeze-thaw, long-term (2-8°C) and accelerated stability trends. Good VLP stability was 
observed at each storage temperature, except for a distinct instability observed at -20°C. The 
interaction of monovalent and trivalent VLP formulations with aluminum adjuvants was 
examined, both in terms of antigen adsorption and desorption over time. The implications of 




1.9.4 Analytical Comparability Assessments of Five recombinant CRM197 Proteins from 
Different Manufacturers and Expression Systems (Chapter 5) 
CRM197, a single amino acid mutant of diphtheria toxoid, is a commonly used carrier 
protein in commercial polysaccharide-protein conjugate vaccines.  In this study, CRM197 proteins 
from three different expression systems and five different manufacturers were obtained for an 
analytical comparability assessment using a wide variety of physicochemical and in vitro 
antigenic binding assays. A comprehensive analysis of the five CRM197 molecules demonstrate 
that recombinant CRM197’s expressed in heterologous systems (E. coli and Pseudomonas 
fluorescens) are overall highly similar (if not better in some cases) to those expressed in the 
traditional system (Corynebacterium diphtheriae) in terms of primary sequence/post translational 
modifications, higher-order structural integrity, apparent solubility, physical stability profile (vs. 
pH and temperature) and in vitro antigenicity. These results are an encouraging step to 
demonstrate that recombinant CRM197 expressed in alternative sources have the potential to 
replace CRM197 expressed in C. diphtheriae as a source of immunogenic carrier protein for 
lower-cost polysaccharide conjugate vaccines. The physicochemical assays established in this 
work to monitor the key structural attributes of CRM197 should also prove useful as 
complementary characterization methods (to routine quality control assays) to support future 









1.10 Conclusions and Future Work (Chapter 6) 
This final chapter of this thesis summarizes the findings about the structural integrity, solubility, 
physicochemical properties and formulation development of four different types of proteins 
namely, mAbs, dmLT, EEV VLPs and CRM197. The results from Chapters 2-5 provide a better 
understanding of the pharmaceutical development of protein containing vaccines by considering 
analytical characterization, formulation development and comparability assessments with 
vaccine stability profiles being a common theme. In addition, the final chapter provides 



















































Figure 1.3. Essential elements of vaccine stability as applied to the pharmaceutical development 











Table 1.1 Overview of various analytical tools for characterization of protein-based vaccines 
 
Parameter Measured Analytical Method 
 
Quantitation of protein 
UV-Visible Spectroscopy (A280) 
Bradford/BCA assay 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Host-cell DNA DNA hybridization and dot blot analysis 
Quantitative polymerase chain reaction (qPCR) 




Native or SDS-PAGE 
Isoelectric focusing (IEF) gels 
Capillary isoelectric focusing (cIEF) 
Reverse phase chromatography (RP-HPLC) 
Hydrophobic interaction chromatography (HIC) 
Ion exchange chromatography (IEX) 
Identity Mass spectrometry 
Peptide mapping 





Far UV circular dichroism 
Fourier Transform Infrared Spectroscopy 
 
Tertiary Structure 
Near UV circular dichroism 
Intrinsic Trp fluorescence spectroscopy 
Intrinsic ANS fluorescence spectroscopy 




Size-exclusion chromatography (SEC) 
Analytical ultracentrifugation (AUC) 
Field-flow fractionation 
Light scattering (static, dynamic and multi angle) 
Electron microscopy 
Light obscuration 
Flow imaging microscopy 
 
In vitro potency 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Biolayer Inferometry (BLI) 
Surface Plasmon Resonance (SPR) 
Cell-based assays 




Antigen-aluminum adjuvant assays 
Front-face fluorescence 
Attenuated total reflection Fourier transform 
infrared (ATR-FTIR) spectroscopy 
Raman spectroscopy 
Isothermal titration calorimetry (ITC) 
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Chapter 2 A Micro-PEG Precipitation Assay as a Relative Solubility Screening Tool for 

























Protein solubility is a key physical parameter not only for chemistry, manufacturing and 
control (CMC) bulk development activities, but also for formulation development including long 
term stability and facile administration of protein based drugs
1-3
. In particular, monoclonal 
antibodies have emerged as a key class of protein drugs, administered either IV by medical 
professionals or by subcutaneous (SC) administration by patients
4
.  The latter typically requires 
the development of high protein concentration, stable liquid formulations that can deliver >100 
mg per one mL injection
3
.  In addition, as part of biopharmaceutical lead identification, in vitro 
and in vivo solubility is considered a critical “drug-like” property.  Solubility measurements can 
be used not only to identify potential protein drug candidates, but to rank order them in terms of 
potential manufacturing, storage or in vivo potency issues
5
. 
There are many methods available for determining protein solubility including 
ultrafiltration, dialysis/concentration or lyophilization/reconstitution
2,6
. These measurements, 
however, are often not practical or easily attainable either due to excessive amounts of protein 
required (several hundred mgs) and/or experimental difficulties such as gel formation and 
aggregation
1
. An alternative approach to measure apparent protein solubility (apparent 
thermodynamic activity) is by addition of polyethylene glycol (PEG) that precipitates the protein 
primarily by exclusion volume effects
7-9
. As described in detail elsewhere, a linear relationship 
between the log of protein concentration vs. the  weight percent PEG in solution, under certain 
conditions, allows calculation of the apparent solubility (i.e., thermodynamic activity) of proteins 
by extrapolation of experimental results to zero PEG concentration
7,8
. It should be noted that this 
extrapolated activity value may contain thermodynamic non-ideality terms and hence the 




been successfully used to determine the apparent solubility of multiple proteins
7,10-14
 and also as 
a formulation screening tool
15
. Recently, Gibson et al. have used a high throughput version of the 
PEG precipitation method to determine the apparent solubility and PEGmidpt values for an IgG1 
mAb produced from different cell lines and formulated in different pH and buffer solutions
15
. 
However, this methodology still requires relatively large amounts of protein (5-10 mgs per 
sample per experimental condition) which may not be available during early stages of drug 
development. 
In the past decade, in addition to the current antiretroviral drugs, new therapeutics are 
being developed to reduce and cure HIV-1 infections
16
. Broadly neutralizing monoclonal 
antibodies (mAbs) against HIV-1 are considered as potential candidates for the development of a 
passive HIV-1 vaccine and have shown promise in the prevention and treatment of HIV-1 
infection
16-23
. These broadly neutralizing mAbs offer several advantages over the current 
antiretroviral drugs such as virus neutralization and cell killing of the HIV infected cells by Fc 
receptor-mediated effector mechanisms
16
. A major subset of these antibodies designated as the 
VRC01 class, target the CD4-binding site on the gp-120 core of the virus and neutralize ~90% of 
diverse strains of the HIV virus
16,22-24
. Apart from the VRC01 class, there are several other 
categories of mAbs currently under development including the 10E8 and PGT classes which 
target the membrane proximal external region on gp41 and recognize epitopes such as the N-
linked glycan at Asn 332 on gp120 respectively
22,24
. The low solubility of the majority of these 




In this work, we have developed a micro-PEG precipitation method requiring between 




VRC01-WT mAb was established as measured by a combination of the curve shape (PEG vs 
protein concentrations), PEGmidpt determinations, and extrapolated apparent solubility values.  
The micro-PEG method was then used as relative solubility screening tool for a developability 
assessment of small amounts of multiple mAbs being evaluated as possible neutralizing mAb 
candidates for HIV-1. We also demonstrate the utility of the micro-PEG method as an early 
formulation screening tool to evaluate various solution conditions (pH, buffers, salt 
concentration, and excipients) for their effect on the solubility profile of the VRC01-WT mAb.   
2.2 Materials and Methods 
2.2.1 Materials 
A total of seven mAbs (10E8-WT, 10E8v5, PGT121, 10E8v4, 35O22, VRC13, and 
VRC01-WT)
19,27-29
 were provided by the National Institutes of Allergy and Infectious Disease 
(NIH) in phosphate buffered saline (PBS) at pH 7.4, except for VRC01-WT which was 
formulated in 25 mM sodium citrate, 50 mM sodium chloride, and 150 mM L-arginine 
hydrochloride at pH 5.8. The PGT antibodies were originally identified by the International 
AIDS Vaccine Initiative (IAVI) and published, (Walker, et al, Nature, 2011) 
29
 Protein 







. All formulation reagents (sodium phosphate, sodium chloride, citric 
acid, sodium citrate, L-histidine, arginine and PEG-10,000) for preparing different buffer 
systems namely phosphate, citrate and histidine were purchased from Sigma-Aldrich (St 
Louis, MO), and were high purity grade (>99%). 
2.2.2 Methods 
The protocol of the micro-PEG assay for assessing relative apparent solubility of mAbs 
was adapted from Gibson et al. (2011)
15




7.4 and PBS containing 40% w/v PEG-10,000 at pH 7.4 were mixed to prepare various 
concentrations of PEG solutions ranging from 0 to 40% w/v PEG. A volume of 200 µL of twenty 
two different PEG-10,000 solutions was added in triplicate to wells of a 96-well polystyrene 
filter plate (Corning #3504, Corning Life Sciences, Corning, NY). The stock solution of VRC01-
WT was diluted to 1 mg/mL with PBS buffer, pH 7.4. Fifty microliters (50 µL) of the protein 
stock solution (1 mg/mL) was then added to each well to a final protein concentration of 0.2 
mg/mL. The plates were incubated overnight at room temperature and then centrifuged at 1,233g 
for 15 min; the filtrate was then collected in a clear 96 well collection plate (Greiner Bio-
One#655001, Greiner Bio-One North America Inc., Monroe, NC).  Thereafter, 200 µL of filtrate 
was transferred into a 96 well UV Star microplate (Grenier#655801). The filtrate was measured 
on a SpectraMax M5 UV-Visible plate reader at 280 nm to determine the protein concentration 






 (provided by Vaccine 
Research Center). This assay is referred to as the standard PEG precipitation assay in this paper. 
To further scale down the standard PEG assay, a Nanodrop spectrophotometer 
(NanoDrop Products, Wilmington, DE) was used as the UV detector for measuring protein 
concentration. The same procedure was followed for determining the protein concentration as 
described for the plate reader method, but with lower amounts and smaller volumes of protein. 
Forty microliters of various PEG-10,000 solutions were added to wells of a 96-well polystyrene 
filter plate and 10 μL of the resulting protein solution (1 mg/mL) was added to the wells 
containing various levels of PEG to a final protein concentration of 0.2 mg/mL. Two microliters 
of the filtrate was measured with the Nanodrop spectrometer at 280 nm to determine the protein 
concentration using an extinction coefficient of 16 at 280 nm for a 1% (10 mg/mL) mAb 




The micro-PEG assay was used to evaluate the relative solubility profiles of various 
monoclonal antibodies (mAbs) that target the HIV-1 viral spike (gp120 envelope glycoprotein 
and gp41 transmembrane glycoprotein) and to compare the relative solubility profiles of VRC01-
WT under different formulation conditions (pH, buffer, salt and arginine).  For the additional 
scaled down version of the micro-PEG assay using 0.1-0.2 mg of protein, experiments with 
VRC01-WT containing different concentrations of arginine (0, 17, 50 and 150 mM) in 50 mM 
citrate buffer, pH 6.0 were first performed using ten different % PEG concentrations, followed 
by repeating at 0 % and 8.3% w/v PEG-10,000 for five replicates and calculating the % VRC01-
WT soluble at 8.3% w/v PEG-10,000.  
The absorbance at 280 nm (protein concentration) vs. PEG-10,000 (% w/v) data were fit 
to a standard four-parameter, modified Hill-slope sigmoidal curve equation (Eq.1 as described in 
Gibson et al, 2011)
15
, using Python (x,y) v.2.7.6.0, an open source scientific and engineering 
software based on the python language. The % PEGmidpt (x-axis midpoint) was calculated from 
the resulting curve fit using equation (1) and the apparent solubility was calculated by fitting the 
data points from the transition region (i.e., points of partially soluble and partially precipitated 
protein) using equation (2) as described previously by Middaugh et al, 1979.
7
 
𝑦 = 𝑏 + (
𝑡−𝑏
1+ 𝑒 𝑠(𝑚𝑖𝑑−𝑥)
)                                  (1) 
where t= top plateau, b= bottom plateau, mid= x-axis midpoint, and s=slope. 
log Sp = log ao – A12[PEG]                                  (2) 
where Sp is the concentration of soluble protein in a solution containing PEG-precipitated 
protein in equilibrium with soluble protein, a0 is the activity of the protein in a saturated PEG-
free environment, A12 is a virial coefficient (primarily corresponding to excluded volume effects) 




For statistical comparisons, the p values for all the above experiments were determined 
using the student t-test in Microsoft Excel 2010 software and a p value of <0.05 was accepted as 
significant. 
2.3 Results 
2.3.1 Comparison of Standard vs. Micro PEG precipitation assay and determination of 
assay precision 
The PEG precipitation assay was performed with VRC01-WT mAb at a final protein 
concentration of 0.2 mg/mL using two different UV-Visible spectrophotometers, a SpectraMax 
M5 plate reader and a Nanodrop instrument. The standard PEG assay required larger volumes 
and thus higher amounts of protein (~5X) compared to the micro PEG assay.  As shown in 
Figure 2.1, PEG precipitation assays run in the two formats resulted in similar shapes of the 
precipitation curves (PEGcurves,, i.e., protein concentration in A280 units vs. amount of added 
PEG) as well as similar results for the VRC01-WT mAb in terms of experimentally determined 
PEGmidpt and relative apparent solubility values (for the latter, well within the relative standard 
deviation of this extrapolation method as described elsewhere and below)
7,15
. 
The precision of the % PEGmidpt and apparent solubility values by the micro PEG assay 
were determined for nine replicates of the VRC01-WT mAb sample.  As shown in Table 2.1, the 
precision of the method was determined from the mean % PEGmidpt and apparent solubility 
values of VRC01-WT mAb which were 8.2% w/v (range 8.2-8.3 % w/v) and 19 mg/mL (range 
13-29 mg/mL), respectively. Table 2.1 also summarizes the statistical parameters for the 
precision of % PEGmidpt and apparent solubility values in terms of SD (standard deviation) and 
RSD (relative standard deviation) results.  The % PEGmidpt values had lower levels of variability 




qualification results with the micro-PEG assay format are in good agreement with previous 
studies using the standard assay format (with a different IgG1 mAb) where the variability in the 
relative apparent solubility value is primarily due to subtle changes in the slope of the linear fit 
over the transition region
15
. 
2.3.2 Evaluation and rank ordering of various mAbs based on their relative solubility 
profile in PBS buffer, pH 7.4 
The micro PEG assay was utilized to rank order and compare the relative solubility 
profiles of VRC01-WT mAb with six additional mAb candidates that bind different epitopes on 
HIV-1 virus (gp120 envelope glycoprotein and gp41 transmembrane glycoprotein)
22,24
. The 
mAbs were all prepared in PBS buffer at pH 7.4 to assess the solubility profiles of these proteins 
under physiological-like conditions. As a first comparison, differences in the overall shapes of 
their PEGcurves (protein vs. PEG concentration) for each of the six additional mAbs were 
evaluated by visual comparison to the VRC01-WT mAb (Figure 2.2). It can be seen that the six 
mAbs varied dramatically in terms of their profiles. For example, the VRC13 mAb closely 
overlaps the VRC01-WT mAb, while the 10E8-WT mAb precipitates from solution at much 
lower concentrations of PEG-10,000 (Figure 2.2). The PEGcurves provide a qualitative way to 
compare the protein vs. PEG concentration profiles between protein samples, whereas; % 
PEGmidpt and the apparent solubility values are quantitative parameters for measuring and 
comparing apparent protein solubility of different samples. 
The data in Figure 2.2 were then analyzed to determine the % PEGmidpt values (Figure 
2.3A) and the relative apparent solubility values (Figure 2.3B) of the different mAbs (as 
described in the Methods section).  Compared to the VRC01-WT mAb, the % PEGmidpt and 




< 10E8v5 < PGT121 < 10E8v4 < 35O22  <VRC13 <VRC01-WT.  Significant differences (p < 
0.05) in % PEGmidpt values between VRC01-WT and the six mAbs were observed. In terms of 
relative apparent solubility values, which showed much higher RSD values due to the 
extrapolation, significant differences (p < 0.05) in the relative apparent solubility values were 
observed between VRC01-WT and three mAbs, namely, 10E8WT, 10Ev5 and PGT121. The 
individual values and overall rank ordering of the various mAbs, via evaluation of PEGcurves, 
PEGmidpt, and apparent solubility values, compared to VRC01-WT are also summarized in the 
supplemental section (see supplemental Table 2.1). 
2.3.3 Evaluation and rank ordering of relative solubility profile of VRC01-WT mAb 
under various formulation conditions 
The effect of solution pH (pH 5.0-8.0) on the PEGcurves (protein vs. PEG concentration) of 
the VRC01 WT mAb, formulated in 50 mM phosphate buffer, is shown in Figure 2.4A. The 
overall curves shifted to the left (as the pH increases from 5.0-8.0), indicating less PEG-10,000 is 
required to cause mAb precipitation. Additional analysis of these data showed decreases in the 
PEGmidpt and relative apparent solubility values of VRC01-WT mAb were observed as the pH is 
increased from 5.0 to 8.0 (See Figure 2.5A and Figure 2.5B for trends and Supplemental Table 
2.2 for individual values). These decreases in PEGmidpt and apparent solubility values with 
increases in solution pH are consistent with the pI range of the VRC01-WT mAb (~9.0-9.6) as 
observed by cIEF (See Supplemental Figure 2.1).  As solution pH approaches the pI of the mAb, 
it is commonly observed that solubility decreases, presumably due to loss of overall charge, and 
thus loss of charge repulsion between mAbs molecules in solution
30
.  
Different solution conditions were evaluated for their effect on the VRC01-WT mAb 




histidine with and without sodium chloride (buffer strength = 50 mM, +/- 0.15 M NaCl, pH 6.0), 
(2) different concentrations of arginine in 50 mM citrate pH 6.0 (17 mM, 50 mM and 150 mM 
arginine), and (3) an initial formulation buffer identified for VRC01-WT mAb (25 mM Na 
citrate, 50 mM NaCl, 150 mM arginine, pH 5.8). These formulation conditions were evaluated 
for their effect on the PEGcurves, % PEGmidpt and relative apparent solubility values of VRC01-
WT mAb.  The PEGcurves (protein vs. PEG concentration) were similar for the mAb in histidine 
and citrate buffer but required more PEG for mAb precipitation in phosphate buffer (Figure 
2.4B). Interestingly, the addition 150 mM NaCl to each of these buffers (Figure 2.4C) shifted the 
curves to the right compared to the PEGcurves without salt, and also showed that the mAb in 
histidine buffer+NaCl required more PEG for precipitation compared to the mAb in phosphate 
buffer+NaCl.  In addition, increasing arginine concentrations (0 to 150 mM) (Figure 2.4D) 
caused the curves to shift to the right (i.e., required more PEG for mAb precipitation) compared 
to the PEGcurves without arginine.  
For ease of statistical comparisons of each of these formulation conditions, the mAb in 
each of the solution conditions (buffer, salt and arginine) was compared with the 50 mM citrate 
formulation. The % PEGmidpt and relative apparent solubility values varied with different 
formulation conditions as shown in Figure 2.5C and 2.5D, respectively. In terms of general 
trends, the mAb in 50 mM citrate had the lowest values and the addition of arginine, and to a 
lesser extent NaCl, greatly increased the values. Combinations of excipients were also effective. 
For example, VRC01-WT mAb formulated in 25 mM citrate, 50 mM NaCl, 150 mM arginine pH 
5.8 showed the highest % PEGmidpt and relative apparent solubility (thermodynamic activity) 
values. Differences in % PEGmidpt and relative apparent solubility values between the 50 mM 




few exceptions (e.g., mAb formulated in 50 mM citrate + 17 mM arginine and 50 mM histidine 
showed no statistically significant differences in the apparent solubility values compared to 50 
mM citrate).  A summary of the % PEGmidpt and relative apparent solubility individual values of 
the VRC01-WT mAb under different formulation conditions is also presented in the 
supplemental data. (Supplemental Table 2.3) 
2.3.4 Scaled down version of the micro-PEG assay 
The experiments described above were performed in triplicate with VRC01-WT mAb 
samples across the protein vs. PEG concentration curves.  This resulted in the need for ~1 mg of 
protein per condition. For initial screening purposes, if not even ~1 mg of protein is easily 
available, the amount of protein required in this micro-PEG assay can be reduced by either 
reducing the number of replicates or by lowering the number of test samples.  As a proof of 
concept of further scaling down the micro-PEG assay, the arginine experiments were repeated 
with fewer concentrations and replicates of PEG-10,000 (% w/v) with the VRC01-WT mAb in 
citrate buffer, pH 6.0 with increasing concentrations of arginine. The PEGcurves (protein vs. PEG 
concentration) are shown in Figure 2.5E. It can be seen from these data that the trends are the 
same using both more and fewer sample points (compare Figure 2.4D to Figure 2.5E).   
Since it may be more difficult to accurately determine % PEGmidpt and relative apparent 
solubility (thermodynamic activity) values with fewer data points (i.e., fewer test samples), an 
alternative approach was used: the % VRC01-WT mAb that was soluble at a set concentration of 
PEG was determined and compared. For example, at 8.3% (w/v) PEG increasing arginine 
concentration increased the % VRC01-WT mAb in solution as shown in Figure 2.5F. Increasing 
arginine concentration increased the % VRC01-WT soluble at 8.3% w/v PEG and statistically 




between control buffer (0 mM arginine) and each of the buffers with increasing concentrations of 
arginine tested (Figure 2.5F). This result can be obtained using only 0.1-0.2 mg of protein by 
initially using only ten different % PEG concentrations with n=1 replicate (requires 0.1 mg 
protein), and then determining the % mAb soluble at a fixed concentration of PEG vs. the control 
(no PEG) using five replicates each, requiring an additional 0.1 mg of protein. Thus, this 
additional scale down of the micro-PEG requires a total of 0.2 mg of protein. 
2.4 Discussion 
The solubility of therapeutic protein can be a critical quality attribute, especially if higher 
doses of the drug will be needed clinically or if large amounts will need to be manufactured.  It is 
important to assess these types of considerations as early in development as possible including 
the molecule discovery phase as well as the early stages of formulation design and 
development
31
. For example, there are typically a plethora of mAb candidates against a target 
during the discovery stage of drug development, but usually only one or a few mAb(s) will 
progress into clinical development. Solubility screening can thus play an important role in 
selecting mAb drug candidates that offer the ability to formulate high concentration dosage 
forms as well as cost-effective manufacturability
5
.   
Direct quantitative protein solubility measurements using ultrafiltration or lyophilization 
are often experimentally difficult to perform due to problems such as gel formation/aggregation, 
or requirement of large amounts of protein for highly soluble proteins
2
. The lack of sufficient 
amounts of protein during discovery research, and even at early stages of development, often 
makes the ultrafiltration and lyophilization approaches impractical. An alternative approach to 
indirectly measure apparent protein solubility is using additives, such as ammonium sulfate or 




and PEG have been used previously as tools for measuring relative apparent solubility 
(thermodynamic activity) of proteins including mAbs as well as for comparing different 
formulations of an IgG1 mAb
6,15,32-34
.  
Kramer et al. have demonstrated a good overall correlation between the apparent solubility 
measurements of different proteins using PEG and ammonium sulfate
6
. These results indicated 
that either of the precipitants can in principle be used to rank order the relative solubility of 
different proteins. Each precipitant, however, has its own advantages and disadvantages and the 
choice of selecting one precipitant over the other is largely based on empirical observations as 
well as different mechanisms that may lead to differences in relative solubility between different 
proteins. For example, the PEG precipitation method assumes inert behavior of PEG towards 
proteins which may not be true for some proteins under some solution conditions.  It has been 
reported that PEG may induce subtle perturbations in protein structure and decrease the 
thermodynamic stability of some proteins
8,14,35,36
. In addition, protein-protein interactions can 
vary as a function of protein concentration and solution conditions which can also be affected by 
addition of PEG. These experimental limitations in turn can make the extrapolated apparent 
solubility values from the PEG precipitation assay a less accurate reflection of the true solubility 
of a protein. In contrast, other studies have shown that ammonium sulfate can stabilize the native 
protein conformation and thus can be used only for comparative solubility measurements while 
more representative solubility measurements can be obtained using PEG
6,33
. In addition, with 
low concentrations of ammonium sulfate, salting-in effects can be observed and the extrapolated 
solubility value obtained from the salting-out region may not be a true representation of protein 
solubility in the absence of salt. Further, ammonium sulfate may not be an effective precipitant 






. Nonetheless, both the methods remain useful tools for rank ordering of the relative 
apparent solubility of different proteins and/or solution conditions that effect protein solubility. 
In recent years, Gibson et al.
15
 and Yamniuk et al.
33
 have reported an automated high 
throughput plate based solubility assay employing PEG and ammonium sulfate, respectively. 
Gibson et al. work using PEG required several mgs of protein for each experiment, which may 
not be attainable during discovery research and early stages of mAb development. In this work, 
we have demonstrated that the scale down version of the PEG assay (micro-PEG assay) requires 
much lower amounts of mAb (0.1 to 1 mg) for apparent solubility measurements, and thus is a 
more practical approach for developability assessments of different candidate mAbs. To this end, 
we used this new method to screen various different candidate bnAbs for HIV-1. In this early 
stage of candidate selection, hundreds of variants could be generated but there is a very limited 
amount of material of each individual protein. Thus, the micro-PEG assay can be extremely 
useful for screening a large number of candidate molecules.  
We have shown in this work that the micro-PEG precipitation assay is straightforward, 
precise and provides an accelerated assessment of experimental parameters that have been 
previously demonstrated to be effective surrogates for assessing protein solubility
7,15
. The micro-
PEG assay has potential utility to provide important information about relative protein solubility 
to not only better compare candidate protein molecules, but also during subsequent drug 
development of the selected candidate including formulation design and comparability 
assessments. For early candidate comparisons, the micro-PEG precipitation method was used in 
this work to rank order a series of broadly neutralizing anti-HIV1 mAb candidates based on both 
qualitative and quantitative experimental parameters such as the shape of the PEGcurves, 




of protein. Moreover, an additional scaled down version of the micro-PEG assay requiring only 
about 0.1-0.2 mgs of protein was demonstrated to generate similar data for rank ordering 
purposes.  Although providing more limited data sets, this version of the assay could be used as 
an initial solubility screening tool in cases where availability protein is severely limited.  
In terms of formulation development applications, it is often a challenge for the 
formulation scientist to find conditions (pH, buffer system and excipient) that enable high 
concentration formulations of therapeutic mAbs (>100 mg/mL) for subcutaneous administration 
3
. To better address this challenge in early development when limited amounts of protein are 
available, we applied the micro-PEG assay to screen different solution conditions with the 
VRC01-WT mAb including buffering agents (citrate, histidine and phosphate), solution pH (pH 
values from 5.0 to 8.0), and excipients (sodium chloride and arginine) to evaluate their relative 
effects on the same experimental parameters and to rank order relative solubility profiles of the 
VRC01-WT mAb. The results from these experiments, clearly demonstrate the potential of this 
method to screen for solution conditions that enhances solubility profiles. In addition, as a 
potential future application of this PEG assay, it is also very important to develop mAb 
formulations that minimize aggregation during long-term storage to reduce the risk of unwanted 
immunogenicity of a protein drug in patients. The inter-relationships between different 
excipients, protein solubility and protein aggregation are complex and highly dependent on the 
protein itself and the type of environmental stress encountered. We are currently using the PEG 
precipitation assay in our labs to assess excipient effects on both relative apparent solubility 
values as well as aggregation profiles over time using another IgG1 mAb (Kalonia et al., 
manuscript in preparation, 2016). Finally, the micro-PEG assay can be utilized in early 






.  For example, the micro-PEG assay can be a quick way to 
initially compare the solubility profiles of pre- vs. post-change for bulk drug substance or final 
drug products, as well as for biosimilar vs. innovator protein drug at the early stages of 
development. Recently, we have successfully utilized the micro-PEG assay for biosimilarity 
assessment of four well-defined IgG1-Fc glycoforms with decreasing oligosaccharide content 
(High mannose-Fc> Man5-Fc>GlcNAc-Fc> N297Q aglycosylated form) as a model system
40
. 
Significant differences and similarities were found in % PEGmidpt values and relative apparent 
solubility (thermodynamic activity) values between these IgG1-Fc glycoforms. Thus, the micro-
PEG assay can play an important role in screening and comparing therapeutic protein candidates 
and contribute towards their accelerated advancement through the different stages of 















Table 2.1. Precision of the Micro-PEG Assay for the Determination of %PEGmidpt and Relative 
Apparent Solubility (Thermodynamic Activity) Values Using VRC01-WT, a Broadly 
Neutralizing HIV-1 IgG1 Monoclonal Antibody. 
Sample size (n=9)         % PEGmidpt (% w/v)    Apparent solubility (mg/mL) 
Mean                 8.2 19 
Range                  8.2-8.3 13-29 
SD                0.1 6 















Figure 2.1. Comparison of the standard PEG protein precipitation assay and micro-PEG assay 
using the VRC01-WT mAb formulated in PBS buffer at pH 7.4. (a) Linear concentration scale 
over a PEG concentration range (0%-20% w/v PEG). (b) Logarithmic scale for extrapolation of 
the linear fit to determine the relative apparent solubility in the absence of PEG (y-intercept). 
















Figure 2.2. Comparison of the PEGcurves (protein vs. PEG concentration) of different broadly 
neutralizing HIV-1 mAbs versus VRC01-WT mAb. Samples are in PBS buffer at pH 7.4. The 







Figure 2.3. Comparison of different broadly neutralizing anti-HIV-1 mAbs versus VRC01-WT 
mAb by the micro-PEG assay. (a) % PEGmidpt values, (b) relative apparent solubility 
(thermodynamic activity) values. Error bars indicate the standard deviation of 3 replicates and 













Figure 2.4. Effect of solution pH, buffers, NaCl, and arginine on the PEGcurves (protein vs. 
PEG concentration) for VRC01-WT mAb. (a) Effect of pH varying from 5.0 to 8.0, (b) effect of 
different buffering agents (citrate, phosphate, and histidine) without NaCl at pH 6.0, (c) effect of 
addition of 150 mM NaCl in the 3 different buffers (citrate, phosphate, and histidine) at pH 6.0, 
and (d) effect of arginine addition (17, 50, and 150 mM) in citrate buffer at pH 6.0. The error 






Figure 2.5. Effect of various formulation conditions on VRC01-WT mAb as measured by the micro-PEG 
assay. (a) %PEGmidpt values as a function of solution pH, (b) relative apparent solubility (thermodynamic 
activity) values as a function of pH, (c) % PEGmidpt values as a function of different buffers, with or 
without NaCl and arginine, (d) relative apparent solubility (thermodynamic activity) values as a function 
of different buffers, with or without NaCl and arginine. Error bars indicate the standard deviation of 3 
replicates and statistical significance (*) compared to the control (50 mM citrate, p value < 0.05) is 
indicated. (e) The PEGcurves (protein vs. PEG concentrations) for VRC01-WT mAb with different 
concentrations of arginine in citrate buffer pH 6.0 using the additional scale-down version of the micro-
PEG assay (mentioned in the text), and (f) %VRC01-WT mAb soluble at 8.3% w/v PEG-10,000 at 
different arginine concentrations. Error bars indicate the standard deviation of 5 replicates and statistical 




Supplemental Table 2.1. Summary of % PEGmidpt and relative apparent solubility 
(thermodynamic activity) values of seven different broadly neutralizing HIV-1 envelope IgG1 
mAb candidates (n=3). 
mAb 
%PEGmidpt (% w/v) Apparent Solubility (mg/mL) 
Mean SD Range Mean SD Range 
10E8-WT 6.0 0.1 5.9-6.0 5 1 4-6 
10E8v5 6.1 0.1 6.1-6.2 5 2 4-7 
PGT121 7.0 0 7.0-7.0 6 1 5-7 
10E8v4 7.0 0 7.0-7.0 14 2 13-16 
35O22 7.2 0 7.2-7.2 13 2 11-14 
VRC13 8.0 0 8.0-8.0 22 4 18-25 
















Supplemental Table 2.2. Summary of % PEGmidpt and relative apparent solubility 
(thermodynamic activity) values of VRC01-WT mAb, as a function of solution pH (5.0-8.0) 
when formulated in phosphate buffer as measured by the micro PEG assay (n=3). 
 
Formulation pH %PEG
midpt (% w/v) Apparent Solubility (mg/mL) 
Mean SD Range Mean SD Range 
 
 
50 mM Phosphate 
5.0 8.8 0.0 8.8-8.8 83 17 66-101 
6.0 8.4 0.1 8.3-8.4 62 13 53-78 
7.0 7.7 0.0 7.7-7.7 29 5 23-32 



















Supplemental Table 2.3. Summary of % PEGmidpt and relative apparent solubility 
(thermodynamic activity) values of VRC01-WT mAb, formulated in different buffers (+/- NaCl), 
different concentrations of arginine, and in various combinations as determined by the micro-




 Apparent Solubility (mg/mL) 
Mean SD Range Mean SD Range 
50 mM Citrate pH 6.0 7.3 0.0 7.3-7.3 27 6 24-34 
50 mM Histidine pH 6.0 7.5 0.1 7.4-7.5 38 10 32-49 
50 mM Citrate 
+17 mM Arginine pH 6.0 
 
7.8 0.1 7.7-7.8 37 9 28-45 
50 mM Citrate 
+50 mM Arginine pH 6.0 
 
8.3 0.1 8.3-8.4 65 13 54-80 
50 mM Phosphate pH 6.0 8.4 0.1 8.3-8.4 62 13 53-78 
50 mM Citrate 
+ 150 mM NaCl pH 6.0 
8.5 0.1 8.4-8.5 50 9 40-55 
50 mM Phosphate 
+ 150 mM NaCl pH 6.0 
8.8 0.0 8.8-8.8 71 10 65-84 
50 mM Histidine 
+ 150 mM NaCl pH 6.0 
9.6 0.1 9.5-9.6 61 9 54-70 
50 mM Citrate 
+150mM Arginine 
 pH 6.0 
9.7 0.1 9.6-9.7 90 12 80-102 
25 mM Na Citrate, 50 
mM NaCl, 150 mM 
Arginine pH 5.8 







Supplemental Figure 2.1. cIEF electropherograms of VRC01-WT mAb showing a 
heterogeneous mixture of charged species with different isoelectric points from ~9.0 to 9.6. The 
pI markers are shown at pI values of 7.05 and 10.45. Triplicate runs of same VRC01-WT mAb 
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Chapter 3 Structural Characterization, Physicochemical Stability Profile and 
Formulation Development of a Double Mutant Heat Labile Toxin (dmLT)-A 

























There is a clinical need for new adjuvants to enhance and broaden mucosal immune 
responses for various vaccine candidates. Vaccines administered by the mucosal route have the 
potential to not only provide both mucosal as well as systemic immunity, but may also result in 
logistical and regulatory advantages over traditional vaccines given by injection 
1-4
. One of the 
reasons for the current limited availability of vaccines that activate mucosal immunity is the lack 
of effective mucosal adjuvants. Bacterial enterotoxins such as cholera toxin (CT) and heat labile 
toxin (LT) are known to be potent mucosal adjuvants; however, their toxicity limits their use in 
humans
5-7
. E.coli LT exists as hetero-hexamer (AB5) complex consisting of a single 
enzymatically active A-subunit (i.e., has adjuvant activity and mediates toxicity) which is non-
covalently linked to a pentameric B-subunit that is responsible for binding to the host’s intestinal 
epithelial cells 
1,8
. The A-subunit is further divided into the enzymatically active A1 subunit and 
A2 peptide acting as a linker between the A1 and B subunit. Two mutations (R192G/L211A) 
were introduced into the A-subunit of LT (dmLT) that minimize the molecules toxicity while 
retaining its ability to stimulate immunogenicity 
8, 9
.  
Multiple studies have shown that the co-administration of dmLT with different antigens 
such as tetanus toxoid, mycobacterial purified protein derivative, inactivated polio as well as 
whole cell vaccines against Helicobacter pyroli, and Streptococcus pnuemoniae enhance 
immune responses in various animal models 
5,8-11
. Recent human studies have also demonstrated 
the adjuvant potential of dmLT to enhance and broaden mucosal immune responses for 
enterotoxigenic E.coli (ETEC) vaccine candidates such as ETVAX and ACE527 
12,13
. These 
Phase I/II human clinical studies have shown that addition of dmLT in these vaccine 




responses and protective efficacy as well as could potentially lower the antigen dose. A more 
recent study has shown that the dmLT protein possesses both antigen and adjuvant properties 
13,14
. Phase I trials are underway to test the antigenic properties of dmLT as a potential stand-
alone vaccine against ETEC caused diarrhea 
15
. 
The inherent structural complexity and marginal stability of protein-based antigens and 
adjuvants requires extensive analytical characterization to monitor their structural integrity and 
conformational stability during process and product development.  In fact, both analytical 
characterization and formulation stability studies are a key part of the overall clinical 
development of vaccine candidates in terms of CMC development and regulatory approval for 
use in patients
16,17
. For example, the therapeutic efficacy of a vaccine depends on the 
physicochemical stability of the antigen and adjuvant which in turn can affect the vaccine’s 
potency during manufacturing, long-term storage, shipping and administration
18
. Therefore, there 
is ongoing need to better characterize and evaluate vaccine antigens and adjuvants to better 
understand the interrelationship of their physicochemical properties with critical biological 
attributes (e.g., ability to generate the appropriate immune response) of the vaccine
19
.  
Development of analytical characterization tools is especially important to facilitate monitoring 
the biomolecule’s key structural and functional properties (critical quality attributes) as a 
function of process and product changes made during clinical development (i.e., clinical lots 




Apart from analytical characterization, formulation development activities also play a key 
role in the overall pharmaceutical development of vaccines. However, systematic formulation 




potency of adjuvants, is often poorly recognized in the field of vaccinology
21
.  For example, in 
vivo animal studies are often used to monitor adjuvant structural integrity, while, sensitive 
biophysical and analytical assays can often help to better understand the structural characteristics 




Since vaccine dosage forms are multicomponent and inherently complex in nature (e.g., 
biological antigens, adjuvants, excipients), it becomes essential as part of their development to 
study the factors that can affect their stability and potency. Recombinant or inactivated vaccine 
antigens, such as proteins, virus-like particles, and inactivated viruses, are often inherently 
marginally stable and are sensitive to external conditions such as changes in pH and temperature, 
surface interactions and agitation, light exposure, and even the presence of impurities from 
excipients
22
. For example, vaccines may be exposed to temperature fluctuations during 
manufacturing, storage, and transport from the manufacturer to the end user (e.g., clinic site) 
23
. 
The fill finish process can induce mechanical stress on the protein antigen or adjuvant causing 
aggregation and structural alterations
24,25
. In addition, the lack of a robust cold chain in 
developing countries 
16
 can expose vaccines to elevated temperatures, as well as freeze thaw 
effects, causing degradation and loss of potency.  
 To design a stable and efficacious vaccine for clinical use, formulation development 
activities include preformulation characterization of the antigen including forced degradation 
studies to identify stability indicating assays, formulation design and excipient screening to 
define stabilizing solution conditions, and accelerated and real time stability studies as well as 
freeze-thaw studies 
19,26
 to ensure that the candidate formulations remain stable and maintain 




vaccine antigen, but also to ensure appropriate interaction with the adjuvant (e.g., binding of 
antigen to aluminum adjuvant) as well as to maintain appropriate solubility, tonicity, and 
compatibility with containers and administration procedures 
26-29
.  
In this work, we have characterized the structural and conformational stability profiles of 
a lyophilized preparation of an early clinical lot of dmLT (after reconstitution) from a 
pharmaceutical perspective including the aggregation propensity of dmLT due to agitation stress. 
Reconstituted dmLT samples were shown to be a heterogeneous mixture of intact holotoxin 
(AB5) and free B5 subunit which also contained low levels of glycated and aggregated protein. 
The physical stability profile of dmLT across different solution pH (5.5-8.0) and temperature 
conditions (10-90
o
C) was also evaluated. Forced chemical degradation studies (e.g., elevated pH 
values, or addition of hydrogen peroxide) of the reconstituted dmLT sample were then used to 
identify specific “hot-spot” sites of Asn deamidation and Met oxidation. These results will not 
only enable characterization of improved manufacturing processes to produce future clinical lots 
of dmLT from an analytical comparability perspective, but will also facilitate monitoring lot-to-
lot variability of dmLT made from the same process. In addition, we also seek to utilize the 
knowledge gained from the structural characterization and elucidation of physicochemical 
degradation pathways of dmLT to develop a more stable bulk formulation of dmLT that does not 
require lyophilization and permits maximal flexibility for use in the future in different vaccine 
dosage forms with different antigens.  
3.2 Materials and Methods 
3.2.1 Materials 
Lyophilized vials of dmLT, produced and purified from E.coli as described elsewhere 
8
, were 




2011) and stored at -20 
o
C.  Freeze-dried samples contained 0.7 mg protein in 42.7 mM Sodium 
phosphate, 10.7 mM Potassium phosphate, 82 mM NaCl, 5% Lactose, pH 7.4 (hereafter referred 
to as formulation buffer). Components of the formulation buffer prepared in the KU laboratory 
for dilution of samples and background correction of analytical methods, including monobasic 
potassium phosphate (N.F. grade), dibasic sodium phosphate (U.S.P grade), sodium chloride 
(U.S.P grade), and lactose monohydrate (N.F. grade), were purchased from Spectrum Chemical 
Mfg. Corp. (Gardena, CA). The lyophilized vials (0.7 mg dmLT/vial) were reconstituted in 0.7 
mL of HPLC grade water (Fisher Scientific, PA) immediately prior to analysis and further 
diluted with formulation buffer as required (samples were not stored at lower 
concentrations/temperatures for analysis at a later time). For excipient screening, dialysis of 
dmLT protein was performed in Slide-A-Lyzer Mini Dialysis Devices (Product #88403, Thermo 
Scientific, Rockford, IL) with a 3,500 Da molecular weight cutoff. All reagents and excipients 
for preparing different formulations were purchased from Sigma-Aldrich (St. Louis, MO). 
Carbohydrates such as trehalose, sucrose and mannitol were purchased from Pfanstiehl Inc. 
(Waukegan, IL). All excipients were of high purity grade (>99 %).  
3.2.2 Methods 
3.2.2.1 Intact Protein Mass Spectrometry 
ESI spectra of dmLT under both non-reducing and reducing conditions were acquired on a 
SYNAPT G2 hybrid quadrupole / ion mobility / Tof mass spectrometer (Waters Corp., Milford, 
MA). The instrument was operated in a sensitivity mode with all lenses optimized on the MH+ 
ion from the control Leucine Enkephalin. The sample cone voltage was 40eV. Argon was 
admitted to the trap cell that was operated at 4eV for maximum transmission. Spectra were 




accumulating data for 2 seconds per cycle. Time to mass calibration was made with NaI cluster 
ions acquired under the same conditions. Mass spectra of [Glu
1
]-Fibrinopeptide B were acquired 
in parallel scans and doubly charged ions at m/z 785.8426 were used as a lock mass reference. 
Samples were desalted on a reversed phase PRP-1 column, 1 cm, 1 mm I.D.  (Hamilton, 10 µm 
particles packed by hand) using a NanoAcquity chromatographic system (Waters Corporation).  
The mobile phase solvents were A (99.9% H2O, 0.1% formic acid) and B (99.9% acetonitrile, 
0.1% formic acid). A short gradient was developed from 1 to 70% B in 4 min with a flow rate of 
20 µL/min. MassLynx 4.1 software (Waters Corporation) was used to collect the data and to 
deconvolute the protein spectra for molecular weight determination. 
3.2.2.2 Peptide Mapping 
 For proteolysis under reducing conditions, a sample of dmLT (50 μg) was incubated with 
20 mM DTT and for 60 min at either 37 ºC or 80 ºC in both the presence and absence of 3M 
guanidine-HCl (GuHCl). The reduced Cys were then alkylated with 40 mM Iodoacetamide at 
37ºC for 30 min. The samples were incubated at 37 ºC overnight with 2 μg of trypsin or 
chymotrypsin. Trifluoroacetic acid (0.05%) was added to quench the proteolysis and 12.5 g of 
digested dmLT was subjected to LC-MS. For proteolysis under non-reducing conditions, a 
similar procedure was followed except DTT was omitted during the reduction step. 
The peptides from the digested protein solution were separated by a liquid chromatography 
system (Thermo Scientific, Waltham, MA) prior to analysis. Peptides were injected onto a C18 
column (1.7 µm, 2.1 x 150 mm, Waters) and an 85 min 0-30% B gradient (A: H2O and 0.05% 
trifluoroacetic acid; B: ACN and 0.05% trifluoroacetic acid; 200 μl/min flow rate) for separation. 
MS was performed using a LTQ-XL ion trap (Thermo Scientific) and the Xcalibur 2.0 software 




(Angiotensin II, Sigma) for maximal sensitivity before running any experiments. The mass 
spectra were acquired in the LTQ over a mass range of m/z 300-2000. The ion selection 
threshold was 20,000 counts and the dynamic exclusion duration was 10 sec.   
Raw experimental files were initially evaluated manually to determine if the ion counts and 
fragmentation of each peptide were sufficient for further analysis. The raw data files were then 
processed using PepFinder 2.0 software (Thermo Scientific). The database used for this 
experiment consisted of dmLT-A and dmLT-B primary sequences 
30
 and the protease sequence. 
Potential Cys carbamidomethylation were included during the analysis. Peptide assignments of 
MS/MS spectra were validated using a confidence score of ≥95% and some manual validation. 
3.2.2.3 SDS-PAGE 
The dmLT samples were run under both non-reducing and reducing conditions by SDS-
PAGE. The dmLT samples were mixed with 4X NuPAGE-LDS sample buffer (Life 
Technologies, Grand Island, NY) to a final concentration of 1X. For reduced samples, 50 mM 
dithiothreitol (DTT) (Life Technologies, Grand Island, NY) was added. The samples were 
incubated at 95 
o
C for 5 min. Ten μg of dmLT protein was analyzed by SDS-PAGE on a 4-12% 
Bis-Tris gradient gel (1.0 mm x 10 wells, #NP0321BOX) using 1X MES running buffer (Life 
Technologies, Grand Island, NY). Protein bands were visualized by staining with Coomassie 
blue R250 (Teknova, Hollister, CA) and destained with ultrapure water. 
3.2.2.4 Far-UV Circular Dichroism Spectroscopy 
Far-UV circular dichroism (CD) spectroscopy of dmLT was performed using a 
Chirascan-plus Circular Dichroism Spectrometer (Applied Photophysics Ltd, Leatherhead UK) 
equipped with a Peltier temperature controller and a 4-position cuvette holder.  Quartz cuvettes 




The spectra of dmLT were collected from 200-260 nm using 1 nm steps and 0.5 s sampling time. 
Thermal melts were performed over a temperature range of 10 to 90 °C. The spectra were 
collected at 2.5 ºC intervals with a 2 min equilibration time at each temperature. The final protein 
concentration of the dmLT sample was 0.2 mg/mL and the measurements were conducted in 
triplicate. 
3.2.2.5 Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR spectra of dmLT were collected with a Bruker Tensor 27 spectrometer (Bruker 
Optics, Billerica, MA) equipped with a temperature controlled BioATR cell and MCT detector 
with constant purging with N2. Spectra were recorded from 4000 to 600 cm
-1
 at 22 °C. A 
resolution of 4 cm
-1
 was used and 256 consecutive scans were collected for dmLT sample at ~0.9 
mg/mL. Buffer spectra were also recorded under each experimental condition and subtracted 
from the sample spectra using a straight baseline between 1770 and 2050 cm
-1
 as the criterion for 
correct subtraction. The resulting blank-subtracted spectra were smoothed with a Savitsky-Golay 
function and second-derivative analysis was used to identify band components in the amide-I 
region. Curve fitting was then performed using a mixed Gaussian–Lorentzian function between 
1700 and 1600 cm
-1
. Subtraction, smoothing and second-derivative analysis were performed 
using OPUS V6.5 software (Bruker Optics).  
3.2.2.6 Intrinsic Tryptophan Fluorescence Spectroscopy 
The intrinsic tryptophan fluorescence of dmLT was measured in triplicate using a Photon 
Technology International (PTI) spectrofluorometer (Lawrenceville, NJ) equipped with a turreted 
four-position Peltier-controlled cell holder and a xenon lamp. Fluorescence emission spectra of 
dmLT at 0.2 mg/mL using 1 cm path length quartz cuvettes were recorded as a function of 




with the slit width set at 4 nm. Emission spectra were collected from 305-405 nm with a step size 
of 1 nm and an integration time of 1 s. The spectra were collected at 2.5 ºC intervals with a 2 min 
equilibration time at each temperature. The initial signal was kept at ~800,000 counts per second 
for fluorescence spectra and an emission maximum of ~20,000 counts per second for light 
scattering spectra. The data analysis was performed using the in-house software (Middaugh 
Suite).  The corresponding buffer spectrum was subtracted from each protein spectrum prior to 
data analysis. The emission peak position was determined using a mean spectral center of mass 
method (MSM) executed in the Middaugh Suite. Although this calculation method increases the 
signal to noise ratio for more accurate determination of lambda max values, it shifts the apparent 
peak position by 5-10 nm from their actual values. The Tonset values were determined by 
identifying the point at which the baseline deviated from linearity using Origin software. 
A second photomultiplier located 180° to the fluorescence detector was used to study 
aggregation behavior of dmLT. The static light scattering intensity values were collected 
simultaneously during the intrinsic fluorescence experiments using a 0.25 nm slit width. The 
scattering intensities at 295 nm were obtained as a function of temperature (10-90ºC). Scattering 
from the buffer alone was subtracted from each protein sample value before data analysis. 
3.2.2.7 Extrinsic Fluorescence Spectroscopy 
8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic fluorescence probe in 
the presence of dmLT with the same instrument as described above. A dye to protein molar ratio 
of 25:1 was used for sample preparation. ANS was excited at 372 nm, and emission spectra of 
ANS was collected from 400-600 nm every 2 nm as a function of temperature from 10 to 90
o
C. 
The corresponding buffer spectrum was subtracted from protein spectrum prior to data analysis. 




(MSM) executed in the Middaugh Suite. The Tonset values were determined by identifying the 
point at which the baseline deviated from linearity using Origin 8.0 software. 
3.2.2.8 Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) thermograms for dmLT were collected with a 
Microcal VP-DSC capillary cell microcalorimeter (GE Health Sciences, Pittsburgh, PA). 
Thermograms were recorded from 10 to 100 °C at a scan rate of 1 °C/min. A protein 
concentration of 0.4 mg/mL was employed and the measurements were performed in triplicate. 
A buffer baseline was subtracted from each protein thermogram and the data were normalized to 
molar heat capacity using Microcal DSC software in Origin 7.0 (OriginLab, Northampton, MA). 
The peaks were fitted using a mathematical model in Origin 7.0 to quantify Tonset and Tm values.  
3.2.2.9 Sedimentation Velocity Analytical Ultracentrifugation 
Sedimentation velocity analytical ultracentrifugation (SV-AUC) experiments were 
performed with an Optima XL-I (Beckman Coulter, Fullerton, CA) analytical ultracentrifuge 
equipped with a scanning UV-Visible optical system. All experiments were conducted at 20 °C 
after 1h of equilibration after the AUC reached temperature, at a rotor speed of 50,000 RPM with 
detection at 280 nm. Samples and reference were loaded into Beckman charcoal-epon two sector 
cells with a 12 mm centerpiece and either sapphire or quartz windows. 
The data were analyzed using Sedfit (courtesy of Peter Schuck, NIH). A partial specific 
volume of 0.73 mL/g was calculated for dmLT using Sednterp (courtesy of Professor Thomas 
Laue, University of New Hampshire) based on amino acid sequence, and used in the analysis. 
The buffer density and viscosity used in the analysis were also calculated using Sednterp 
software based on buffer composition. A continuous c(s) distribution was used with 200 scans. A 




of this range, with a resolution of 300 points per distribution and a confidence level of 0.95. 
Baseline, radial independent noise, and time independent noise were fit, while the meniscus and 
bottom positions were set manually. Integrations were performed in Origin (OriginLab 
Corporation, Northampton, MA) after importing the distributions. 
3.2.2.10 Hydrophobic Interaction Chromatography (HIC) 
A Shimadzu Prominence UFLC HPLC system equipped with a diode array detector was 
used.  20 g of protein was injected onto a TSKgel Butyl-NPR column (4.6 x 100mm, 2.5µm 
TOSOH Biosciences P/N 42168) for each run, and the experiment was performed in triplicate. 
The mobile phases consisted of (A) 2M ammonium sulfate, 20 mM sodium phosphate, pH 6.8; 
(B) 20 mM sodium phosphate, pH 6.8. The columns were operated at 25ºC and equilibrated with 
mobile phase A (20 mM sodium phosphate, 2 M ammonium sulfate, pH 6.8) prior to sample 
injection. A flow rate of 0.7 mL/minute was used with a 60 min run time. Chromatographic 
separation was then conducted in a step wise gradient of 0-5 min (0% B), 5-35 min (0→60% B), 
35-40 min (60→100% B), 40-45 min (100% B), and 45-60 min (0% B). Protein peaks were 
monitored using the absorbance signal at 214 nm. LC solutions software (Shimadzu) was used 
for data analysis. 
3.2.2.11 Reversed-Phase Ultra High Performance Liquid Chromatography (RP-UHPLC) 
A Thermo Ultimate 3000 UHPLC system (Thermo Scientific) equipped with a diode 
array detector was used.  20 g was injected onto a Waters Acquity C18 column (2.1 x 150 mm, 
1.7 µm Waters Corporation) for each run, and the experiment was performed in triplicate. The 
columns were operated at 60 ºC and equilibrated with 99% mobile phase A (0.1% TFA, water) 
and 1% mobile phase B (0.1% TFA, acetonitrile) prior to sample injection. A flow rate of 0.2 




1-60% B (10 min), 75% B (12 min), 75%B (15 min), 75-1% B (22 min), 99% B (28 min) and 
1% B (35 min). Chromeleon software (Thermo Scientific) was used for data analysis.  
3.2.2.12 Construction of Three Index Empirical Phase Diagram (EPD) and Radar Plots 
For the physical stability studies, dmLT was dialyzed into the formulation buffer (pH 5.5-
8.0, at 0.5 pH unit increments). Dialysis was performed at 4
o
C using Slide A Lyser dialysis 
devices (ThermoScientic, Rockford, IL) with 3.5-kDa molecular weight cutoff with four buffer 
exchanges. Samples were then diluted to 0.2 mg/mL for intrinsic tryptophan fluorescence and 
static light scattering measurements while a higher concentration of 0.4 mg/mL was used for 
DSC. Data from intrinsic tryptophan fluorescence peak position, the static light scattering signal 
at 295 nm, and DSC were used in the construction of the three-index EPD and radar chart using 
in-house software (Middaugh Suite).  
A detailed description of the construction of three-index EPD and radar chart can be found 
elsewhere 
31,32
. Briefly, the three index EPD and radar chart use a specific color (red (R), green 
(G), blue (B)) and shape (an equiangular polygon) respectively to reflect the characteristics of 
the underlying biophysical data, that define protein structural states as a function of solution 
variables like temperature and pH. For three-index EPD from this work, data from static light 
scattering, differential scanning calorimetry and MSM peak position were mapped to red, green 
and blue color respectively. Data sets obtained from each of above biophysical techniques were 
assigned to a color gradation from black to the full color of their technique, with minimum value 
in the dataset assigned a black color and maximum value to the full color intensity. However, for 
DSC the color assignment was reversed where the maximum value was mapped to black and the 
least value to maximum color intensity (i.e. green for DSC) for better visualization. Thus, a color 




pH and temperature space, which was mapped to a specific structural state of dmLT. For 
example, in the native state of dmLT, the light scattering, MSM peak position and DSC will have 
their least signals (black color) but this combination showed a green color, because the DSC 
color assignment was reversed and shows the maximum color for the lowest values. The 
individual RGB components were also displayed in a separate panel alongside the 3-index EPDs 
(Figure 4D) because it is difficult to determine the amount of an RGB component with a given 
color. The explicit display of its RGB components helps to better understand the interpretation of 
a color and more distinctly detect changes in the structure of the protein. A k-means clustering 
algorithm using in-house software (Middaugh Suite) was applied to the datasets to better probe 
regions of structural similarities and differences. 
Radar plots use a polar coordinate system incorporating n axes, in which each axis 
represents a value of one technique. The changes in signal for each technique was integrated and 
normalized from 0 to 1 to construct structure indexes, which are mapped to points in the polar 
coordinates which are connected to form a polygon. Zero and 1 represent the most native-like 
structure and the most altered state, respectively.  Small polygons represent more native-like 
structure, while larger polygons represent more altered structures. A K-means clustering 
algorithm was employed to define boundaries of different apparent phases. In this study, intrinsic 
tryptophan fluorescence peak position, static light scattering signal at 295 nm, and differential 
scanning calorimetry thermograms were used for construction of the radar charts. These 
techniques monitor different structural aspects of dmLT: Trp fluorescence (peak position) 
monitors tertiary structure, light scattering aggregation behavior and DSC measures the overall 




3.2.2.13 Aggregation study of dmLT 
For colloidal stability studies during agitation stress, lyophilized vials of dmLT (BPR # 
1037.00) were reconstituted in 0.7 mL of HPLC grade water prior to analysis resulting in a 
dmLT solution in 42.7 mM Sodium phosphate, 10.7 mM Potassium phosphate, 82 mM NaCl, 
5% Lactose, pH 7.4 (formulation buffer) at 0.9 mg/mL. The protein solution was further diluted 
to 0.2 mg/mL using the formulation buffer. Three mL Fiolax clear, Schott (Lebanon, PA) glass 
vials were then filled with 1.1 mL of 0.2 mg/mL dmLT in formulation buffer and stoppered 
(Cat#10122128, West Pharmaceutical, PA). The vials were then shaken sideways at 300 RPM 
for 2h at room-temperature. Control vials were filled with 1.1 mL of the formulation buffer alone 
and shaken under similar conditions. All techniques were performed in triplicate. 
3.2.2.14 Turbidity 
The reconstituted dmLT samples were visually assessed for visible particles with an 
Adelphi Apollo II liquid viewer (Adelphi Co., UK). Turbidity was measured for all samples in 
triplicate using a Hach 2100 AN Laboratory Turbidimeter, at a concentration of 0.2 mg/mL. 
Prior to analysis, the instrument was calibrated using standards in the range of <0.1 NTU to 
2,000 NTU. The turbidity of the empty tube and buffer were subtracted from all readings prior to 
reporting. 
3.2.2.15 UV-Visible Absorption Spectroscopy 
The UV-Visible absorption spectra of dmLT were recorded with an Agilent 8453 UV-
Visible spectrophotometer (Palo Alto, CA) equipped with a Peltier temperature controller. 
Spectra were collected from 190-1100 nm at an experimental resolution of 1 nm in 1 cm path 
length quartz cuvette. The concentration was calculated based on the reported extinction 








and after centrifugation (5000 rpm for 15 min, Thermo Scientific, Sorvall Centrifuge, MA). The 
instrument was first blanked using the formulation buffer prior to measuring solutions containing 
dmLT. All UV-Visible absorbance spectra were corrected for light scattering using a technique 
included in the manufacturers data analysis software (Chemstation UV-Vis analysis software, 
Agilent Technologies):  first, the spectra data where the optical density values are only due to 
light scattering (350-400 nm) are fitted to an equation, and then this curve is extrapolated across 
the entire protein spectrum and then subtracted from the spectrum, to produce the light-scatter 
corrected absorbance spectra.  The optical density value at 350 nm (OD350) was also recorded 
from the uncorrected spectra. A similar procedure was followed for measuring protein 
concentration after dialysis, both before and after centrifugation. The percentage loss in protein 
compared to protein stock was also calculated. 
3.2.2.16 Micro-Flow Imaging 
The total number and distribution of sub-visible particles in the range of 2 µm to 100 µm 
were examined using a MFI DPA-4200 (Protein Simple, Santa Clara, CA) system with a 100 µm 
silane coated flow cell. Measurements were made in triplicate at ambient temperature for all 
samples. Illumination was optimized using particle free water prior to all measurements.  
3.2.2.17 Resonant Mass Measurement (RMM) 
The total number and distribution of sub-micron particles in the range of 200 nm to 1 µm 
were examined using an Archimedes particle metrology system (Malvern Instruments Inc., 
Westborough, MA) equipped with Hi-Q microsensor. Prior to analysis, the flow cell was flushed 
with particle free water to achieve a clean baseline. All measurements were performed in 




each measurement was set to 200 particles. A particle density of 1.37 g/mL was used in the 
analysis.  
3.2.2.18 Nanosight Tracking Analysis (NTA) 
The total number and distribution of sub-micron particles in the range of 50 nm to 1 µm 
were examined using A NanoSight LM-14 (Malvern Instruments Inc., Westborough, MA) 
equipped with CCD camera and 635 nm laser. Measurements were made in triplicate at ambient 
temperature for all samples. Three sixty second measurements were taken from different areas of 
the flow cell per triplicate for a total of nine measurements per experimental condition. 
NanoSight NTA version 2.2 software was used for data analysis, with a camera gain of 5 and a 
detection threshold of 25. 
3.2.2.19 Size Exclusion Chromatography (SEC) 
A Shimadzu Prominence UFLC HPLC system equipped with a diode array detector was 
used.  dmLT samples (+/- shaking, in triplicate) were centrifuged for 5 min at 13,000 rpm, and 
20 g was injected onto a TSK-Gel BioAssist G3SWxl column (7.8 x 300 mm, TOSOH 
Biosciences, King of Prussia, PA) and the corresponding guard column (TOSOH Biosciences).  
The columns were operated at 30 ºC and equilibrated with at least 10 column volumes of mobile 
phase (0.2 M sodium phosphate, pH 6.8) prior to sample injection. A flow rate of 0.7 mL/min 
was used with a 30 min run time. A gel filtration standard (Bio-Rad, Hercules, CA) was 
subjected to SEC before and after three runs of dmLT to ensure column and HPLC system 
integrity.LC solutions software (Shimadzu, Kyoto, Japan) was used for data analysis. 
3.2.2.20 Forced Deamidation Method 
Forced deamidation studies were carried out with dmLT formulated under three different 




a) 42.7 mM Sodium Phosphate, 10.7 mM Potassium Phosphate, 82 mM NaCl, 5% Lactose, 
pH 7.4 (formulation buffer) 
b) 42.7 mM Sodium Phosphate, 10.7 mM Potassium Phosphate, 82 mM NaCl, 5% Lactose, 
pH 8.0  
c) 250 mM Ammonium Bicarbonate, 21.4 mM Sodium Phosphate, 5.4 mM Potassium 
Phosphate, 82 mM NaCl, 5% Lactose, pH 9.0 
The dmLT samples in the three different formulations (at 0.4 mg/mL) were incubated in 
triplicate at 4
o
C for 7 days. On days 0 and 7, the samples were subjected to intact mass analysis 
and peptide mapping. 
3.2.2.21 Forced Oxidation Method 
For forced oxidation studies, dmLT samples at 0.4 mg/mL in formulation buffer were 
oxidized in triplicate for one hour at ambient temperature at each of the following H2O2 
concentrations:  0.025 %, 0.05 %, 0.1 %, 0.25 %, 0.5 % and 1%  v/v. Reactions were quenched 
with D-Met and all samples were subjected to intact mass analysis, RP-UHPLC and peptide 
mapping. 
3.2.2.22 Thermal and agitation stress studies of dmLT 
For excipient screening studies as a function of both a thermal stress and shake-stress, 
lyophilized dmLT samples (BPR # 1037.00) were reconstituted in HPLC grade water at room 
temperature. Reconstitution time was less than 1 min. Multiple vials of reconstituted dmLT were 
then pooled and the protein concentration was determined (~1 mg/mL). The samples were 
centrifuged for 15 min at 5,000 rpm and the protein concentration was determined (~0.9 mg/ml). 
The dmLT protein was dialyzed in Slide-A-Lyzer Mini Dialysis Devices (Product #88403, 




against various base buffers, (10 mM Sodium Phosphate, containing 50 or 150 mM NaCl, pH 
6.0) or (50 mM sodium phosphate, 50 mM NaCl, pH 7.4) overnight at 4°C with three buffer 
changes at three hr. intervals, and incubation overnight before dialysate recovery. The protein 
concentration in the dialysate was determined both pre and post centrifugation (13,000 rpm for 5 
min). Excipients were prepared as concentrated solutions in the indicated base buffers. Each of 
the excipients, dmLT, and additional base buffer were then combined to achieve the 
concentrations of excipients indicated in the text and a final concentration of 0.15 mg/mL dmLT. 
For shake stress studies, 2 mL Fiolax clear, Schott (Lebanon, PA) glass vials were filled with 0.6 
mL of 0.15 mg/mL dmLT and stoppered (Cat#10122128, West Pharmaceutical, PA). The vials 
were then shaken sideways at 300 RPM for 4 hr. at room-temperature. Additionally, control vials 
were filled with 0.6 mL of each buffer without dmLT and shaken under similar conditions. All 
analytical techniques mentioned below were performed in triplicate on control/non-shake 
samples and the 4 hr. shaking stress samples. 
3.2.2.23 Freeze-thaw studies of dmLT 
The dmLT vials were reconstituted with water and dialyzed against the indicated base 
buffers (see above) in Slide-A-Lyzer Mini Dialysis Devices (Product #88403, Thermo Scientific, 
Rockford, IL) with a 3,500 Da molecular weight cutoff overnight at 4°C with three buffer 
changes at three hr. intervals, and incubation overnight before dialysate recovery. Excipients 
were prepared as concentrated solutions in indicated base buffer. Each of the excipients, dmLT, 
and additional base buffer were combined to achieve the final formulations as indicated in text. 
Then, 1.1 mL of dmLT at 0.4 mg/mL was filled in 3 mL Fiolax clear, Schott (Lebanon, PA) 
glass vials and then frozen at -80
o
C for 24 hrs. The vials were thawed at room temperature for 
~20 min for complete thawing. Samples were then frozen again at -80
o




(F/T) cycles were repeated five times. Samples were analyzed at 0, 1 and 5 F/T cycles using UV-
Visible absorption spectroscopy, hydrophobic interaction chromatography described above. 
3.2.2.24 OD350 measurements 
Thermal stress measurements were performed using a Cary 100 UV-Visible 
spectrophotometer (Varian medical Systems, Inc., Palo Alto, California) equipped with a 12 cell 
holder with a Peltier type temperature controller.  Samples contained 0.15 mg/ml protein with a 
total volume of 225 µl in 1 cm path length quartz cells.  Optical density at 350 nm (OD350) was 
monitored as the temperature was raised in increments of 1.25˚C from 10 to 90˚C with a heating 
rate of 60˚C/h.  Protein samples were run in triplicate and corresponding buffer blanks were run 
and subtracted from each sample.  The OD350 value was plotted against temperature, and the 
temperature at which the OD350 value reached an optical density value of 0.1 was determined. 
3.2.2.25 Chemical Stability Studies with dmLT in Candidate vs Current Formulation 
(Oxidation and Glycation) 
Forced glycation studies were carried out with dmLT in the two formulations namely: 
a) 42.7 mM Sodium Phosphate, 10.7 mM Potassium Phosphate, 82 mM NaCl, 5% Lactose, 
pH 7.4 (Current formulation) 
b) 50 mM Sodium phosphate, 50 mM NaCl, 10% sucrose, 5 mM methionine, 0.1% PS-80, 
pH 7.4 (Candidate Formulation) 
The dmLT samples in the two different formulations (at 0.4 mg/mL) were incubated in triplicate 
at 40
o
C for 7 days. On days 0 and 7, the samples were subjected to intact mass analysis 
For forced oxidation studies, dmLT samples at 0.4 mg/mL in the current and candidate 
formulation was oxidized in triplicate for four hours at 37
o




concentrations:  0, 1, 2.5 and 5 mM. Reactions were quenched with 70 mM of D-Met and all 
samples were subjected to intact mass analysis. 
3.3 Results 
3.3.1 Primary Structure and Post-translational Modification Analysis 
Figure 3.1A shows the intact mass spectrometry data of dmLT under non-reducing 
conditions. This shows three peaks that corresponded to the dmLT A chain (27,645.5 + 0.2 Da), 
B chain (11,719.1 + 0.1 Da) and modified B chain (12,043.0 + 0.4 Da). The modified B chain 
with a molecular weight increase of 323.5 Da could potentially be a glycated species since 
lactose, a known reducing sugar, is present in the lyophilized formulation (see below). Based on 
the relative abundance of the native and glycated B-chain (Figure 3.1A), there was only partial 
(~20%) glycation of the B-chain.  
The dmLT protein was then subjected to peptide mapping analysis to confirm the primary 
amino acid sequence of the protein. Two different proteases (chymotrypsin and trypsin) were 
required for digesting the A-chain and B-chain of dmLT, respectively, with high sequence 
coverage.  Figure 3.1B and 3.1C shows the UV214 nm chromatogram of the A-chain and B-chain, 
respectively. The A chain of dmLT was completely digested at 37
o
C with chymotrypsin in the 
presence of 3M GuHCl, but complete digestion of the dmLT-B chain was only accomplished by 
reduction at a higher temperature (80ºC) in 3M GuHCl and then treating the sample with trypsin 
overnight at 37 ºC.  Using these optimized conditions, sequence coverage of > 95% was attained 
for both the A and B-chain of dmLT (Supplemental Figure 3.1). The requirement of two 
different experimental conditions to achieve proteolysis suggested not only higher proteolysis 





Post translational modifications such as Met oxidation or Asn deamidation were not detected 
in either A-chain or B-chain by peptide mapping analysis (data not shown). However, a glycated 
peptide was identified within the dmLT B-chain following trypsin proteolysis. A mass difference 
of 324 Da (seen by intact mass spectrometry as described above) was observed between two 
peptides peaks, eluting at 44.4 min (monoisotopic mass of 2,814.6 Da) and 45.1 min 
(monoisotopic mass of 2,517.6 Da) indicated by arrows in Figure 1C. Following automated 





(containing a carbamidomethylation modification at Cys
86
). Given the labile nature of a lactose 
moiety in mass spectrometry, the 44.5 min species was identified manually using the MS/MS 







 containing a +324 Da modification. Additional analysis of overlapping 
peptides supported Lys
84
 as the site of glycation (data not shown). Interestingly, no glycation was 
observed at Lys
91





3.3.2 Protein Size and Purity 
A combination of SDS-PAGE, sedimentation velocity analytical ultracentrifugation (SV-
AUC), hydrophobic interaction chromatography (HIC) and reversed phase ultrahigh pressure 
chromatography (RP-UHPLC) were used to evaluate the protein size and purity. Reconstituted 
dmLT was composed of two protein bands as observed under denaturing conditions by both non-
reducing and reducing SDS-PAGE (Figure 3.2A). The apparent molecular weights of these two 
bands (~28 and ~12 kDa) corresponded to the A chain (theoretical MW: 27.6 kDa) and B chain 
(theoretical MW: 11.7 kDa) of dmLT. Protein purity was estimated to be >99 % and no other 




The size and purity of dmLT were then assessed under non-denaturing solution conditions 
by sedimentation velocity analytical ultracentrifugation (SV-AUC). SV-AUC showed two main 
species at 3.5 + 0.1 s and 4.3 + 0.1 s (Figure 2B), which accounted for 26 + 3 % and 72 + 4 % of 
the total peak area, respectively for triplicate measurements. The deconvoluted molecular 
weights of these two species corresponded to ~59 kDa (3.5s) and ~86 kDa (4.5s) species. The 59 
kDa species is consistent with a putative B5 species and the 86 kDa population probably 
corresponds to an intact AB5 dmLT complex. A small amount (~1 + 1 %) of larger species (~6-
8s) was also observed in the reconstituted sample that represents larger oligomeric or aggregated 
species (inset, Figure 3.2B).  
To further assess the heterogeneity of free B5 versus intact dmLT (AB5), HIC and RP-
UHPLC methods were developed (Figure 3.2C and 3.2D).  The HIC results also showed that this 
particular dmLT sample contained a heterogeneous mixture of the intact holotoxin (AB5), and 
free B5 subunit that accounted for 73 ± 1 % and 27 ± 1% of the total peak area, respectively for 
triplicate measurements (consistent with SV-AUC results). By RP-UHPLC analysis, the relative 
% of AB5 was 31 + 1 % and free B5 was 69 + 1 % for triplicate measurements. Interestingly, the 
relative % peak area of free B-chain versus AB5 complex was seen as comparatively more by 
RP-UHPLC than by HIC, likely due to the presence of trifluoroacetic acid in the RP-UHPLC 
mobile phase which exposed dmLT to low pH conditions (unlike the HIC mobile phase in which 
dmLT remained under neutral pH conditions). Low pH conditions have been shown to cause the 
dissociation of the A-subunit from the B-subunit as demonstrated by Lonnroth et al. and Van 
Heyningen et al. for the related cholera toxin
33,34
. As a result, the free B chain peak area 
increased while a reduction in peak area of AB5 complex was observed.  To further confirm the 




UHPLC and subjected to intact mass spectrometry (Supplemental Figure 3.2) which showed 
their molecular weights to be consistent with the presence of free B chain (MW ~11,719 Da) and 
AB5 (A-chain MW ~27,645 Da and B-chain MW ~11,719 Da). The glycated B-chain (MW 
~12,043 Da) was present in both the free B-chain and AB5 components.  
3.3.3 Higher Order Structure (HOS) and Overall Conformational Stability 
Circular dichroism (CD) and Fourier transform infrared spectroscopy (FTIR) were used to 
monitor the overall secondary structure of dmLT. At 10
o
C, CD in the far UV region (200-260 
nm) showed a broad minimum between 215-220 nm suggesting beta-sheet structure as the 
predominant secondary structure (Figure 3.3A). The second derivative spectrum in the Amide 1 
region (1700-1600 cm
-1
) of dmLT by FTIR spectroscopy showed multiple peaks suggesting the 
presence of several secondary structural components within the protein (see Figure 3.3 B and 
Supplemental Table 3.1 for peak assignments). The majority of these peaks (1631, 1676 and 
1690 cm
-1
) corresponded to beta structure in the protein supporting the CD results.  The overall 
secondary structure content within the dmLT sample was further quantified using deconvolution 
of the Amide I peak. The relative percentage of alpha helix, beta sheet and beta turns/unassigned 
were 26 + 3 %, 58 + 8%, and 16 + 9 %, respectively for triplicate measurements.  
Intrinsic Trp fluorescence spectroscopy was performed to evaluate the overall tertiary 
structure of dmLT (at 10
o
C) and to monitor the conformational stability of the protein as a 
function of temperature (10 to 90
o
C). The fluorescence spectrum of dmLT (see Figure 3.3C 
inset) showed the wavelength of maximum intensity (λmax) at 332 nm at 10
o
C indicating a 
relatively hydrophobic environment for the average Trp residue. After heating up to 90
o
C, λmax 
red shifted to 348 nm indicating the average Trp residues to be in relatively more hydrophilic 




heating. The plot of peak position as a function of temperature (Figure 3C) showed two thermal 
transitions in the dmLT molecule above 45
o
C indicated by arrows. 
The aggregation behavior of dmLT was studied by simultaneous monitoring of light 
scattering (at 295 nm) during intrinsic fluorescence spectroscopy. Light scattered from the dmLT 
solution as a function of temperature (10 to 90°C) was monitored (Figure 3.3D) which resulted 
in significant scattering beginning at ~46°C (Tonset) presumably due to aggregation of the A chain 
in dmLT. Further increase in temperature increased the scattering intensity before dropping twice 
above 55 and 80°C, a result probably due to precipitation of the A chain and B chain, 
respectively (see Figure 3.3D).  
Extrinsic ANS (8-Anilinonaphthalene-1-sulfonic acid) fluorescence spectroscopy was also 
used, as a complementary technique to intrinsic Trp fluorescence, to monitor changes in the 
overall tertiary structure of dmLT by detecting increased fluorescence intensity of ANS, due to 
exposure to increased apolar environments presumably as a result of structural changes and/or 
aggregate formation in the protein. A blue shift in the emission maximum from 490 nm (at 10°C) 
to 480 nm (at 90°C) (Figure 3.3E, inset) indicated increased accessibility of the ANS dye to 
protein’s apolar interior/surfaces suggesting tertiary structure alterations in dmLT (and/or 
aggregation) with the increase in temperature. An increase in fluorescence peak intensity (Tonset 
of 45°C) was observed as the sample was heated from 10 to 90°C (Figure 3.3E) implying protein 
unfolding and concomitant protein aggregation at higher temperatures, an observation consistent 
with intrinsic Trp fluorescence and static light scattering results. Similar to intrinsic Trp 
fluorescence results, two thermal structural transition events were also observed by ANS 




The overall conformational stability of dmLT was further assessed by differential scanning 
calorimetry (DSC) as the sample was heated from 10 to 100°C. As shown in Figure 3.3F, two 
major endothermic peaks were observed at approximately 52°C and 80°C, with onset 
temperatures of ~45°C and 70°C, respectively. These two major peaks were further fitted to four 
transitions (Tm1, Tm2, Tm3, Tm4) by the best mathematical fit shown in red in Figure 3.3F. The 
resulting thermal unfolding temperature values for dmLT are shown in Supplemental Table 3.2. 
From the DSC data, it is apparent that the thermal unfolding and stability of dmLT primarily 
reflects the behavior of the two individual protein subunits (A and B chain).  To summarize, all 
the above biophysical techniques revealed two thermal events in dmLT molecule, one for A-
subunit and other for the B-subunit. Based on the properties of the independent B-chain of 
cholera toxin (a close relative of LT and ~80% homologous to LT in terms of nucleotide 
sequences) and its comparison to the intact toxin
35
, the lower temperature transition in dmLT can 
be attributed to structural alterations in the A-subunit while the higher temperature transition 
corresponds to the B-subunit. 
3.3.4 Elucidation of Physicochemical Degradation Pathways of dmLT 
3.3.4.1 Physical stability profile of dmLT as a function of pH and temperature 
The physical stability profile of the reconstituted dmLT was evaluated in the formulation 
buffer under a wider range of pH conditions (pH 5.5 to 8.0) vs. temperature (10 to 90
o
C) with 
respect to tertiary structural integrity, aggregation and overall conformational stability using 
intrinsic tryptophan fluorescence, static light scattering, and differential scanning calorimetry, 
respectively (Figures 3.4 A, B and C). An increase in Trp fluorescence peak position (Figure 
3.4A) of dmLT was observed with increases in temperature for each of the pH conditions 




position was observed for dmLT at each of the pH conditions evaluated vs. an increase in 
temperature indicating structural alterations in the protein.  Also, an increase in scattered light 
with increases in temperature was observed for dmLT at each of the pH conditions with two 
transition events again seen (see Figure 3.4B), of which the Tonset values were calculated as 
shown in Supplemental Table 3.3. For lower pH conditions (pH 5.5-6.0), the thermal transition 
temperature values (Tm) were lower (~43ºC) than values seen at the higher pH conditions (pH 
6.5-8.0), which were ~45ºC. These results indicated that the aggregation propensity of dmLT as 
a function of temperature was slightly lower at pH 6.5-8.0 than at pH 5.5-6.0. Finally, DSC 
thermograms showed increased overall conformational stability of dmLT from pH 5.5 to pH 8.0, 
with the protein being thermally more stable between pH 6.5-7.5 in comparison to pH 5.5, 6.0 
and 8.0 (Figure 3.4C), consistent with the results from static light scattering.  
Using the large biophysical datasets from the above three techniques, two data 
visualization tools were utilized, a three index EPD (left panel) and a radar chart (right panel) to 
better assess the overall physical stability profile of dmLT as a function of pH and temperature 
(Figure 3.4D). The three index EPD displayed changes in the structural characteristics of dmLT, 
as measured by the three different biophysical techniques (intrinsic tryptophan fluorescence, 
static light scattering, and differential scanning calorimetry), as a function of temperature and pH 
(see supplemental methods for construction and interpretation of three index EPDs). The datasets 
from the three techniques were mapped to red (static light scattering), green (differential 
scanning calorimetry) and blue (MSM peak position from intrinsic Trp fluorescence) colors, 
respectively (an RGB system), as shown in a separate panel alongside the 3-index EPD. The 
display of individual RGB components helps to better understand the interpretation of the final 




biophysical techniques. The different colors highlighted regions with similar structural 
characteristics, designated as Regions I-VI. The changes in color represented structural 
alterations in dmLT as a function of pH and temperature as reflected in the biophysical stability 
data sets from the individual biophysical measurements. The EPD shows 6 regions that 
represented 6 structural states of dmLT; the native conformation (Region I, green), altered A-
chain (Region II, light magenta), partially altered dmLT structure (Region III, light green), 
altered B-chain (Region IV, dark magenta), extensively altered dmLT structure (Region V, light 
blue), and an aggregated state of dmLT (Region VI, light yellow) observed only at pH 5.5. Radar 
plots were also constructed to visualize the same physical stability data sets using a different 
method (see supplemental methods section).  Overall, the construction of three index EPD and 
radar plots both gave similar results and indicate that dmLT in formulation buffer displays six 
different conformational states (Regions I-VI) as a function of pH and temperature, with the 
protein’s structural integrity and conformational stability most favored between solution pH 6.5-
7.5 and at temperatures below 50 
o
C.  
3.3.4.2 Aggregation of dmLT as a function of agitation 
To assess the aggregation propensity of dmLT, agitation stress was used in which 
reconstituted dmLT vials were shaken sideways at 300 RPM for 2h at room temperature (see 
supplemental methods section). The aggregates formed were characterized using various 
analytical methods based on their different sizes ranging from ~5nm to over 100µm as outlined 
in Table 3.1. The shake-stressed samples after 2h of dmLT had a lower optical density values at 
280 nm (~20% loss in protein), higher turbidity and an overall higher concentration of sub-
micron and sub-visible sized particles compared to the control samples.  A small increase in 




in the B5 components of dmLT. Additionally, the monomer peak decreased in the shake stressed 
dmLT samples compared to the control samples as assessed by SEC and SV-AUC. The total area 
of the SEC monomer peak was substantially lower in the shake stressed samples compared to the 
control samples, indicating formation of larger, insoluble aggregates/particles (also confirmed by 
SV-AUC). Overall, these results highlight the propensity of dmLT to aggregate upon agitation 
and exposure to air-liquid interfaces, which may be encountered during manufacturing and 
transport of dmLT formulation. 
3.3.4.3 Effect of elevated pH and the presence of oxidants on the chemical stability of 
dmLT 
Forced chemical degradation studies using elevated pH and temperature or the addition of 
hydrogen peroxide of the reconstituted dmLT sample were used to determine specific sites prone 
to Asn deamidation and Met oxidation.Protein glycation was also monitored. Intact mass 
spectrometry analysis of dmLT (Figure 3.5A) incubated at 4
o
C for 7 days at pH 7.4, 8.0 and 9.0 
showed that dmLT incubated at pH 9.0 had one Da increase in the mass of the A-chain, while no 
mass change observed under pH 7.4 and 8.0. This can be attributed to the Asn deamidation 
reaction which results in the formation of a mixture of isoaspartate and aspartate above pH 6.0 
36
. 




) residue in the 
A-chain of dmLT was most susceptible to deamidation under basic conditions. However, 
additional optimization of the LC-MS peptide map is ongoing to more fully quantify the extent 
of deamidation and the amounts of deamidation byproducts.  
Results of intact mass spectrometry analysis of dmLT samples exposed to two 
concentrations of hydrogen peroxide (0% and 1% v/v), produced three peaks corresponding to 




(Figure 3.6A). In addition to the above main peaks, several oxidized species were observed with 
increasing hydrogen peroxide concentration. RP-UHPLC results of hydrogen peroxide treated 
dmLT (Figures 3.6B and 3.6C) showed an oxidation peak (~10.80-10.85 min) with the main free 
B5 peak compared to the control (0% H2O2). The areas of oxidized peaks increased, while the 
area of the main free B5 peak at ~10.9 min concurently decreased with increasing H2O2. A small 
AB5-oxidized peak was observed at high concentration of hydrogen peroxide (i.e., >0.5% H2O2) 
but its peak area did not contribute substantially to the overall decrease in total peak area of AB5. 
Peptide mapping was used to confirm and identify the Met residues of dmLT (3 Met residues in 
A-chain and 4 Met residues in B-chain) that are generally susceptible to oxidation
36
. Utilizing 
two different proteolysis methods, 100% of the A and B chain sequence of dmLT was identified. 
Therefore, the relative amount of Met oxidation was quantified for each Met residue within the 
protein; however oxidation of Met101 in the dmLT B chain could not be quantified due to low 
abundant peptides in the presence of H2O2. The relative percentages of each Met residue 
oxidized in the A and B-chains are shown in Figures 3.6D and E, respectively. In the absence of 
H2O2, no measurable oxidation of the Met residues in dmLT was observed. In the presence of 
H2O2, most of the Met residues were not substantially oxidized at lower concentrations H2O2 
(<0.25%) except Met37 of the A chain, which was markedly oxidized at 0.25% H2O2. These 
results suggest that Met37 in the dmLT A chain is more susceptible to oxidation than the other 
Met residues in the dmLT protein. 
Finally, the presumptive glycation reaction in dmLT, incubated under pH 7.4 at 40
o
C for 
7 days was monitored by intact mass analysis (Figure 3.5B). The relative abundance of the 
glycated B chain increased and additional modified B-chain peaks (+381 Da and +648 Da mass 




involve quantification and identification of the additional modified glycated B-chain peaks by 
further peptide map analysis. 
3.3.5 Screening of pharmaceutical excipients to improve physical stability of dmLT 
 Since thermal and agitation induced aggregation was identified as a major physical 
degradation pathway for dmLT (see above), assays used to monitor dmLT aggregation were used 
to identify stabilizing conditions and additives as a first step to design an optimized formulation. 
To permit effective screening of excipients that minimize thermal (heat) and agitation induced 
aggregation, high throughput stability-indicating assays such as increases in optical density at 
350 nm (during heating) and micro-flow imaging particle counting (after agitation) were 
implemented. By starting the excipient screening with the goal of minimizing aggregation, we 
subsequently identified conditions/excipients that would also minimize the chemical degradation 
pathways such as Asn deamidation, Lys glycation and Met oxidation. A base buffer of 10 mM 
sodium phosphate, 150 mM NaCl, pH 6.0 was chosen for these initial excipient screening studies 
since this solution pH resulted in suboptimal dmLT physical stability (based on biophysical 
studies described above), allowing for efficient screening of excipient’s ability to improve dmLT 
stability. Ten different categories of pharmaceutical excipients were evaluated including 
carbohydrates, polyols, amino acids, carboxylic acids, salts, metal ions/chelators, detergents, 
cyclodextrins, polymers/proteins, and polyions/osmolytes (see Supplemental Table 3.4 for 
complete list of excipients examined in this work). 
 Figure 3.7 shows the effect of excipients on the aggregation propensity of dmLT during 
thermal stress.  The average delta temperature value to reach 0.1 OD350 unit in the dmLT control 
formulation plus excipient vs. dmLT control formulation alone (10 mM sodium phosphate, 150 




stability of dmLT in terms of aggregation behavior.  Carbohydrates and polyols including 
glycerol, sucrose, mannitol, trehalose, sorbitol and lactose showed a larger stabilizing effect 
towards minimizing dmLT aggregation compared to other excipients such as amino acids and 
detergents, which ranged from moderate to low/no increase in dmLT stability against 
aggregation.  The effect of these additives on the aggregation propensity of dmLT during 
agitation (shaking of vials containing dmLT in different solutions) as measured by MFI is shown 
in Figure 3.8, where the excipients added to the control formulation were sorted from highest to 
lowest values of total sub-visible particle concentration. With the exception of trehalose, the sub-
visible particle concentration of the dmLT solutions after shaking was lower with each of the 
tested excipient conditions compared to the control formulation alone. Excipients such as 
hydrolyzed gelatin, human albumin and sodium acetate were found to be the most stabilizing 
against shaking induced aggregation. However, since albumin and gelatin are proteins, their 
effect on dmLT aggregation in OD350 assay could not be evaluated since the additives themselves 
may aggregate. Sodium acetate was not further investigated due to its minimal effect on 
thermally induced aggregation as compared to carbohydrates. A tabular summary of the results 
from OD350 measurements (thermal stress, Figure 3.7) and total sub-visible particle concentration 
from MFI measurements (agitation stress, Figure 3.8) for the dmLT samples in the presence of 
various excipients are also summarized in Supplemental Table 3.4.  
Different concentrations of top performing aggregation inhibitors from four different 
excipient categories (sugars, amino acids, metal chelators and detergents) were then selected and 
further evaluated to explore the concentration dependence of their stabilizing effect on dmLT 
using both thermal and agitation stresses (Table 3.2). Higher concentrations of polyols and 




from the OD350 assay. Several different amino acids exhibited a slight positive concentration 
effect by increasing the thermal stability of dmLT while chelators/detergents did not have a 
detectable effect.  For agitation induced aggregation of dmLT monitored by MFI, all of the tested 
concentrations of stabilizers had a protective effect against shaking induced destabilization of 
dmLT measured by the total number of sub-visible particles.  Amino acids and polysorbate 20/80 
appeared to be the most promising excipients in limiting sub-visible particle formation during 
agitation stress. 
Based on these results, only a selected number of the most promising excipients were 
chosen for further combination screening based on their demonstrated stabilizing effect on dmLT 
(Table 3.2) as well as practical considerations from a formulation development perspective such 
as their effect on solution osmolality. For example, for the selection of sucrose, even though 
many of polyols/sugars (such as glycerol, sorbitol, mannitol and lactose) inhibited thermally 
induced aggregation of dmLT to a greater extent than sucrose, these additives were not selected 
for further optimization. Glycerol and mannitol solutions of equal w/v ratio have higher 
osmolality values compared to sucrose solutions. When sucrose and glycerol are compared at 
equivalent osmolality (10 % sucrose vs 5% glycerol), sucrose is equally effective at inhibiting 
heat-induced aggregation of dmLT, and in addition, resulted in a lower number of sub-visible 
particles formed during agitation. Similarly, sorbitol and lactose solutions also showed higher 
number of sub-visible particle formation than sucrose solutions during agitation. Moreover, 
sorbitol and mannitol may manifest a lesser ability to protect during freezing and thawing 
compared to disaccharides at equivalent solution osmolality values
37-40
, a consideration of 
importance for dmLT as described below. Finally, lactose is a reducing sugar which can glycate 




potentially lead to protein instability as well as formation of advanced glycation products 
41,42
.  
As shown below, addition of sucrose in the formulation does inhibit glycation of dmLT, 
compared to lactose, under forced degradation conditions of elevated temperature.  Based on 
these considerations, 10 % sucrose was selected as a sugar-based stabilizer to improve overall 
stability of dmLT against aggregation without the concern of causing protein glycation.   
In addition, polysorbate-80 and methionine were the other two stabilizers selected for 
further work to develop a stabilizing formulation of dmLT (Table 3.2). Polysorbate-80 greatly 
minimized agitation induced aggregation of dmLT (despite its mild destabilizing effect on 
thermally induced aggregation). Methionine showed some stabilization against agitation induced 
aggregation (and no destabilization against thermally induced aggregation) of dmLT (Table 3.2), 
yet was primarily selected for its ability to mitigate the potential of oxidative stress (oxidation 
was identified as major chemical degradant pathway of dmLT as shown during forced oxidation 
studies above. As shown below, addition of Met in the formulation does inhibit hydrogen 
peroxide induced oxidation of Met residues in dmLT.    
3.3.6 Salt optimization for dmLT stability 
Sodium chloride was observed to be essential to maintain the solubility of dmLT in 
solution during dialysis. Higher sodium chloride concentrations in combination with other 
excipients, however, can lead to high solution osmolality which may be undesirable for clinical 
administration. Therefore, to balance sufficient dmLT solubility with total solution osmolality 
values, different concentrations of sodium chloride (50, 100, and 150 mM) in 10 mM sodium 
phosphate buffer pH 6.0 (+/-10% w/v sucrose) were tested to identify the salt concentration-
dependence of the stabilizing effect on dmLT.  As shown in Figure 3.9A, in the absence of 




measured by the OD350 thermal stress assay. In the presence of sucrose, however, dmLT 
formulated with 50 and 100 mM NaCl showed higher thermal stability in comparison to 150 mM 
NaCl.  In terms of agitation stress as shown in Figure 3.9B, MFI results showed that the 50 mM 
sodium chloride containing solutions of dmLT produced a lower number of sub-visible particles 
compared to 100 and 150 mM sodium chloride. These results demonstrated that, in general, 
dmLT samples formulated with sucrose were thermally more stable toward aggregation 
compared to samples without sucrose, and a combination of sucrose (10% w/v) and 50 mM NaCl 
limited aggregation and particle formation caused by agitation stress. Finally, dmLT formulated 
in the presence of 10% w/v sucrose and 50 mM sodium chloride at pH 6.0 had lower solution 
osmolality than formulations containing higher sodium chloride concentrations (~450 mOsm for 
50 mM NaCl vs ~650 mOsm for 150 mM NaCl). Based on these results, 10 mM sodium 
phosphate, 50 mM NaCl, 10% w/v sucrose, pH 6.0 was selected as the base buffer for further 
optimization of dmLT physical stability in combination with other promising excipients such as 
methionine and polysorbate-80. 
3.3.7 Identifying optimal combinations of lead stabilizers 
Combinations of the lead stabilizers were tested to determine any potential additive or 
synergistic effects on dmLT stability and to check for incompatibility between excipients. Based 
on the considerations outlined above, a candidate formulation including sodium phosphate 
buffer, sodium chloride, sucrose, methionine and PS-80 was identified which showed protection 
against aggregation induced by thermal and agitation stresses, and potentially could help prevent 
oxidation in dmLT. 
The effect of both solution pH and phosphate concentration on the physical stability of 




at both pH 6.0 and 7.4 were evaluated (in combination with 50 mM NaCl, 10% sucrose, 5 mM 
methionine and 0.01 % v/v PS-80). The phosphate concentration did not appear to affect the 
thermal stability of dmLT at pH 6.0 (Figure 3.10A) as measured by the OD350 assay.  
Interestingly at pH 7.4, however, an increase in phosphate concentration increased the thermal 
stability of dmLT as measured by the same OD350 assay. To further understand these results, 
differential scanning calorimetry was employed to assess the effect of the higher phosphate 
concentration on the overall conformational stability of dmLT at the two different pH values. 
Figure 3.10B shows the thermal melting temperature (Tm) values for dmLT formulated in both 
10 and 50 mM phosphate at both pH 6.0 and 7.4 (in combination with 50 mM NaCl, 10% 
sucrose, 5 mM methionine and 0.01 % v/v PS-80).  No major differences were observed in the 
Tm values of dmLT formulated in 10 vs. 50 mM phosphate at pH 6.0. However, dmLT 
formulated in 50 mM phosphate at pH 7.4 had slightly higher Tm values compared to 10 mM 
phosphate pH 7.4 (a ~2
o
C increase in Tm1, corresponding to unfolding of the A-chain of dmLT). 
These studies showed two different pathways of excipient stabilization of dmLT at the two 
different pH conditions, pH 6.0 and 7.4 (see discussion section below). At pH 6.0, the presence 
of sucrose had a major stabilizing effect on dmLT, while phosphate concentration did not affect 
thermal stability.  Conversely at pH 7.4, a higher phosphate concentration showed higher dmLT 
thermal stability. Based on these results, two candidate dmLT formulations were identified for 
additional evaluations (1) 10 mM sodium phosphate (pH 6.0), 50 mM NaCl, 10% w/v sucrose, 5 
mM methionine, 0.01 % v/v PS-80, and (2) 50 mM sodium phosphate (pH 7.4), 50 mM NaCl, 
10% w/v sucrose, 5 mM methionine, 0.01 % v/v PS-80. 
The effect of multiple freeze-thaw (F/T) cycles (0, 1 and 5 cycles) on dmLT in these two 




prepare the lyophilized dosage form, was evaluated using UV-Visible spectroscopy to monitor 
protein concentration (and aggregation) as well as MFI to measure subvisible particle formation. 
The current lyophilized dmLT formulation showed a higher protein loss (~17 %) as compared to 
the two candidate formulations (~6%) after five F/T cycles (Supplemental Figure 3.4A). The 
current formulation also showed a greater number of sub-visible particles/aggregates in 
comparison to both the candidate formulations after five F/T cycles. Between the two candidate 
formulations, the pH 6.0 formulation showed higher numbers of particles than the pH 7.4 
formulation after five F/T cycles (Supplemental Figure 3.4B). 
Based upon these results, the candidate formulation at pH 7.4 was further optimized to 
limit protein loss during multiple F/T cycles. The loss of protein during F/T in the candidate 
formulation at pH 7.4 was minimized by increasing the PS-80 concentration from 0.01 % v/v PS-
80 to 0.05 and 0.1 % v/v PS-80 as shown in Figure 3.11. The effect of increasing PS-80 
concentration in the candidate formulation on the freeze-thaw stability of dmLT was monitored 
by a combination UV-Vis spectroscopy (protein loss), hydrophobic interaction chromatography 
(HIC, to measure relative percent AB5) and MFI (particle formation).  Increasing the PS-80 
concentration in the candidate formulation mitigated protein loss following freeze-thaw as 
measured by A280 using UV-Vis spectroscopy compared to the current formulation (Figure 
3.11A). No protein loss was observed in the candidate formulation with 0.1% PS-80, pH 7.4 
formulation after 5 FT cycles. The HIC analysis showed no loss of native dmLT (AB5) for the 
candidate formulation with 0.1% v/v PS-80 while a substantial loss of native dmLT (~19 %) was 
observed in the current formulation after five F/T cycles (Figure 3.11B). The size distribution 
and total number of sub-visible particles/aggregates formed during F/T in all the formulations 




particles increased slightly in the candidate formulation with 0.01% PS-80 but no change in the 
number of sub-visible particles was observed in the candidate formulation with 0.05% or 0.1% 
PS-80 after five FT cycles. The majority of sub-visible particles in all samples were 2-5 µm.  In 
summary, increasing the PS-80 concentration from 0.01 to 0.1 % v/v helped to minimize the 
protein loss and loss of the AB5 species, without causing any major change in the total number or 
distribution of sub-visible particles after 5 F/T cycles. 
3.3.8 Summary of physicochemical stabilization of dmLT in candidate bulk formulations 
The optimized candidate formulation for bulk dmLT which displayed increased thermal 
stability, reduced propensity to aggregate, robust freeze-thaw stability as well possession of 
acceptable solution tonicity was 50 mM sodium phosphate, 50 mM NaCl, 10 % w/v sucrose, 5 
mM methionine, 0.1 % v/v PS-80, pH 7.4.   
The new candidate formulation provided improved physical stability of dmLT, compared 
to the current formulation (used for lyophilization), upon agitation and F/T stresses as observed 
by the lower number of sub-visible particle formed and the lack of loss of protein concentration 
after five F/T cycles, respectively (Table 3.3). Although the aggregation propensity of dmLT 
upon thermal stress in the new candidate bulk formulation was slightly higher than in the current 
formulation (~2
o
C difference in OD350 values), given such high thermal stability values in either 
formulation (>70
o
C), it is unlikely that the two formulation will differ in thermal stability when 
exposed to more moderate temperatures during accelerated and real time stability studies. 
Furthermore, no major differences were observed between dmLT in the two formulations in 
terms of relative AB5 ratio as measured by HIC and overall conformational stability (Tm values) 




The new candidate bulk formulation also improved the chemical stability profile of 
dmLT, in terms of Lys glycation and Met oxidation, in comparison to dmLT in the current 
formulation (used for lyophilization). After incubation of dmLT at 40
o
C for 7 days in the 
candidate formulation, no increase in relative abundance of the glycated B-chain, nor the 
formation of additional modified B-chain peaks (+381 Da and +648 Da mass increases), was 
observed by intact mass spectrometry (see Supplemental Figure 3.5 and Supplemental Table 
3.5). In contrast, dmLT in the current formulation under the same stress conditions showed 
increases in these chemically modified (glycated) species (see Supplemental Figure 3.5 and 
Supplemental Table 3.5). Results of intact mass spectrometry analysis of dmLT in the two 
formulations exposed to different concentrations of hydrogen peroxide (0, 1, 2.5 and 5 mM) 
showed oxidized dmLT species (+16 Da) in the current formulation at 1, 2.5 and 5 mM H2O2 
(see Supplemental Figure 3.6 and Supplemental Table 3.6). However, no dmLT oxidation was 
detected in the candidate bulk formulation up to 2.5 mM H2O2, and thus, the new formulation 
appeared to be overall better than the current formulation in terms of protecting dmLT against 
oxidation stress (see Supplemental Figure 3.6). 
A comparative summary of the physicochemical properties of dmLT in the current 
(lyophilized and reconstituted) and new candidate formulation (bulk stored frozen) in terms of 
aggregation propensity due to thermal, agitation and F/T stresses, conformational stability as 
measured by DSC, chemical stability under forced oxidation and glycation conditions, AB5 ratio 
as measured by HIC, and solution osmolality are summarized in Table 3.4.  
3.4 Discussion 
The development and eventual successful commercial manufacturing of a well-defined, 




will depend in part of a detailed mechanistic understanding of the protein’s physicochemical 
properties, integrity and stability as well as the interrelationships between these structural 
properties and functional attributes. Extensive analytical characterization is often necessary to 
study the complex nature of protein based vaccines to ensure their purity, potency and stability 
during production, storage and administration 
18,19
. In this work, we utilize a series of biophysical 
and biochemical analytical technologies to better characterize the primary structure, post 
translational modifications, size and higher order structure of dmLT as well as to identify the 
potential physicochemical degradation pathways of this adjuvant. By developing a set of stability 
indicating methods to monitor the key structural attributes of dmLT, it will now be possible to 
rapidly evaluate the effect of process and formulation changes implemented for production of 
future clinical lots on the structural integrity of the dmLT molecule without relying solely on 
extensive biological testing such as animal potency assays.   
Based on the HIC and SV-AUC analysis, this particular lot of dmLT is a heterogeneous 
mixture of the intact holotoxin (AB5, ~75%) and free B5 subunit (~25%) in solution, although it 
is possible the AB5:B5 ratio could vary between lots or with different preparations depending on 
the purification protocols used. One possible reason for the presence of free B5 subunit might be 
the differing efficiencies of the A- and B subunit Shine-Delgarno sequences on the polycistronic 
mRNA that codes for both subunits. Alternatively, the inherent instability of the A-chain 
(observed by a variety of biophysical measurements) may cause a relatively larger loss during 
expression and purification. Joffré et al.
43
 have reported the presence of free B subunit and intact 
holotoxin AB5 in several LT preparations produced from different ETEC strains using an ELISA. 
In our work, each of the biophysical techniques (DSC, fluorescence spectroscopy, static light 




the other for the B-subunit. Our findings are consistent with the work of Goins et al.
35
 concerning 





C (B-subunit). Since LT is ~80% homologous to CT in terms of nucleotide sequences 
and overall structurally similar to CT
35,44
, the dmLT results in this work are well correlated with 
the previous studies of CT.  The work presented here clearly demonstrates that the A-subunit, 
which possesses the adjuvant activity, is thermally less stable than the B-subunit as observed by 
a variety of complementary biophysical techniques.  
Vaccines often encounter a wide variety of environmental stresses during manufacturing, 
storage, transport and administration to patients. Stresses such as pH changes, temperature 
fluctuations, agitation or light exposure can affect the stability and potency of vaccines
45,46
. 
Forced physical and chemical degradation studies are employed during the development of 
vaccines to elucidate potential causes and molecular mechanisms of degradation, develop 
stability indicating methods
45
, and design stable formulations including pharmaceutical 
excipients
26
 to minimize degradation. The major physical instability pathways of a vaccine 
constitute structural/ conformational changes and aggregation of either the antigen or adjuvant. 
Structural alterations in the protein antigen could result in the loss of key epitopes or exposure of 
additional epitopes, previously buried within the protein structure, potentially leading to the 
formation of non-neutralizing antibody responses against the vaccine antigen that may compete 
with formation of neutralizing antibodies
46,47
. In this study, the forced physical degradation 
studies as a function of pH and temperature identified structural/conformational changes in 
dmLT by multiple biophysical techniques. Optimal stability conditions of dmLT between pH 
6.5-7.5 and temperatures below 50
o
C were established from the biophysical stability data sets 




high throughput assays for screening stabilizers can be developed and used as a key part of 
formulation development experiments of dmLT (Toprani et al.
48
). This approach has been 




Protein aggregation is known to affect potency as well as reduce yields of a number of 
vaccine antigens
50-53
, making it critical to characterize protein aggregates and control their 
formation during vaccine development. Adjuvants can undergo colloidal instability leading to 
potency loss. For example, lyophilization or freeze-thaw induced aggregation of aluminum salt 
adjuvants in vaccines is well reported
54
.  A major challenge with studying aggregates during 
protein/vaccine formulation is the multiple size ranges within which aggregates can be grouped 
and the need for several orthogonal techniques to probe the different size aggregates
55
. Our 
results find that dmLT is highly prone to aggregation during agitation stress with different sized 
aggregates formed ranging from 1 nm to >100 µm with a concomitant loss of protein content. 
While these observations were derived from an early clinical lot of material, the data indicate 
aggregation as a major physical degradation pathway of dmLT which may present challenges 
during manufacturing or lead to loss of potency during long term storage. Future work needs to 
minimize the agitation-induced aggregation as part of formulation development of this adjuvant 
as well to study the activity of these aggregates in comparison to native dmLT in terms of 
adjuvant activity. 
Chemical instabilities involving modifications of covalent bonds in proteins such as 
deamidation, oxidation, glycation, etc. represents a major degradation pathway for protein 
vaccines 
36
. Investigation of these chemical instabilities is very relevant in formulation 




conformation, stability, bioactivity, efficacy and immunogenicity
42,56,57
. For vaccines, Asn 
deamidation in critical epitopes of the recombinant protective antigen leads to a change in the 
conformation of epitopes that causes reduction in potency and immunogenicity of a recombinant 
anthrax vaccine
58,59
. As a part of chemical stability studies, we have identified a glycated B-chain 
species in this lyophilized dmLT formulation by intact mass spectrometry. The presence of 
reducing sugars is known to cause glycation in therapeutic proteins by a condensation type 
reaction with Lys residues known as the Maillard reaction
60-62
. A lactose glycan on the B chain 
would increase the protein’s molecular weight by 324 Da, which was consistent with the 
observed molecular weight of the modified B chain. Although the involvement of Lys91 in 
binding of lactose to B-chain of LT within the sugar binding site is well established
63
, we 
observed an adjacent lysine residue, Lys84, as the site of glycation. We suspect the surface 
exposed nature of Lys84 make it more susceptible to glycation during the lyophilization process 
given that lactose is present in the lyophilization buffer. As part of forced degradation studies, 
increased amounts of glycated B-chain (and additionally modified peaks) were observed under 
temperature stress, which is consistent with observed protein glycation
42
. 
Preliminary forced deamidation studies indicate the N-terminal asparagine which is 
followed by Gly in the A-chain of dmLT to be the most susceptible to Asn deamidation. It is 
well known that Asn-Gly and Asn-Ser residues are more prone to deamidation than any other 
Asn residue sequences
36,64
.  In the presence of H2O2, we report the high susceptibility of the 
Met37 residue in the dmLT A chain towards oxidation compared to the other Met residues in 
dmLT. Additionally, we show that RP-UHPLC and LC-MS can be used as orthogonal 




work not only reveal the major degradation pathways of dmLT but also will help in future to 
generate stable and robust formulations of dmLT.  
During the clinical development and post approval lifecycle management of a vaccine 
product, changes to the composition, manufacturing process, equipment or facilities can occur 
65,66
. For example, changes in manufacturing facilities (e.g., scale-up to larger facility) or changes 
in the final vaccine dosage form (e.g., lyophilized to liquid formulation) may occur to meet 
market demands. These types of process and product changes can potentially affect the identity, 
strength, purity, quality and potency of the antigen/adjuvant or the final vaccine product. 
Comparability assessments requiring an extensive combination of analytical and biological tests 
20,67,68
 are performed to evaluate the impact of such changes with regard to the safety and 
efficacy of the vaccine product. As the dmLT adjuvant advances in clinical development, it is 
likely to undergo manufacturing or process changes that could potentially cause physicochemical 
changes in the protein. The analytical and stability indicating methods developed in this work 
could be very useful not only to demonstrate analytical comparability and quality consistency 
between pre- and post-change dmLT, but also monitor lot-to-lot variability of dmLT made from 
the same process. For example, an LC-MS peptide map can be used to identify any post-
translational modifications in the protein primary structure by comparing the peptide map 
profiles for the pre and post-change dmLT while HIC and SV-AUC can be potential QC or 
characterization assays to assess purity in different batches of the dmLT adjuvant. Furthermore, 
the stability profile of vaccines is a key component to comparability assessments, since stability 
is often a very sensitive indicator of subtle alterations in higher order structure.  Data 




sets cannot only be used in formulation development, but as part of comparability studies as has 
been demonstrated with a wide variety of protein based drug and vaccine candidates 
32,49,69
.  
Preformulation characterization and formulation development activities of vaccine 
candidates (both antigens and adjuvants) are critical activities for their clinical development and 
regulatory approval. A proper vaccine formulation should not only be stable (including the 
antigen and adjuvant are physically compatible), but the vaccine also must remain potent and the 
adjuvant must enhance the immunogenicity of the vaccine antigen. It is therefore imperative to 
assess and identify the structural integrity as well as physicochemical degradation pathways of 
antigen and adjuvant as part of formulation development. A rational design of stable formulation 
conditions is possible based on understanding the causes and mechanisms of vaccine antigen and 
adjuvant stability (and interactions), to maintain vaccine potency throughout the shelf life at the 
defined storage temperature(s).  In this work, we have developed an improved bulk formulation 
of the dmLT adjuvant with the goal of providing long term frozen storage as well as flexibility 
for potential use with different vaccine antigens administered by various routes (e.g., injection, 
oral, nasal, etc.). The systematic formulation strategy described in this paper provides an 
overview of the physicochemical stability of dmLT in the presence of different excipients and 
not only helps to elucidate degradation pathways, but provides strategies for dmLT stabilization 
within a pharmaceutical dosage form.  
The major physicochemical instabilities identified with the current formulation of dmLT 
were glycation and oxidation of specific Lys and Met residues, respectively, as well as protein 
aggregation induced by agitation and thermal stress. Physical instability due to either heat and/or 
freeze stress of antigens or adjuvants can be a major cause of potency loss in various vaccines 






lack of integrity of the vaccine cold-chain exposes vaccines to temperature fluctuations (either 
accidental heat exposure or freezing) during shipping, handling, distribution and administration 
to patients 
16,23,70
. This puts an additional requirement on vaccine manufacturers to develop more 
thermostable vaccines or vaccine formulations to make their products more widely available in 
global markets.  
With the aim to develop a more stable bulk dmLT formulation that does not require 
lyophilization, this work involved identifying pharmaceutical excipients that enhanced dmLT 
stability (i.e., minimized aggregation during thermal and agitation stresses). Sucrose and 
phosphate were identified as stabilizers that increased dmLT thermal stability against 
aggregation and limited its aggregation. Sucrose is a widely used pharmaceutical excipient that 
stabilizes biomolecules, including antibodies, protein drugs and vaccines
71-73
 by offering 
protection against elevated temperatures as well as freezing stress via preferential exclusion 
mechanisms
74,75
. Additionally, its non-reducing nature doesn’t cause glycation in proteins unless 
exposed to very low pH or high temperatures 
42
. In fact, our results demonstrated that dmLT in 
the candidate formulation (containing sucrose) showed essentially no Lys glycation formation 
during elevated temperature studies compared to dmLT in the current formulation (containing 
lactose) under the same conditions which displayed increased formation of glycated protein. 
The investigation of the effect of phosphate on the thermal stability of dmLT at two pH 
conditions revealed that relatively higher concentrations (50 mM) of phosphate at pH 7.4 showed 
an increased thermal stability of dmLT compared to pH 6.0. At pH 7.4, a potential reason for the 
increased thermal stability (in terms of aggregation propensity) of dmLT under higher phosphate 
concentrations can probably be attributed to phosphate binding or intermolecular electrostatic 




charged below its pI
76
. The theoretical pI of the A-subunit of dmLT based on its amino acid 
sequence is ~6.48. In the pH 7.4 formulation, above the A-subunit’s pI, the A-subunit is expected 
to have a net negative charge with a smaller proportion of positive charges. Addition of increased 
amounts of phosphate anions can effectively shield positive charges on the protein surfaces. This 
would cause an increase in intermolecular charge-charge repulsions between dmLT molecules 
making it less favorable for the two molecules to interact (aggregate) with an increase in stability 
as was observed in this work by OD350 thermal melt results. In contrast, at pH 6.0 (closer to the 
theoretical A chain pI=6.48), the A-subunit of dmLT has anisotropic charge distribution which 
may give rise to dipoles which in turn could make attractive forces between dmLT molecules to 
dominate, making aggregation more favorable. Multiple studies on different proteins have also 
demonstrated the role of increasing repulsive charge-charge interactions in stabilizing protein 
solutions (i.e., colloidal stability) and thereby reducing/preventing protein aggregation
77-79
. 
Agitation is a common physical stress experienced during manufacturing, shipping and 
handling of protein based drugs and vaccines
80
. It can cause protein structural alterations at the 
air-liquid interface leading to formation of nucleating aggregated species in the bulk solution 
causing more extensive aggregation in the bulk formulation
80,81
. To protect dmLT against 
aggregation caused by agitation stress, polysorbate-80 was identified as a stabilizing excipient. 
PS-80 mitigated aggregate/particle formation in dmLT during agitation by presumably 
outcompeting proteins for the air-water interface and thus inhibiting surface adsorption and 
structural alterations of proteins due to the hydrophobic nature of air water interfaces. PS-80 is a 
non-ionic surfactant widely used with protein drugs and some vaccines to prevent aggregation 
against a number of interfacial stresses including agitation and freeze thaw
82,83
.  PS-80 is also 




aggregation and reduce the unfolding of proteins at ice-water interfaces
84
. These effects are 
presumably responsible for the stabilization of dmLT (no loss of protein) observed in this work 
during multiple freeze-thaw cycles. 
Protein oxidation is a major chemical degradation pathway for protein drugs
57
. Oxidation 
can be induced during manufacturing by trace metal ions leached from equipment or exposure of 
proteins to light and oxygen from the surrounding air. Certain excipients such as non-ionic 
surfactants can also form peroxides which are a major catalyst of protein oxidation 
57
. Oxidation 
can affect pharmaceutical properties of proteins, including solubility, conformation, biological 
activity and shelf-life
57
. There are many potential ways to protect against oxidation such as site-
directed mutagenesis to remove labile amino acid residues, development of solid state vs liquid 
formulations, or addition of excipients with anti-oxidant properties such as methionine in the 
formulation. To protect dmLT against oxidation, the amino acid methionine was added in the 
formulation since Met can act as an oxidation scavenger. Lam et.al 
85
 have reported that addition 
of methionine to a formulation of rhuMAb HER2 protected it against temperature and light 
induced oxidation. The authors concluded that exogenous methionine can act as an antioxidant 
by either inhibiting the free radical chain reactions during oxidation or by competing with the 
endogenous methionine residues in the protein for reactions with hydroxyl radicals. In fact, our 
results demonstrated that dmLT in the candidate formulation containing methionine showed 
reduced levels of oxidation of Met residues in the dmLT protein compared to dmLT in the 
current formulation under the same forced oxidation conditions.  
One important aspect of vaccine formulation development is to permit stable, long term 
frozen storage of the bulk vaccine antigen (or in this case, dmLT adjuvant). Freezing protein 




a decreased risk of microbial growth, elimination of agitation during transport and flexibility in 
subsequent fill-finish manufacturing 
86
. For example, if the bulk protein vaccine antigen (or in 
this case, dmLT adjuvant) can withstand freeze-thaw cycle, it may be frozen at the bulk 
manufacturing site until transport to the fill finish site, and the subsequent drug product could 
potentially be stored and shipped frozen to a clinical site.  However, freeze-thaw stress can 
negatively impact the structural integrity and potency of protein drugs and vaccine
84,87,88
, 
including the freeze-thaw induced aggregation of aluminum salt adjuvants used in recombinant 
protein vaccines 
89,90
 leading to loss of biologic activity 
91
.  Freeze-thaw studies provide data on 
the impact of freezing on structure and conformation of protein adjuvants and antigens. 
Currently, majority of vaccines in preclinical or clinical development are based on recombinant 
proteins which require an adjuvant to increase their potency
92,93
. Hence, if the vaccine requires 
freezing for storage with dmLT as an adjuvant, then both the antigen and dmLT adjuvant should 
be able to withstand freeze-thaw effects. The freeze-thaw study here showed that dmLT in the 
newly developed formulation was freeze-thaw stable for up to five FT cycles. Neither 
aggregation nor loss of protein was observed after five freeze thaw cycles.  
A combination of the key excipients such as phosphate ion, sucrose, methionine and 
polysorbate 80 showed protection of dmLT against thermal, agitation, and freeze-thaw stresses.  
This was due to inhibition of aggregation as well as minimization of chemical alterations 
including Lys glycation and Met oxidation.  The potential benefits of this candidate formulation 
can not only be in protecting and stabilizing the dmLT protein adjuvant against different stresses, 
but also offering flexibility in terms of combining dmLT with different antigens. Furthermore, an 
additional benefit of the candidate bulk formulation of dmLT offers is its pH (pH 7.4) since 




transitioning from formulation pH to physiological pH conditions
94
. Finally, the replacement of 
lactose with sucrose in the new candidate formulation should eliminate Lys glycation of dmLT 
with a simultaneous increase in thermal and freeze-thaw stability of dmLT. 
In conclusion, this work not only demonstrates the use of an extensive analytical toolset 
to characterize the higher order structure and physicochemical stability profile of an early 
clinical lot of dmLT, but also establishes the utility of these analytical tools for use as a part of 
future analytical comparability assessments to evaluate the effect of the inevitable process and 
formulation changes that occur during clinical development. Furthermore, this study provides the 
initial development of a new candidate bulk formulation of dmLT adjuvant by better 
understanding the protein’s key structural features, identifying its physicochemical degradant 
pathways, and identifying stabilizing excipients to minimize protein instability by the use of 
appropriate stability indicating analytical assays. The dmLT protein adjuvant has shown potential 
to function as a mucosal adjuvant with a wide variety of antigens in both animal and human 
studies by a variety of administration routes 
13
. For further pharmaceutical development of dmLT 
in the new candidate bulk formulation, long term bulk storage stability studies, and compatibility 
testing with different vaccine antigens in a final drug product will be necessary. In addition, 
immunogenicity studies in animal models of dmLT in candidate formulations along with a co-
administered antigen are also suggested. For example, the adjuvanticity and antigenicity of 
dmLT with a tetanus toxoid antigen has been evaluated in mice by measuring serum anti-antigen 








Table 3.1. Aggregation Propensity of Reconstituted dmLT in Formulation Buffer in Stoppered 
Glass Vials After Agitation for 2 h as Measured by Various Analytical Methods. Data represent 
the average and SD for n = 3 replicates. NTU, nephelometric turbidity unit. 
Size Range Analytical Methods Time zero T=2hr 
 





A280 = 0.24+ 0.0 
OD350 = 0.0 +0.0 
A280 = 0.19 + 0.02 
OD350 = 0.62 + 0.01 
Turbidimetry 0.5+ 0.0 NTU 20.8 + 0.2 NTU 
2-100 µm Micro-Flow Imaging Total particles/mL 




= 2.1+ 0.13 x10
6
 
0.1-1 μm Resonant Mass 
Measurement 
Total particles/mL 














= 86.4 + 29.5 x10
6
 
~1-100 nm Sedimentation 
Velocity-Analytical 
Ultracentrifugation 
B5 = 34 +1 % 
AB5 =66 +1 % 
Aggregates =0 + <1 % 
B5 = 82 +4 % 
AB5 =17 +4 % 
Aggregates =1 + 1 % 
Size-Exclusion 
Chromatography 
Monomer = 100 + <1 % 
Soluble+Insoluble 
Aggregates = 0 + <1 
Monomer = 65+1% 
Soluble+Insoluble 















Table 3.2. Concentration optimization of lead stabilizing excipients for their stabilizing effect on 
dmLT (0.15 mg/mL) aggregation due to thermal stress as measured by OD350 thermal melt and 
agitation stress as monitored by MFI. All excipients were formulated in 10 mM sodium 
phosphate, 150 mM NaCl, pH 6.0. Data represents mean and standard deviation of three 
replicates. NA indicates not applicable. 








(Total particles4hr-0hr > 
2µm,number/mL) 
Mean SD Mean SD 
Glycerol 
5 % w/v 3.8  0.2 96360  475 
7.5 % w/v 20.0  0.2 41429  9753 
10 % w/v 23.0  0.5 3956  2063 
15 % w/v NA  NA 16228  1311 
Sorbitol 
5 % w/v 3.5  0.2 49199  11559 
7.5 % w/v 16.1  0.1 92553  602 
10 % w/v 18.0  0.2 83439  7221 
15 % w/v 20.8  0.1 23767  2478 
Mannitol 
 
5 % w/v 2.8  0.2 1105  1055 
7.5 % w/v 14.4  0.8 433  791 
10 % w/v 15.8  0.2 5375  2743 
15 % w/v 20.9  0.5 -702  2198 
Sucrose 
5 % w/v 2.0  0.2 -2419  127 
7.5 % w/v 3.1  0.5 -336  538 
10 % w/v 3.6  0.4 4322  533 
15 % w/v 19.9  0.3 33934  8183 
Lactose 
5 % w/v 3.3  0.3 717  117 
7.5 % w/v 13.4  0.2 15616  4412 
10 % w/v 15.5  0.2 36470  14092 
15 % w/v 18.1  0.2 14196  7817 
Aspartic acid 
 
25 mM 0.1  0.2 9017  3617 
75 mM 1.2  0.1 7718  4069 
150 mM 3.9  0.1 7927  11322 
Methionine 
25 mM -0.2  0.1 4494  3747 
75 mM 0.1  0.1 6255 6446 
150 mM 2.2  0.2 -2224 4911 
Arginine 
25 mM 0.5  0.2 -1794  602 
75 mM -0.1  0.2 -3523 1861 
150 mM -0.2  0.2 2672 4301 
Histidine 
25 mM 0.6  0.2 22812  3262 
75 mM 0.7  0.2 994 258 
150 mM 0.7  0.2 1657 2920 
EDTA 
0.05 mM -0.3  0.6 -4672  1168 
0.1 mM -0.5  0.5 8195 691 
1 mM 0.4  0.1 39368 10677 
Polysorbate 80 
0.01 % v/v -0.3  0.4 -9167 2773 
0.025 % v/v -0.7  0.0 -10018 495 
0.05 % v/v -0.4  0.3 7241 7172 
Polysorbate 20 
0.01 % v/v -0.5  0.1 15616 1794 
0.025 % v/v -0.8  0.2 -12947 5294 





Table 3.3. Comparison of final candidate formulation vs current dmLT formulation in terms of 
relative percent AB5 as measured by HIC, solution osmolality as well as physicochemical 
stability (thermal, agitation, freeze-thaw, chemical and conformational stability) properties as 
































































Tm values (DSC) 
 
50 mM sodium 
phosphate, 











8.9 +  
2.9 x 102 
72.5 + 0.2 
 















1 and 2.5 
mM H2O2 
Tm1= 50.9 +  0.2 
Tm2= 52.8 + 0.1 
Tm3= 79.3 + 0.1 















275.2 +  
11.8 x 102 
74.4 + 0.2 
 











1, 2.5 and 
5 mM 
H2O2 
Tm1= 51.3 + 0.2 
Tm2= 52.8 + 0.1 
Tm3= 79.5 + 0.1 











Figure 3.1. Primary structure analysis of dmLT. (a) Representative deconvoluted MS spectrum 
of intact mass protein spectrometry analysis of dmLT sample under nonreduced conditions and 
MW values from n = 3 measurements, (b) representative UV214 nm chromatograms from 
peptide map analysis of chymotrypsin-digested dmLT, (c) representative UV214 nm 
chromatograms from peptide map analysis of trypsin-digested dmLT with an inset showing the 
MS1 spectrum of the 2 peptide peaks which eluted at 44.4 min (948.2 m/z precursor ion) and 
45.1 min (840.2 m/z precursor ion), (d) MS2 spectrum of the 948.2 m/z precursor ion 





Figure 3.2. Protein size and heterogeneity analysis of dmLT. (a) SDS-PAGE analysis of dmLT 
under nonreducing (-DTT) and reducing conditions (+DTT), (b) SV-AUC studies of 
dmLT.Sedimentation coefficient distribution are shown from 0 to 14 svedbergs. The inset shows 
the distributions from 6 to 14 svedbergs to better visualize the aggregate peaks, (c) representative 
HIC chromatogram of dmLT sample, and (d) representative RP-UHPLC chromatogram of dmLT 











Figure 3.3. Higher order structure and overall conformational stability of dmLT in formulation 
buffer (see materials section) at pH 7.4. (A) representative second derivative FTIR spectrum of 
dmLT in the Amide I region (see supplemental Table 3.1 for individual peak assignments), (B) 
far-UV CD spectrum at 10 °C, (C) thermal melt for intrinsic Trp fluorescence peak position (10 
to 90 
o
C); the inset shows intrinsic tryptophan fluorescence spectra’s at 10 °C and 90 
o
C, (D) 
static light scattering at 295 nm (10 to 90 
o
C), (E) extrinsic ANS fluorescence peak intensity (10 
to 90 
o
C); the inset shows the extrinsic ANS fluorescence spectra at 10 and 90 
o
C. Two major 
transitions as indicated by arrows, one for A-chain (~50
o
C) and the second for B-chain (~70
o
C) 
are observed using variety of biophysical measurements. (F) Representative DSC thermogram of 
dmLT. The black line represents raw thermogram and the red line represents the curve fitted data 
to four peaks.  The Tm1, Tm2 values indicate the thermal melting transitions for the A-chain and 
Tm3, Tm4 values indicate the thermal melting transitions for the B-chain of dmLT.  Error bars 





Figure 3.4. Biophysical characterization and 3-index EPD and radar chart analysis of dmLT 
versus temperature across the pH range of 5.5-8.0 in formulation buffer. Biophysical 
measurements including (a) intrinsic Trp fluorescence, (b) static light scattering at 295 nm, and 
(c) DSC, and (d) 3-index EPDs (left panel) and radar chart (right panel) for dmLT were 
generated using the data sets obtained from intrinsic Trp fluorescence peak position, static light 
scattering at 295 nm, and DSC. The error bars have been removed from the data sets for better 





Figure 3.5. Forced deamidation and glycation studies of dmLT as a function of pH and 
temperature, respectively. (a) Intact protein MS analysis of dmLT sample after 1 week of 
incubation at 4
o
C under 3 different pH conditions (7.4, 8.0, and 9.0), (b) intact protein MS of 
dmLT at pH 7.4 after 1 week of incubation at 40
o
C, showing an increase in glycation of the B 




















Figure 3.6. Forced oxidation studies of dmLT as a function of hydrogen peroxide concentration. 
(a) Representative intact protein MS analysis of dmLT samples after incubation with different 
concentrations of H2O2, 0% and 1% v/v, respectively. (b) Representative RP-UHPLC 
chromatograms as a function of H2O2 concentration, (c) % of total area of the free B chain and 
AB5 complex peaks as a function of H2O2 concentration, (d) hydrogen peroxide effect on the 
relative oxidation percentage of 3 methionine residues in dmLT A chain, and (e) hydrogen 
peroxide effect on the relative oxidation percentage of 3 out of 4 methionine residues in dmLT B 
chain. Note that oxidation of Met101 in the dmLT B chain could not be quantified due to low 






Figure 3.7. OD350 studies of aggregation propensity (delta temperature values) of dmLT 
containing solutions after thermal stress in presence of different excipients. Average delta 
temperature value at which the OD350 value reaches 0.1 absorbance unit for dmLT (0.15 mg/mL) 
in control buffer plus excipient vs. dmLT in control buffer alone (10 mM sodium phosphate, 150 
mM NaCl, pH 6.0 with no additional excipient; highlighted box). The dmLT samples are shown 
in order of highest to lowest OD350 (indicating highest to lowest stability in terms of aggregation 
behavior). Error bars represent the standard deviation from triplicate experiments. The inset 
shows the representative OD350 thermal melt experiment of dmLT formulated in control buffer 
alone and control buffer in the presence of glycerol, mannitol and sorbitol. Excipients in green, 
yellow and red showed a large increase, moderate increase and low/no increase in stability, 
respectively. *For 15% glycerol, OD350 value did not reached 0.1 absorbance unit and hence 






Figure 3.8. MFI studies of subvisible particle formation in dmLT containing solutions after 
agitation stress as a function of excipient addition. Total increase in the sub-visible particle 
concentration (after 4 h of agitation minus time zero results from the same solution) is shown for 
each of the dmLT samples in order of decreasing particle concentration. The control (dmLT 
(0.15 mg/mL) in 10 mM sodium phosphate, 150 mM NaCl, pH 6.0 with no additional excipient) 
is indicated by black bar and is included for reference. Error bars represent the standard deviation 
from triplicate experiments. Excipients added to dmLT in control buffer in green, yellow and red 






   
 
Figure 3.9. Effect of sodium chloride concentration on dmLT physical stability profile at 0.15 
mg/mL in a base buffer containing 10 mM phosphate buffer, ±10% w/v sucrose, pH 6.0. (A) 
Thermal stress as monitored by OD350 temperature values of dmLT as a function of salt 
concentration. Average temperature value at which the OD350 value reaches 0.1 of different 
concentrations of salts is shown, and (B) agitation stress as measured by MFI in terms of total 
increase in sub-visible particle concentration (agitation for 4 h minus time zero for same 
solution) is shown for each of the dmLT samples. Error bars represent the standard deviation 















       
 
Figure 3.10. Effect of phosphate buffer concentration and pH on the thermal stability of dmLT 
at pH 6.0 and pH 7.4 in two different candidate formulations (see text for formulation 
conditions). (A) Temperature to reach 0.1 absorbance unit as measured by OD350 thermal melts 
assay with dmLT in different solutions, and (B) Tm values for dmLT in two different candidate 
formulations (pH 6.0 and pH 7.4) containing an additional 10 and 50 mM phosphate ion as 
















Figure 3.11. Effect of PS-80 concentration (0.01, 0.05 and 0.1% w/v) on freeze-thaw (0, 1 and 5 
freeze-thaw cycles) stability of dmLT compared to dmLT in the current formulation.(A) 
Absorbance at 280 nm showing protein loss with increasing freeze thaw cycles, (B) % of native 
dmLT (AB5 complex) as a function of freeze-thaw cycles as measured by HIC, and (C) radar 
plot analysis of the number and size distribution of sub-visible particles formed upon freeze-thaw 
as measured by MFI. The dmLT protein concentration was 0.4 mg/mL in the four formulations 
namely F1: 50 mM sodium phosphate, 50 mM NaCl, 10% w/v sucrose, 5 mM methionine, 
0.01% v/v PS-80 pH 7.4; F2: 50 mM sodium phosphate, 50 mM NaCl, 10% w/v sucrose, 5 mM 
methionine, 0.05% v/v PS-80 pH 7.4; F3: 50 mM sodium phosphate, 50 mM NaCl, 10% w/v 
sucrose, 5 mM methionine, 0.1% v/v PS-80 pH 7.4 and F4: 42.7 mM sodium phosphate, 10.7 
mM potassium phosphate, 82 mM NaCl, 5% lactose, pH7.4 (current formulation buffer). Error 




Supplemental Table 3.1. Assignment of secondary structure of dmLT based on the second 
derivative of the Amide I region (1700-1600 cm-1) as measured by FTIR. Data represent the 
average and standard deviation for n=3 replicates. 
Wavenumber (cm
-1
) Type of secondary structure 
1690.7 + 0.7 Beta turns 
1676.6 + 1.1 Beta sheet 
1660.6 + 0.9 Alpha helix/random coil 
1650.2 + 0.8 Alpha helix/loops/disordered 























Supplemental Table 3.2. Summary of thermal onset temperature values (Tonset1, Tonset2) and 
thermal melting Temperature values (Tm1, Tm2, Tm3, and Tm4) for the dmLT protein as 
measured by DSC.  The dmLT is at 0.4 mg/mL in formulation buffer at pH 7.4.  Values represent 















dmLT pH 7.4 
 
46.3 + 0.4 
 
73.1 + 0.2 
 
51.0 + 0.1 
 
52.7 + 0.1 
 
80.8 + 0.2 
 























Supplemental Table 3.3. Summary of thermal onset temperature values (Tonset) and thermal 
melting temperature values (Tm) for the dmLT protein (0.2 mg/mL) in the formulation buffer 
under different pH conditions (pH 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0) measured by static light 
scattering (SLS) and differential scanning calorimetry (DSC). The values represent the average 
and standard deviation of n=3 replicates.    
 












SLS 5.5 43.1 + 0.1 NA NA NA NA NA 
6.0 44.9 + 0.1 
6.5 45.3 + 0.0 
7.0 45.5 + 0.1 
7.5 46.0 + 0.0 
8.0 45.1 + 0.0 
DSC 5.5 45.2 + 0.0 67.6 + 0.1 47.1 + 0.3 50.7 + 0.0 77.6 + 0.3 80.3 + 0.5 
6.0 45.5 + 0.0 72.1 + 0.0 49.4 + 0.1 52.2 + 0.0 79.9 + 0.1 82.3 + 0.1 
6.5 45.8 + 0.1 72.5 + 0.1 50.5 + 0.4 52.7 + 0.1 80.6 + 0.1 83.1 + 0.1 
7.0 45.9 + 0.1 72.5 + 0.1 50.2 + 0.1 52.9+ 0.1 80.5 + 0.2 83.0 + 0.2 
7.5 46.7 + 0.1 73.2 + 0.1 50.8 + 0.2 52.8 + 0.1 81.1 + 0.1 83.3 + 0.1 
8.0 42.5 + 0.1 47.8 + 0.1 
*70.5 + 0.1 
*(Tonset3) 















Supplemental Table 3.4. List of pharmaceutical excipients selected for further optimization for 
formulation design of dmLT. Excipients with a (+) sign indicate the excipient added to base 
buffer (10 mM sodium phosphate, 150 mM NaCl, pH 6.0) that showed a potential stabilizing 
effect on inhibiting dmLT aggregation as measured by OD350 assay for thermal stability and as 
measured by MFI for agitation stability. The excipients highlighted in yellow in Supplemental 
Table 3.4 were chosen for further optimization based on their most effective overall stabilizing 
effect with dmLT. 
Excipient Category Excipient Thermal Stress Agitation stress 
Salts/Buffers 
Sodium acetate + + 
Sodium sulfate (salt) + + 
Sodium succinate +   
Proteins 
Human Albumin   + 
Hydrolysed Gelatin   + 
Protamine sulfate   + 
Amino acids and Miscellaneous 
Arginine   + 
Aspartic acid + + 
Glutamic acid + + 
Glycine   + 
Histidine   + 
Isoleucine   + 
Lactic acid   + 
Lysine   + 
Methionine + + 
Proline + + 
Urea   + 
Arginine + Glutamic acid   + 
Arginine + Glutamic acid + Isoleucine     
Metal ions/Chelators/Reducing 
agents 
Calcium chloride   + 
DTT   + 
EDTA   + 
Magnesium chloride   + 
Detergents 
Brij 35   + 
Poloxamer 188 (Pluronic F-68)   + 
Polysorbate 20   + 
Polysorbate 80   + 
Triton X-100     
Carbohydrates 
Lactose + + 
Sucrose + + 
Trehalose +   
Polyols 
Glycerol + + 
Mannitol + + 
Sorbitol + + 
Cyclodextrins 2-OH propyl b-CD   + 
Polymers/Osmolyte/Polyions 
Carboxymethyl cellulose   + 
Dextran sulfate   + 
Dextran 40   + 
PEG-3350   + 




Supplemental Table 3.5. A summary of the intact protein mass spectrometry analysis of dmLT 
in the candidate vs current formulation after forced glycation studies. Data represent the average 
and standard deviation for n=3 replicates. 
 





Day = 0 
 
 
A chain = 27645.6 + 0.4 
B-chain =11718.8 + 0.1 
Glycated B-chain = 12043.3 + 0.3 
 
 
A chain = 27645.5 + 0.2 
B-chain =11718.9 + 0.2 
Glycated B-chain = 12043.5 + 0.1 
 
 
Day = 7 
 
A chain = 27646.1 + 0.4 
B-chain =11719.2 + 0.1 
Glycated B-chain = 12044.0 + 0.0 
 
A chain =27646.1 + 0.2 
B-chain =11719.6 + 0.1 
Glycated B-chain = 12043.8 + 0.1 
                                12101.2 + 0.2 




















Supplemental Table 3.6. A summary of the intact protein mass spectrometry analysis of dmLT 
in the candidate vs current formulation after forced oxidation studies. Data represent the average 















Oxidized A-chain (+16 Da) 
Oxidized B-chain (+16 Da) 
Oxidized glycated B-chain (+16 Da) 
27645.6 + 0.4 
11719.2 + 0.2 




27645.3 + 0.3 
11719.0 + 0.2 







Oxidized A-chain (+16 Da) 
Oxidized B-chain (+16 Da) 
Oxidized glycated B-chain (+16 Da) 
27645.3 + 0.2 
11719.0 + 0.1 




27646.0 + 0.2 
11719.1 + 0.1 







Oxidized A-chain (+16 Da) 
Oxidized B-chain (+16 Da) 
Oxidized glycated B-chain (+16 Da) 
27645.2 + 0.3 
11719.2 + 0.2 




27646.0 + 0.3 
11719.1 + 0.1 







Oxidized A-chain (+16 Da) 
Oxidized B-chain (+16 Da) 
Oxidized glycated B-chain (+16 Da) 
27645.6 + 0.3 
11718.9 + 0.2 
12043.8 + 0.1 





12043.5 + 0.1 
27662.1 + 0.2 
11735.0+ 0.4 












Supplemental Figure 3.1. Sequence coverage from peptide map analysis of dmLT with 
either trypsin or chymotrypsin-digestion. (A) sequence coverage of dmLT A-chain, (B) sequence 







Supplemental Figure 3.2. Intact mass analysis of peaks collected during HIC and RP-
UHPLC of dmLT. (Panels A, C) Peak 1 collected from HIC and RP- UHPLC showing B-chain, 













Supplemental Figure 3.3. Biophysical characterization and three-index EPD and radar 
chart analysis of dmLT versus temperature across the pH range of 5.5-8.0 in formulation 
buffer.  Biophysical measurements include (A) intrinsic Trp fluorescence, (B) static light 
scattering at 295 nm, (C) differential scanning calorimetry, (D) three index empirical phase 
diagrams (left panel) and radar chart (right panel) for dmLT were generated using the datasets 
obtained from intrinsic Trp fluorescence peak position, static light scattering at 295 nm and 








Supplemental Figure 3.4. Effect of freeze-thaw (0, 1 and 5 freeze-thaw cycles) on stability 
of dmLT in two candidate formulations vs current formulation. (A) Absorbance at 280 nm 
showing protein loss with increasing freeze thaw cycles, (B) radar plot analysis of the number 
and size distribution of sub-visible particles formed upon freeze-thaw as measured by MFI. The 
dmLT protein concentration was 0.4 mg/mL in the three formulations namely candidate 
formulation F1- (10 mM phosphate, 50 mM NaCl, 10% w/v sucrose, 5 mM methionine, 0.01% 
v/v PS-80 pH 6.0), candidate Formulation F2- (50 mM phosphate, 50 mM NaCl, 10% w/v 
sucrose, 5 mM methionine, 0.01% v/v PS-80, pH 7.4) and Formulation F3- Current dmLT 
formulation, (42.7 mM sodium phosphate, 10.7 mM potassium phosphate, 82 mM NaCl, 5% 





Supplemental Figure 3.5. Forced glycation studies of dmLT formulated in candidate vs 
current formulations. (A and B). Representative intact protein mass spectrometry analysis of B-
chain of dmLT in current formulation sample at time zero and after incubation at 40 
o
C for 7 
days, respectively, showing an increase in glycation of the B-chain as well as formation of 
additional glycated B-chain products (+381 and +648 Da), and (C and D) representative intact 
protein mass spectrometry analysis of B-chain of dmLT in new candidate formulation at time 






Supplemental Figure 3.6. Forced oxidation studies of dmLT in candidate vs current 
formulation. A) Representative intact protein mass spectrometry analysis of dmLT in candidate 
formulation incubated for four hours at 37
o
C with 0, 1, 2.5 and 5 mM hydrogen peroxide, and B) 
representative intact mass spectrometry analysis of dmLT in the current formulation incubated 
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Chapter 4 Structural Characterization and Formulation Development of a 

























Equine encephalitis viruses (EEV), including Eastern (EEEV), Western (WEEV) and 
Venezuelan (VEEV), are mosquito-borne enveloped single-stranded RNA viruses in the 
Alphavirus genus of the Togaviridae family
1,2
. These viruses measure 60 to 70 nm in diameter. 
EEV infections can cause debilitating diseases with moderate morbidity and potentially severe 
mortality in equids and humans 
3
. EEV infections usually begin with non-specific illness, such as 
fever, chills, myalgia and abdominal pain, followed by, in severe cases, neurological signs 
indicative of encephalitis, such as confusion, seizures, coma and paralysis
4-6
. Children and the 
elderly have a higher risk for developing severe disease after EEV infection. EEEV, WEEV and 
VEEV have different geographic distributions and epidemiologic profiles. For example, EEEV 
primarily occurs in eastern Canada and United States
7,8
, with a fatality rate of approximately 30-
70%
9
. WEEV infections are mainly reported in western Canada and states west of the 
Mississippi river in the United States with an overall mortality rate of approximately 3-7%
1
. 
VEEV outbreaks have occurred in Central and South America
2
 with a mortality rate of 1-3 %. 
Due to the severity of the disease that can be caused by EEV infections and their potential 
use for bioterrorism, EEEV, WEEV and VEEV have been identified as category B priority 
pathogens by the National Institute of Allergy and Infectious Diseases
10,11
.  Currently, there are 
neither known antiviral treatments nor any commercially licensed human vaccines against EEV 
infections.  There is a live attenuated vaccine (TC-83) against VEEV for use in US military 
personnel, however, the low efficacy and potential side effects of the vaccine hinder its 
widespread use in the general population
12,13
.  The Vaccine Production Program at the Vaccine 
Research Center at NIAID/NIH has initiated a program to develop an effective virus-like particle 




prior Phase I clinical experience with a related Chikungunya virus VLP
14
 and early non-clinical 
EEV studies. Three strains of EEV, Eastern, Western and Venezuelan, are under investigation as 
components of a multivalent recombinant VLP vaccine product candidate.  
In this work, we characterized the structural integrity and physical stability of purified 
recombinant VLPs of three strains of EEV using a variety of physicochemical techniques. A 
comparison of the similarities and differences between the VLPs, both intrinsic physical 
properties and degradation profiles versus thermal and pH stress, are presented.  Furthermore, a 
series of pharmaceutical excipients were evaluated for their stabilizing effect on the thermal 
stability of these VLPs to identify stabilizers for a new bulk formulation. An optimally stable 
new bulk formulation was developed based on the results from excipient screening studies as 
well as subsequent stability assessments (storage and freeze-thaw stability). The adsorption of 
the three VLPs to aluminum salt adjuvants and the stability profile of the aluminum adjuvanted 
VLPs was also evaluated. In addition, the time dependence of the ability to desorb these VLPs 
from the adjuvant’s surface after storage was also examined. The implications of these findings 
for future development of a stable parenteral multivalent VLP vaccine formulation, both with 
and without aluminum adjuvants, are also discussed.  
4.2 Materials and Methods 
4.2.1 Materials 
Venezuelan equine encephalitis virus-like particles (VEE VLPs), eastern equine 
encephalitis virus-like particles (EEE VLPs) and western equine encephalitis virus-like particles 
(WEE VLPs) were expressed by transient transfection of HEK293 cells (VRC293) with plasmids 
encoding the viral capsid protein (C) and two envelope glycoproteins (E1 and E2) of the native 




which includes a combination of tangential flow filtration and tandem flow-through column 
chromatography. Each of the three VLPs was supplied by National Institute of Allergy and 
Infectious Diseases, (National Institutes of Health), in a 25 mM Tris buffer containing 100 mM 
sodium citrate, pH 8.5.  The VLP solutions were shipped to KU on dry ice and stored frozen at -
80
o
C upon receipt. The initial characterization of the VLPs was performed in the Tris/Citrate 
buffer described above. For the remaining studies, the VLP samples were thawed and buffer 





 dialysis cassettes (3.5 kDa MWCO, Thermo Scientific, Rockford, IL). 
All reagents and excipients for preparing different formulations were purchased from Sigma-
Aldrich (St. Louis, MO). Carbohydrates such as trehalose and sucrose were purchased from 
Pfanstiehl Inc. (Waukegan, IL). All excipients were of high purity grade (>99%). 
4.2.2 Methods 
4.2.2.1 Transmission electron microscopy (TEM) 
Ten μL of the three VLP samples were applied to a carbon grid (Ted Pella, Redding, CA) 
and left to air dry. Each preparation was fixed by adding 1 % v/v Glutaraldehyde solution 
(Sigma-Aldrich, St. Louis, MO) for two min by immersing the carbon coated side of the grid 
onto a drop of glutaraldehyde solution suspended on parafilm, which was immediately blotted 
dry using blotting paper. The grids were washed twice with ultrapure water. The VLP samples 
were then negatively stained by adding 2% uranyl acetate (Sigma-Aldrich, St. Louis, MO) for 2 
min. The morphology of the VLPs were studied using an FEI Tecnai F20 XT Transmission 
Electron Microscope equipped with a CCD camera (ThermoFisher, Waltham, MA). The particle 





4.2.2.2 Dynamic light scattering (DLS) 
DLS was performed using the dynamic light scattering mode of a ZetaPALS zetasizer 
(Brookhaven Instruments Corporation, Holtsville, NY) using quartz cuvettes that were cleaned to 
remove dust and air-dried.  Four hundred microliter of each VLP sample at 0.2 mg/mL was 
analyzed.  For each sample, ten measurements were recorded three times using an acquisition 
time of 30 sec. The z-average diameter was then calculated using the instrument software. All 
measurements were performed at ambient temperature. 
4.2.2.3 SDS-PAGE 
The VLP samples were run under both non-reducing and reducing conditions by SDS-
PAGE. The VLP samples were mixed with 4X NuPAGE-LDS sample buffer (Life Technologies, 
Grand Island, NY) to a final concentration of 1X. For reduced samples, 50 mM dithiothreitol 
(DTT) (Life Technologies, Grand Island, NY) was added. The samples were incubated at 70 
°
C 
for 5 min. Ten μg of VLP protein was analyzed by SDS-PAGE on a 4-12% Bis-Tris gradient gel 
(1.0 mm x 10 wells, #NP0321BOX) using 1X MES running buffer (Life Technologies, Grand 
Island, NY). Protein bands were visualized by staining with Coomassie blue R250 (Teknova, 
Hollister, CA) and destained with ultrapure water. 
4.2.2.4 UV-Absorbance Spectroscopy 
UV absorbance spectra were obtained using an Agilent 8453 UV-visible absorbance 
spectrophotometer (Agilent Technologies, Santa Clara, CA). Absorbance spectra were recorded 
over the wavelength range of 190-400 nm with a step size of 1 nm. All measurements were 
conducted in triplicate at room temperature using 1 cm path length cuvettes. All UV-Visible 




manufacturers data analysis software (Chemstation UV-Vis analysis software, Agilent 
Technologies). 
4.2.2.5 Far-UV Circular Dichroism Spectroscopy 
Far-UV circular dichroism (CD) spectroscopy of VLPs was performed using a Chirascan-
plus Circular Dichroism Spectrometer (Applied Photophysics Ltd, Leatherhead UK) equipped 
with a peltier temperature controller and a 6-position cuvette holder.  Quartz cuvettes (0.1 cm 
path length) sealed with a teflon stopper (Starna Cells Inc., Atascadero, CA) were used.  The 
spectra of each VLP were collected from 200-260 nm using 1 nm steps and 0.5 s sampling time 
at 10 °C. The final protein concentration of the VLP sample was 0.2 mg/mL and the 
measurements were conducted in triplicate. For, thermal melts a temperature range of 10-87.5 °C 
at 2.5 °C intervals and an equilibration time of 2 min at each temperature was used. All thermal 
measurements were performed in duplicate. Data analysis was performed using in-house 
Middaugh Suite software. The CD signal at 214 nm was extracted to detect change in secondary 
structure with increasing temperature. Baseline measurement of the buffer was performed and 
subtracted prior to data analysis.  
4.2.2.6 Intrinsic Tryptophan Fluorescence Spectroscopy 
The intrinsic tryptophan fluorescence of VLPs was measured using a Photon Technology 
International (PTI) spectrofluorometer (Lawrenceville, NJ) equipped with a turreted four-
position peltier-controlled cell holder and a xenon lamp.  An excitation wavelength of 295 nm 
was used (>95% tryptophan emission), and emission spectra at 10
o
C were collected from 305 to 
405 nm by a photomultiplier with a step size of 1 nm and an integration time of 1 s.  Thermal 
melts were performed over a temperature range of 10-87.5 °C at 2.5 °C intervals and an 




duplicate with 1 cm path length quartz cuvettes. . The data analysis was performed using the in-
house software (Middaugh Suite).  The corresponding buffer spectrum was subtracted from each 
protein spectrum prior to data analysis. The emission peak position was determined using a mean 
spectral center of mass method (MSM) executed in the Middaugh Suite. Although this 
calculation method increases the signal to noise ratio for more accurate determination of lambda 
max values, it shifts the apparent peak position by 5-10 nm from their actual values. 
4.2.2.7 Turbidity (OD350 measurements) 
Thermal stress measurements were performed using a Cary 100 UV-Visible 
spectrophotometer (Varian medical Systems, Inc., Palo Alto, California) equipped with a 12 cell 
holder with a peltier type temperature controller.  Samples contained 0.15 mg/ml protein with a 
total volume of 225 µl in 1 cm path length quartz cells.  Optical density at 350 nm (OD350) was 
monitored as the temperature was raised in increments of 1.25˚C from 10 to 90˚C with a heating 
rate of 60˚C/h.  VLP samples were run in duplicate and corresponding buffer blanks were run 
and subtracted from each sample.   
4.2.2.8 Differential Scanning Calorimetry (DSC) 
DSC thermograms for the three VLPs were collected with a Microcal VP-DSC capillary 
cell microcalorimeter (MicroCal/GE Health Sciences, Pittsburgh, PA). Thermograms were 
recorded from 10 to 100 °C at a scan rate of 1 °C/min. The concentration of VLP was 0.15 
mg/mL and the experiment was performed in triplicate. A buffer baseline was subtracted from 
each protein thermogram and the data were normalized to molar heat capacity using Microcal 
DSC software in Origin 7.0. The peaks were fitted using mathematical model fit in Origin 7.0 to 




4.2.2.9 Construction of Three Index Empirical Phase Diagram (EPD) 
For the physical stability studies, the three VLPs were dialyzed into the 20 mM phosphate, 
150 mM NaCl buffer (pH 6.5-8.5, at 0.5 pH unit increments). Dialysis was performed at 4
o
C 
using Slide A Lyser dialysis devices (ThermoScientic, Rockford, IL) with 3.5-kDa molecular 
weight cutoff with four buffer exchanges. Samples were then diluted to 0.15 mg/mL for circular 
dichroism, intrinsic tryptophan fluorescence and turbidity measurements. Data from these three 
techniques were used in the construction of the three-index EPD and radar chart using in-house 
software (Middaugh Suite).  
A detailed description of the construction of three-index EPD can be found elsewhere
15,16
. 
Briefly, the three index EPD use a specific color (red (R), green (G), blue (B)) scheme to reflect 
the characteristics of the underlying biophysical data, that define protein structural states as a 
function of solution variables like temperature and pH. For three-index EPD from this work, data 
from circular dichroism, MSM peak position and turbidity measurements were mapped to red, 
green and blue color respectively. Data sets obtained from each of above biophysical techniques 
were assigned to a color gradation from black to the full color of their technique, with minimum 
value in the dataset assigned a black color and maximum value to the full color intensity. 
However, for circular dichroism and MSM peak position color assignments were reversed where 
the maximum value was mapped to black and the least value to maximum color intensity (i.e. 
green for MSM peak position) for better visualization. Thus, a color produced by the summation 
of these RGB components produced a single color at each point in pH and temperature space, 
which was mapped to a specific structural state of the VLPs. The individual RGB components 
were also displayed in a separate panel alongside the 3-index EPDs (Figure 3) because it is 




of its RGB components helps to better understand the interpretation of a color and more 
distinctly detect changes in the structure of the protein. A k-means clustering algorithm using in-
house software (Middaugh Suite) was applied to the datasets to draw the dotted lines. 
4.2.2.10 Excipient Screening 
Intrinsic Trp fluorescence spectroscopy based thermal melt analysis was employed to 
screen for pharmaceutical excipients for their ability to enhance the conformational stability of 
each of the three VLPs. Fluorescence experiments were performed as mentioned in the 




C increments) in a 
buffer containing 10 mM sodium phosphate and 100 mM NaCl, pH 7.5. The VLP concentration 
used in this study was 0.1 mg/ml. Twenty-six (26) excipients (listed in Figure 4) were examined 
for their ability to shift the unfolding onset temperature (Tonset) and the midpoint of the unfolding 
transition temperature (Tm) of VEEV VLPs to higher temperatures. Seven different categories of 
excipients were screened including carbohydrates, polyols, amino acids/carboxylic acids, metal 
chelators, non-ionic surfactants, cyclodextrins and polymers/polyions. To determine Tm values, 
the first derivative spectra of Trp peak position versus temperature plots were calculated and the 
peak temperature of this derivative spectrum was considered to be the Tm.  
4.2.2.11 Freeze-thaw studies 
The VLPs were dialyzed against 10 mM sodium phosphate, 50 mM NaCl, pH 7.5 in 
Slide-A-Lyzer Dialysis Cassettes (Product #66110, Thermo Scientific, Rockford, IL) with a 
3,500 Da molecular weight cutoff overnight at 4°C with three buffer exchanges at 3h intervals, 
and an overnight incubation before dialysate recovery. Excipients were prepared as concentrated 
stock solutions in indicated base buffer (10 mM NaPO4, 50 mM NaCl, pH 7.5). Each of the 




indicated in text. Then, 1.1 mL of VLP at 0.15 mg/mL was filled in 3 mL Fiolax clear, Schott 




C for 24 h. The vials were thawed at room 
temperature for ~20 min for complete thawing. Samples were then frozen again at -20 and -80
o
C 
and the freeze-thaw (F/T) cycles were repeated 5X. Samples were analyzed at 0, 1 and 5 F/T 
cycles using UV absorption spectroscopy, dynamic light scattering and differential scanning 
calorimetry (DSC) as described in supplemental methods section. 
4.2.2.12 Accelerated and Real-Time Stability 
All three VLPs were prepared in a similar manner as described above in the freeze-thaw 
method and the six formulations (as indicated in text) were incubated at 4, 25, 40, -20 and -80
o
C 
for 28 days. On days 0, 14 and 28, the samples were analyzed by dynamic light scattering and 
the z-average diameter was determined. All measurements were performed in triplicate. 
4.2.2.13 Adsorption studies of EEV VLPs with aluminum salt adjuvants 
The three VLPs were first tested separately to determine whether they adsorb 
preferentially to aluminum hydroxide (Alhydrogel®) or aluminum phosphate (Adjuphos®). Fifty 





the original sample buffer (25 mM Tris, 100 mM sodium citrate, pH 8.5) for 30 min at 4 
o
C and 
then centrifuged @ 2,100 rcf for 10 min. The amount of unadsorbed protein was determined by 
measuring the amount of free protein in the supernatant using UV absorbance spectroscopy after 
centrifugation. An adsorption isotherm for each of the three VLPs and their 1:1:1 mixture in both 
the base buffer (10 mM NaPO4, 50 mM NaCl, pH 7.8) and the formulation buffer (10 mM 
NaPO4, 50 mM NaCl, 5% sucrose, 5% sorbitol, 0.05% Pluronic F-68, pH 7.8) was constructed 
by mixing varying amounts of VLPs (0-240 µg) with 50 µg Alhydrogel® and the total volume 
was adjusted to 0.5 mL. Samples were incubated at 4
o




before being centrifuged (Thermo scientific- Sorvall legend micro 17R centrifuge) at 2,100 rcf 
for 10 min at 4
o
C. Supernatant (300 µl) was then removed and examined by UV spectroscopy. 
The absorbance at 280 nm (light scattering corrected) was used to determine the amount of 
unbound VLPs in the supernatant. A graph (binding isotherm) of the amount of VLPs bound (y-
axis) against the total amount of VLPs added (x-axis) was plotted. 
4.2.2.14 Desorption studies of EEV VLPs from aluminum adjuvant 
To prepare Alhydrogel
®
-adsorbed VLPs, 40 µL of stock Alhydrogel
®
 (10 mg/ml) was 
incubated with VLP samples (760 µl, in the formulation buffer) at 4
o
C for 1 h on an 
inverting/tumbling shaker, in a total volume of 800 µL. The final concentration of the VLPs and 
Alhydrogel
®
 in the mixture was 120 and 500 µg/mL, respectively. The mixture was then 
centrifuged at 2,100 rcf for 10 min at 4
o
C to separate unbound VLPs from Alhydrogel
®
-adsorbed 
VLPs. After removing the supernatant (720 µl) of each sample, the pellets (Alhydrogel
®
-
adsorbed VLPs) were then resuspended in 500 µl desorption media and incubated at 4
o
C or room 
temperature for different time points (0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h) on an inverting/tumbling 
shaker.  Samples were then centrifuged (Thermo scientific- Sorvall legend micro 17R centrifuge) 
at 2,100 rcf for 10 min to separate Alhydrogel
®
 from the solution. After centrifugation, the A280 
value (light scattering corrected absorption at 280 nm) of the supernatant was determined by UV 
spectroscopy to calculate the amount of VLPs desorbed from Alhydrogel
®
. 
The time dependence of susceptibility to desorption was also examined since the 
reversibility of this process often decreases with time
17,18
. Three desorption time durations (0.5, 
4, and 24 h) were further selected to determine the effect of longer storage times on the VLP-
adjuvant desorption process and strength of binding. The EEE VLPs were adsorbed on the 
surface of Alhydrogel
®
 and stored for a period of 8 weeks at 4
o




removed from incubation/storage at various time points (0 day, 1 day, 3 days, 1, 2 , 4 , 6 , and 8 
wk) to study desorption by 500 mM sodium phosphate, pH 7.8 (selected as the desorption 
medium). The amount of desorbed VLP was measured using UV spectroscopy (A280) with light 
scattering correction applied. The amount of desorbed VLPs was compared to control samples to 
calculate the percent removed from the surface of the adjuvant after a set duration (0.5, 4, and 24 
h) of desorption. 
4.3 Results 
4.3.1 Size Analysis of EEE, WEE and VEE virus-like particles 
As part of initial characterization, the size and morphology of the three VLPs (EEE, WEE 
and VEE) were studied using TEM analysis. As seen in Figures 4.1A, 4.1B and 4.1C, each of the 
three VLPs are enveloped, mostly spherical in shape with diameters ranging from 64-74 nm. 
These results are in good agreement with the hydrodynamic diameter values obtained by 
dynamic light scattering, DLS (Dh, 67-72 nm) as well as with the previously reported sizes
2,19,20
 
of the three equine encephalitis viruses (Figure 4.1D). In addition, the polydispersity values of 
each of the three VLP samples as measured by DLS varied between 3-7 % indicating that these 
VLP preparations were relatively homogenous. 
4.3.2 Protein purity and overall higher order structure (HOS) of EEE, WEE and VEE 
virus-like particles 
A combination of SDS-PAGE, UV-Visible absorption, circular dichroism and intrinsic 
tryptophan fluorescence spectroscopy were used to evaluate the purity and overall higher order 
structure of the proteins contained in the VLPs (formulated in a Tris-citrate, pH 8.0 buffer; see 
Materials). The three VLPs showed two or three protein bands as observed using SDS-PAGE 




49 kDa markers correspond to the E1 and E2 envelope proteins (theoretical MW:  47 kDa) while 
the protein band at ~29 kDa corresponds to the capsid protein (theoretical MW: 29 kDa). A 
separation of the E1 and E2 protein bands were apparent for EEE VLP, while for WEE and VEE 
VLPs, one band was primarily observed for the two envelope proteins, probably due to a 
similarity in MW between the E1 and E2 proteins. Overall protein purity levels (bands 
corresponding to VLP proteins) was estimated to be >99 % by SDS-PAGE.  
UV absorbance spectra were utilized to provide an indication of the nucleic acid and protein 
content of these VLP solutions. Each of the three VLPs showed a peak maximum of 265 nm 
(after light scattering correction) as shown in Figure 4.2B. Since the UV absorbance spectra of 
pure protein species have a peak at 280 nm, while those of pure nucleic acids are present at 260 
nm
21
, the observed peak maximum indicates the presence of both proteins and nucleic acids in 
these VLP samples. Viruses with internalized nucleic acids have been shown by Zlotnick et al 
22
 
to have similar UV absorbance spectra. In addition, since a pure protein (~100 %) displays a 
A260/A280 ratio of 0.57 while a mixture of 90% protein and 10 % nucleic acid has an A260/A280 
ratio of 1.32
23,24
, the observed A260/280 ratios of 1.25-1.40 (Figure 4.2) indicate each of the three 
VLP samples  contain ~10 % nucleic acids (see Discussion). 
Circular dichroism (CD) was used to monitor the overall secondary structure of the proteins 
contained in each of the three VLPs.  At 10
o
C, CD spectra in the far UV region (200-260 nm) 
showed a broad minimum between 209-220 nm suggesting a mixture of alpha and beta-sheet 
secondary structures (Figure 4.2C). Intrinsic Trp fluorescence spectroscopy was performed to 
evaluate the overall tertiary structure of the proteins within the VLPs (at 10
o
C). The fluorescence 
emission spectra (Figure 4.2D) showed the wavelength of maximum intensity (λmax) at 332 nm at 
10
o




VEE VLP indicated that the average Trp amino acid residues in proteins in this VLP were in a 
relatively more hydrophobic environment compared to the Trp residues within the proteins 
contained in the EEE and WEE VLPs. 
4.3.3 Physical stability profile of EEE, WEE and VEE VLPs as a function of pH and 
temperature 
The physical stability profile of the three VLPs with respect to secondary and tertiary 
structural integrity as well as aggregation propensity was evaluated using circular dichroism, 
intrinsic tryptophan fluorescence, and turbidity (OD350 as a function of temperature) analysis, 
respectively in 20 mM sodium phosphate, 150 mM NaCl buffer under a wide range of pH 
conditions (pH 6.5 to 8.5) and temperature (10 to 87.5 
o
C) (Supplemental Figure 4.1 A, B and 
C). The pH and temperature stability profile of the overall secondary structure of the proteins of 
the three VLPs were monitored using CD signals at 214 nm plotted as a function of temperature 
in the pH range of 6.5-8.5 (Supplemental Figure 4.1 A) and the corresponding Tonset values of the 
thermal transitions are summarized in Supplemental Table 4.1. The pH and temperature stability 
profile of the overall tertiary structure of the proteins of the three VLPs were monitored using 
intrinsic Trp fluorescence peak position, (Supplemental Figure 4.1B) versus temperature for each 
of the pH conditions evaluated and the corresponding Tonset values of the thermal transitions are 
summarized in Supplemental Table S1. 
To assess the effect of solution pH on the stability of the overall secondary structure of the 
proteins contained in each of the three VLPs, the CD signal intensity at 214 nm as a function of 
solution pH (6.5-8.5) and temperature (10 to 87.5 
o
C) was evaluated (Supplemental Figure 4.1A).  
For EEE VLPs, the CD signal intensity remained consistent up to ~50 
o
C at pH 6.5, after which a 




alterations in the secondary structure of EEE VLPs. As shown in Supplemental Table S1, the 
onset temperatures (Tonset) of the transitions in CD signals were largely pH dependent with 
values steadily increasing with pH from 6.5 to 7.5, remaining consistent through 8.5. For the 
WEE VLPs, the Tonset values of the main transition occurred around 52 
o
C at pH 6.5, with values 
of ~55 
o
C at the other pH conditions. Overall, the secondary structure of WEE VLPs appeared to 
be more stable at higher pH values (≥ 7.0) and less stable at lower pH value (pH 6.5). For VEE 
VLP, under all tested pH conditions, the CD signal at 214 nm did not change substantially as 
temperature was increased, indicating no major change in secondary structure with increases in 
temperature. The lack of a distinct thermal transition prevented accurate calculation of Tonset 
values. 
To assess the effect of solution pH on the stability of the overall tertiary structure of the 
proteins contained in each of the three VLPs, the fluorescence wavelength maximum values as a 
function of solution (pH 6.5 to 8.5) and temperature (10 to 87.5 
o
C) was evaluated (Supplemental 
Figure 4.1B).  An increase in Trp fluorescence peak position, (i.e. a red shift was observed with 
increasing temperature for each of the pH conditions) was seen for all VLP samples, probably 
reflecting changes in the tertiary structure of the VLPs. For EEE VLPs, peak positions remained 
largely unchanged up to ~40 ºC, with a dramatic alteration occurring at ~40 ºC to 49 ºC, with 
onset temperature values increasing as the pH increased from 6.5 to 8.5.  The maximum peak 
position values of WEE VLPs showed apparent transitions at ~30 
o
C, with the main transition at 
45 
o
C (pH 6.5), 47 
o
C (pH 7.0 through 8.0), and 48 
o
C (pH 8.5). For VEE VLPs at each of pH 
conditions examined, peak positions slowly red shifted as the temperature increased from 10 to 




major perturbation in tertiary structure. Thus, the overall tertiary structure of the proteins in the 
three VLPs appeared to be less stable at pH 6.5 and more stable between pH values 7.0-8.5.   
Finally, the aggregation propensity of these VLPs was examined by measuring changes in 
turbidity (O.D. at 350 nm) as a function of temperature and pH (Supplemental Figure 4.1C) and 
the corresponding Tonset values of the thermal transitions are summarized in Supplemental Table 





lower pH values resulting in lower Tonset values. The WEE VLPs showed similar trends at pH 6.5 
showing turbidity at ~48 
o
C, pH 7.0 around 50 
o
C, and the higher pH conditions around ~53
o
C. 
The VEE VLPs showed minimal aggregation from pH 7.5-8.5. Interestingly, pH 6.5 condition 
showed the highest change in O.D. with a Tonset of ~53
o
C, while at pH 7.0, VEE VLPs had a 
slightly higher Tonset at ~54
o
C, but displayed markedly lower overall change in the O.D. signal 
indicating less turbidity. Hence, all three VLPs appeared to be colloidally most stable between 
pH values 7.0-8.5 and less stable at low pH. 
The biophysical stability results were summarized using a three index empirical phase 
diagram data visualization tool described previously
25,26
. For EEE, WEE and VEE VLPs, (as 
seen in Figure 4.3A, 4.3B and 4.3C, respectively), the three-index EPDs revealed three distinct 
regions. The first region (I) or the native region represented by the yellowish-green colors 
demonstrated most stable regions for the VLPs with characteristics similar to native like 
structures as seen by the presence of red and green colors in CD and fluorescence panels 
respectively, and absence of color (black) in turbidity panels. For EEE and WEE VLPs (Figure 
4.3 A and B, respectively), this region covers the range of pH 6.5 to 8.5 and temperatures from 
10 to ~50 
o
C. Similarly, for VEE VLPs (Figure 4.3 C), the first region covers the range of pH 6.5 




conformational stability than EEE and WEE VLPs across all the pH conditions (especially at 
higher pH). The second region (II) is denoted by the orange-red colors and represents 
conformationally altered states of the VLPs as observed by black regions in the fluorescence 
panels. However, the secondary structure is observed to remain unchanged in this region as seen 
by the presence of red color in the CD panels. For EEE and WEE (Figure 4.3 A and B, 
respectively) this region lies from ~50 
o
C to ~60 
o
C, but for VEE (Figure 4.3 C) it is more wide 
spread. For all of the VLPs, this region II suggests the presence of molten globule like states 
indicating loss of tertiary structure but intact secondary structure. Finally, the bluish-pink 
regions, which represents conformationally altered and aggregated states of the VLPs, defines 
the third region (III). The VLPs in this region manifest changes in intrinsic Trp fluorescence and 
CD ellipticity (seen by presence of black regions in their individual panels) along with a 
significant contribution from turbidity data (blue colored regions). This third region is 
representative of aggregated states occupying the pH ranges above 60
o
C. At these elevated 
temperatures, EEE and WEE (Figure 4.3 A and B, respectively) were prone to aggregation over 
all tested pH conditions, as indicated by the presence of bluish colors from turbidity 
measurements. However, VEE appeared to be prone to aggregation only at pH 6.5 (Figure 4.3 
C). Hence, overall, the EPDs indicated that although VEE showed lesser propensity to aggregate 
in the conformationally altered states, it had lower thermal conformational stability compared to 
EEE and WEE VLPs. We emphasize, however, that these EPDs do not reflect thermodynamic 
behavior. Furthermore, they are a result of effects of multiple proteins and as such are only 




4.3.4 Screening of pharmaceutical excipients to improve physical stability of VLPs in 
solution 
To screen excipients for their ability to enhance the thermal stability of the three VLPs, 
intrinsic tryptophan fluorescence spectroscopy vs temperature melt analysis was employed. 
Initial evaluation of this method was conducted using the least thermally stable VLP (VEE 
VLPs; see above). A base buffer containing 10 mM sodium phosphate and 100 mM NaCl, pH 
7.5, was chosen for the excipient screening studies since this solution pH resulted in optimal 
VLP physical stability (see above). Seven categories of pharmaceutical excipients including 
carbohydrates, polyols, amino acids/carboxylic acids, metal chelators, non-ionic surfactants, 
cyclodextrins and polymers/polyions were examined for their effect on the transition onset 
temperature (Tonset) and the midpoint of the unfolding transition temperature (Tm) of VEE VLPs.  
Figure 4.4 shows the average Tonset and Tm values of VEE VLPs in presence of 
different excipients. The delta values represent the difference between VEE VLPs formulated in 
10 mM sodium phosphate, 100 mM NaCl, pH 7.5 with added excipient minus the VEE VLPs 
formulated in same buffer without additive (control), and values are sorted from highest to 
lowest, indicating highest to lowest stability of VEE VLPs (Figure 4.4). The inset graph shows a 
representative plot of the effect of a selected stabilizer (sorbitol) and a destabilizer (alpha-
cyclodextrin) on the thermal stability of the VEE VLP. It can be seen that 18 out of the 26 tested 
excipients shifted Tonset values to higher temperature, with the increase ranging from 1.5 °C to 14 
°C. Six of these 18 excipients were not further evaluated as stabilizers due to a minimal influence 
on Tm values given experimental error.  The top performing stabilizers identified in this initial 
screen included sorbitol, trehalose, mannitol, sucrose, pluronic F-68, glycine and 2-






well as increasing Tm values up to ~4°C. Similar stabilizing effects with these lead stabilizers 
were also observed for both EEE and WEE VLPs as summarized in Supplemental Table 4.2. 
 Based on the above results, different concentrations of the top performing stabilizers 
(from four different excipient categories including sugars, amino acids, cyclodextrins and 
detergents) were then evaluated to explore the concentration dependence of their stabilizing 
effect on VEE VLPs using thermal stress (Table 4.1).  Higher concentrations of sugars (sorbitol, 
trehalose and sucrose) and detergent (pluronic F-68) resulted in an improved VEE VLP thermal 
stability profile as seen by increased  Tonset values from the intrinsic Trp fluorescence thermal 
melt results. Glycine and 2-(hydroxypropyl)-γ-cyclodextrin showed a slight increase in delta 
Tonset values compared to sugars and pluronic F-68. The shift in Tm values due to concentration 
effects of these excipients was less apparent, increasing the values by ~1 to 4 
o
C for most of the 
stabilizing excipients. Similarly, higher concentrations of sugars and pluronic F-68 increased the 
 Tonset values of WEE and EEE VLPs as summarized in Supplemental Table 4.3.  
As a final set of experiments, different concentrations of sodium chloride (25, 50, 75 and 
100 mM) were tested to explore the salt concentration-dependence of its stabilizing effect on 
VEE VLP. No major differences were observed across the different sodium chloride 
concentrations on the thermal stability of VEE VLP (data not shown), permitting the use of 
lower sodium chloride concentrations to achieve lower solution tonicity in the presence of other 
excipients. However, sodium chloride was observed to be essential to maintain the solubility of 
VEE VLPs in solution during dialysis into various solutions (data not shown). Therefore, for 
subsequent formulation development experiments described below, a balance between sufficient 
VEE VLP solubility and total solution osmolality values was required (because high solution 




lowered from 100 to 50 mM resulting in selection of a base buffer (10 mM sodium phosphate, 50 
mM NaCl, pH 7.5) for further optimization of VEE VLP physical stability in combination with 
other promising excipients such as sorbitol, sucrose and pluronic F-68 as described below.  
4.3.5 Optimization of lead stabilizers to design candidate bulk formulations 
Various concentrations and combinations of three best performing excipients (sorbitol, 
sucrose, pluronic F-68) in the presence of 10 mM sodium phosphate and 50 mM NaCl, pH 7.5, 
were tested to identify any additive or synergistic effects on VEE VLP stability as well as on 
total solution osmolality values. As shown in Table 4.2, tested excipients as well as their 
combinations resulted in an increase in thermal stability of VEE VLP. There was no major 
difference in the extent of stabilization (Tonset and Tm values) between 5 and 10 % of sugars/sugar 
alcohols. Lower concentrations of sucrose and sorbitol, however, resulted in solutions with low 
osmolality values. Similarly, all of the tested excipients and their combinations had a stabilizing 
effect on the thermal stability of EEE and WEE VLPs (see Supplemental Table 4.4). Based on 
the osmolality consideration, lower concentrations of sugars and their combinations with 
pluronic F-68 were further evaluated for their stabilizing effect on freeze-thaw and accelerated 
stability studies.  
4.3.6 Freeze-thaw and accelerated stability studies of three VLPs in candidate bulk 
formulations 
Based on the results described above, six candidate bulk formulations were selected for the 
three VLPs, and their effect on freeze-thaw and accelerated storage stability conditions were 
evaluated (since the bulk may be stored frozen long term and then thawed for use in the drug 
product). The candidate formulations included: (F1) 10 mM sodium phosphate, 50 mM NaCl, pH 




(F4) control buffer +  7.5 % sorbitol, 0.05% pluronic F-68;  (F5) control buffer + 5% sorbitol, 
5% sucrose; and (F6) control buffer +  5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68.  Each of 
the three VLPs were formulated in the six-candidate bulk formulations, and were first evaluated 
for freeze-thaw stability.  
The effect of multiple freeze-thaw (F/T) cycles (0, 1 and 5 cycles) on the physical stability 
of the three VLPs in these six candidate liquid formulations at -20 and -80
o
C was evaluated using 
UV-Visible spectroscopy to monitor VLP (protein) concentration, dynamic light scattering to 
monitor particle size and differential scanning calorimetry to assess the overall conformational 
stability of the VLPs.  As shown in Figure 5 for the VEE VLPs, there was a substantial loss of 
protein concentration (Figure 4.5A) after 5 FT cycles at -20
o
C as well as an increase in the size 
of VEE VLP as measured by DLS (Figure 4.5B) across all the candidate bulk formulations. In 
addition, DSC data also showed that VEE VLPs were conformationally destabilized upon freeze 
thaw stress at -20
o
C in all of the candidate formulations (Figure 4.5C). Similar results were 
observed for EEE and WEE VLPs during freeze thaw stress at -20
o
C (see Supplemental Figures 
S2 and S4).   
The freeze-thaw physical stability of the VEE VLPs was also evaluated at -80
o
C. As seen in 
Figure 4.6A, VEE VLP formulated in the F6 formulation did not show detectable protein loss 
following five freeze-thaw cycles as measured by A280 using UV-Vis spectroscopy compared to 
other candidate formulations F1-F5. The DLS analysis (Figure 4.6B) showed no major changes 
in the hydrodynamic diameter of VEE VLP in formulations F5 and F6 compared to formulations 
F1-F4.  Lastly, DSC analysis also did not detect any major conformational changes in VEE 
VLPs formulated in F5 and F6 compared to formulations F1-F4. Overall, F6 was the most stable 
formulation for VEE VLPs to protect against freeze-thaw stress at -80
o




WEE VLPs formulated in F6 had the best overall freeze-thaw stability profile at -80
o
C compared 
to formulations F1 to F5 (Supplemental Figure 4.3 and 4.5). 
We employed accelerated stability studies to compare the different candidate bulk 
formulations. Each of the three VLPs, each of the three VLPs was formulated in the six 
candidate bulk formulations and stored at 4, 25, 40, -20 and -80
o
C for 28 days, and the particle 
size (hydrodynamic diameter) of the VLPs was monitored by DLS. As shown in Figure 4.6 for 
VEE VLPs, the F6 formulation did not show any increase in VLP particle size while the other 
formulations showed an increase in size of VEE VLP to varying extents at 4, 25, 40 and -80
o
 C 
after 28 days. VEE VLPs in all of the formulations (including F6) stored at -20
o
C were unstable 
and showed a substantial increase in the particle size of VEE VLP. Both EEE and WEE VLPs 
showed similar trends of increases in the size of particles across all formulations at -20
o
C. The 
F6 formulation appeared to be the most stable for all three of the VLPs across the 4, 25, 40 and -
80
o
C storage conditions (see Supplemental Figures 4.6 and 4.7). 
4.3.7 Drug product formulation development-Aluminum adjuvant interaction and 
stability studies with the three VLPs 
In preliminary experiments, the individual binding of EEE, WEE and VEE VLPs to two 
different aluminum salt adjuvants, Alhydrogel® and AdjuPhos®, were first studied in the 
original formulation buffer (25 mM Tris, 100 mM sodium citrate, pH 8.5 used prior to initiation 
of this work) to select between the two adjuvants (see Methods). As seen in Figure 4.8A, all 
three VLPs were found to nearly completely bind to Alhydrogel® (98-100 %). EEE bound to 
both Alhydrogel® and AdjuPhos® equally well while only 24% WEE and 37 % VEE were 
bound to AdjuPhos®. Based on these results, Alhydrogel® was selected for subsequent adjuvant 




The final drug product vaccine is targeted to contain the three EEV VLPs, aluminum 
adjuvant, and a stable formulation buffer.  The adsorptive capacity (maximum amount of VLP 
that can be adsorbed to a given amount of adjuvant matrix) of EEV VLPs to Alhydrogel
®
 was 
determined by constructing binding isotherms of the three EEV VLPs (0-240 µg) with 50 µg of 
Alhydrogel® adjuvant in total volume of 0.5 mL each of  base buffer (10 mM sodium phosphate, 
50 mM NaCl, pH 7.8) and the lead candidate formulation buffer F6 (10 mM sodium phosphate, 
50 mM NaCl, 5% sucrose, 5% sorbitol, 0.05% Pluronic F-68, pH 7.8; the pH of this buffer was 
adjusted from pH 7.5 to pH 7.8 based on results from a separate short term stability study, data 
not shown). As shown in Figures 4.8B and 4.8C, the adsorptive capacity of the EEE and WEE 
VLPs to 50 µg Alhydrogel
®
 in the base buffer was similar (~140 µg), while the VEE VLPs had 
lower adsorptive capacity (~100 µg). Interestingly, in the new formulation buffer, EEE VLPs had 
the highest levels of maximum adsorption (~130 µg) to 50 µg Alhydrogel
®
, followed by WEE 
VLPs (~110 µg) and VEE VLPs (~ 95 µg). Next, with a goal to develop a trivalent adjuvanted 
vaccine containing all three VLPs, a 1:1:1 mixture of varying amounts of EEE, WEE and VEE 
(0-240 µg) with 50 µg of Alhydrogel® was incubated in total volume of 0.5 mL with both base 
buffer and the new formulation to generate a binding isotherm. The adsorptive capacity of the 
trivalent mixture was very similar in both the base and lead candidate formulation buffers (~100 
µg bound to 50 µg of Alhydrogel®; data not shown). 
The conformational stability of Alhydrogel
®
-adsorbed VLPs in either the base buffer or the 
lead candidate formulation buffer was evaluated using intrinsic tryptophan fluorescence 
spectroscopy as a function of temperature. The fluorescence thermal melts (peak position versus 
temperature graphs) are shown in Supplemental Figure 4.8, and the corresponding Tonset and Tm 




Figure 4.8F, respectively. At lower temperatures, the peak positions (lambda max) for the VLP 
samples with adjuvant were observed to be slightly red shifted (~2 nm) compared to the 
corresponding VLP samples with no adjuvant. This slight increase in the MSM peak position 
presumably signifies a subtle structural alteration in the VLP proteins when adsorbed on the 
surface of the adjuvant. The thermal onset (Tonset) and melting (Tm) temperatures for the VLPs 
were then determined from the thermal melting curves.  Adsorption of the VLPs to the aluminum 
adjuvant reduced their thermal stability (Tonset, ~2-3
o
C and Tm, ~1-3
o
C) in both the base buffer 
and candidate formulation buffer. The formulation buffer, however, increased the thermal 
stability (Tonset) of the non-adjuvanted individual VLPs and their 1:1:1 mixture compared to the 
VLPs in the base buffer.  This effect was not observed, however, when comparing the Tm values 
(see Figures 4.8E and 4.8F). 
The ability to desorb each of the aluminum adjuvant adsorbed VLPs was examined in the 
presence of various additives listed in Supplemental Figure 4.9A. Additionally, the effect of 
increased incubation time and temperature on desorption process of the 1:1:1 mixture of the 
VLPs was examined under various conditions (Supplemental Figure 4.9B). The most effective 
solution for desorbing the VLPs was 0.5 M sodium phosphate (pH 7.8), with ~90 and 100% 
desorption being observed after 3 h and 16 h incubation at room temperature (RT), respectively. 
For conditions that were tested at both 4°C and RT, no major differences in VLP desorption from 
the adjuvant were observed between these two temperatures. Next, desorption of each individual 
VLP, and a 1:1:1 mixture of the three VLPs in 0.5 M sodium phosphate (pH 7.8) was evaluated 
(Supplemental Figure 4.9C), and nearly 100% desorption of the VLP samples was observed 
demonstrating that 0.5 M sodium phosphate pH 7.8 was effective at removing the adsorbed 






The concentration dependence of sodium phosphate mediated desorption of VLPs from 
Alhydrogel
® 
was investigated for each individual VLP and the mixture of the three VLPs to 
examine the strength of interaction between the antigens and adjuvant. No VLP desorption was 
observed when the concentration of sodium phosphate was below 20 mM as shown in Figure 
4.9A.  However, WEE, VEE and EEE VLPs displayed significant desorption starting at 50, 100 
and 200 mM sodium phosphate, respectively, indicating the weakest, intermediate and highest 
strength of adsorption to Alhydrogel
®
, respectively. Additionally, the time dependence (kinetics) 
of VLP desorption from adjuvant in the presence of 0.5 M sodium phosphate showed desorption 
values of ~70% at 0 h, which followed an increase to 90% at ~1 h, followed by a leveling off at 
~98-99% after 24 h (Figure 4.9B).  
Finally, three time durations (0.5, 4, and 24 h) for desorption in 0.5 M sodium phosphate 
were selected to examine the effect of storing the VLP-adjuvant samples for over 8 weeks at 4
o
C 
to evaluate if there is a storage time dependence of susceptibility towards desorption of VLPs 
from the aluminum adjuvant. As shown in Figure 4.9 C, D, E and F, in general, the percentage 
desorption of EEE, WEE and VEE VLPs and the trivalent mixture, respectively, decreased over 
8 weeks. For example, for the mixture of three VLPs, about 95% and 56% desorption was 
observed at zero day and 0.5 h storage time, respectively.  However, there appeared to be a 
general trend of continuing decreasing VLP desorption from the aluminum adjuvant with an 
increase in the storage time (up to 8 weeks) for the VLP-adjuvant samples.  
4.4 Discussion 
Virus-like particle (VLP) based vaccines consist of highly ordered repetitive structures that 
form spontaneously upon recombinant expression of one or more structural viral proteins
27
. 




viral genetic information potentially yielding safer vaccine candidates
28,29
. During 
pharmaceutical development of VLP based vaccine candidates, an extensive analytical 
characterization toolset is used to study the complex nature of these vaccines to ensure that the 
native conformation of the protein epitopes is maintained during manufacturing, storage and 
administration. Additionally, stability indicating analytical methods are also required to elucidate 
molecular mechanisms of vaccine degradation, to monitor the accelerated and long term stability, 
and to design new formulations by screening different conditions and additives. Furthermore, 
analytics serve as the foundation for comparability assessments to monitor critical quality 
attributes (CQA’s) of vaccines during both product and process related changes such as changes 
in cell lines, scale-up of the bulk process or changing a lyophilized to a liquid dosage form
30-32
.  
The particle size range of the VLPs was relatively homogeneous and closely resembled the 
native viruses as measured by TEM and DLS. The morphology and composition of the three 
VLPs were spherical (~70 nm in diameter), comprised of capsid, E1 and E2 proteins as 
determined by TEM and SDS-PAGE analysis. The VLPs also contained some residual nucleic 
acid (presumably host-cell DNA and/or RNA) impurity, as suggested by the high A260/A280 ratio 
measured by UV-Visible spectroscopy and confirmed by nucleic acid quantitation (data not 
shown). In comparison, there are currently two licensed recombinant VLP based vaccines, one 
against human papillomavirus (HPV) and another against hepatitis B virus (HBV). Each contains 
only a single viral surface protein (L1 and HBsAg, respectively) and are expressed in yeast. HPV 
VLPs are predominantly spherical or ellipsoidal in shape, lack a lipid envelope and are ~50-60 
nm in diameter
33-35
 while HBV VLPs are also spherical, contain a lipid envelope derived from 






It is critical to monitor both the higher order structure (HOS) and concomitant stability of 
vaccine antigens to ensure that the vaccine can be reproducibly manufactured, retains critical 
quality attributes during any process changes (comparability) and remains stable during storage.  
Understanding the changes in the structural integrity of the antigen as a function of stress (pH, 
temperature, ionic strength) helps in outlining the physical stability parameters along with 
development of a stable formulation. In this work, the physical stability profiles of the three 
VLPs were evaluated using different spectroscopic techniques to monitor their secondary 
structure, tertiary structure and aggregation propensity. Although the nucleic acid dominates the 
UV absorption spectra of the VLPs, the lack of fluorescence of DNA permits isolated analysis of 
the protein components by fluorescence spectroscopy. The DNA is most-likely encapsulated 
within the particles; therefore aggregation events are expected to be primarily driven by the 
external protein shell. Therefore, we discuss the VLPs behavior in terms of protein although we 
cannot exclude contributions by the nucleic acids. Additionally, these biophysical techniques 
coupled with three index empirical phase diagrams were used to evaluate the higher order 
structure (HOS) and stability of each of the VLPs over a wide range of pH and temperature. The 
utility of such data visualization approaches for a better understanding of the physical stability 
profiles of variety of proteins and vaccines (for formulation development and comparability 
assessments) has been widely demonstrated in previous work
38-42
. Here, the comparison of 
stability profiles of the three VLPs using the 3-index EPD approach helped in detecting 
differences in the HOS and physical stability of the VLPs under stress conditions. Overall, the 
EPD (see Figure 3) showed that all of the VLPs were more stable at basic pH 7.5-8.5 compared 




between the secondary and tertiary structures and aggregation propensities of the three variants 
which suggested the VEE VLP may be the least physically stable of the three VLPs. 
In addition to identifying an solution pH for optimal VLP stability, this work examined 
various classes of pharmaceutical excipients for their ability to enhance the thermal and freeze-
thaw stability of the three EEV VLPs. Sucrose, sorbitol and pluronic F-68 were identified as 
candidate stabilizers and their combination increased the thermal and freeze-thaw stability of 
each of the VLP. Sugars such as sucrose and sorbitol are known to act via preferential exclusion 
mechanism and stabilize proteins and vaccines against thermal and freezing stress.
43-46
 Pluronic® 
copolymers, a class of non-ionic detergents is known to prevent agitation and freezing induced 
aggregation for a number of proteins by outcompeting protein molecules at air-water interfaces 
and preventing freezing induced structural perturbations leading to aggregation.
47,48
 A total of six 
candidate formulations comprising of a base formulation (F1, no excipients) and combinations of 
the above three excipients (Formulations F2-F6) were short listed for accelerated and freeze-
thaw stability studies. 
Freezing of protein solutions is known to potentially negatively impact protein structure and 
can cause aggregation and/or conformational destabilization (which may in turn affect the 
potency of protein antigen vaccines)
49-51




C, the EEV 
VLPs showed higher losses of protein amount, increased hydrodynamic diameters and a higher 





C). These results for VLPs in Formulation 1 (lacking additives) 
may possibly be attributed to flexibility differences or supercooling phenomena. For example, 
the observed lower stability at -20
o
C could reflect the comparatively higher flexibility of VLP 








reduces due to increased viscosity of the frozen matrix minimizing aggregation during freeze 
thaw. The phenomenon of supercooling causes more uniform nucleation, rapid formation of ice 
crystals and subsequent interaction with the glass surface of the vials, potentially destabilizing 
the VLPs at -20
o
C. In contrast, at -80
o
C there is heterogeneous nucleation from the vial surface 
to the center of the solution, minimizing protein-surface interactions and aggregation as 
demonstrated by Kerwin et al.
52
  
For VLPs in formulations F2-F6, an increase in freeze-thaw stability was observed 
compared to F1 formulation across all VLPs at both -20 and -80 
o
C. However, the extent of 




C, which may primarily be attributed to their Tg’ 
values (e.g., sorbitol has Tg’ ~-45
o




. Multiple studies have shown that 
proteins formulated with sugars when frozen above their Tg’ value, result in destabilization of 
protein structure and increased aggregation. This is due to crystallization of freeze-concentrated 
sugars and the higher mobility of protein molecules in a less viscous frozen matrix
53-56
. 
Similarly, in our work we observed increased aggregation in the form of increases in 
hydrodynamic diameters and losses in protein amount for all the VLPs when frozen above the 
Tg’ values (at -20
o
C) vs when frozen below the Tg values (at -80
o
C). Finally, DSC is a powerful 
tool to assess the conformational changes in a protein in the form of a Tm shift or changes in the 
shape of the endothermic peaks
57,58
. DSC proved here to be a sensitive tool to detect VLP 




C in different formulations. Overall, the freeze-
thaw stability data demonstrated that Formulation F6 imparted the maximal relative stability to 
the VLPs under freeze-thaw stress. 
VLP based vaccines generally induce stronger immune responses than other protein subunit 
based vaccines due to the repetitive display of antigenic epitopes
59,60




have found that these immune responses can be further augmented by the use of aluminum 
containing adjuvants
61,62
. Both the HPV and HBV licensed VLP vaccines are formulated with 
aluminum adjuvants.  The most commonly used aluminum adjuvants are aluminum hydroxide 
(Alhydrogel®) and aluminum phosphate (Adju-Phos®). The adsorption of antigens to these 
adjuvants depends on several factors such as charges on the antigen and adjuvant, as well as 
solution pH, ionic strength and buffer components
63,64
.  All of the three VLPs demonstrated 
nearly complete binding to Alhydrogel®. The VLPs are probably adsorbed to Alhydrogel® 
primarily through electrostatic interactions, since at pH 8.5 of the adsorption buffer, the 
positively charged Alhydrogel® (pI of ~11) interacts with negatively charged clusters on the 
surface of the VLPs. In the case of Adju-Phos® binding, an opposite trend is expected since the 
negatively charged Adju-Phos® (pI of ~5) might not bind to all of the VLPs due to electrostatic 
repulsion. We observed minimal binding of WEE and VEE VLPs to Adju-Phos®. However, it is 
was surprising to find that EEE VLP showed complete binding to Adju-Phos® indicating 





 and Jones et.al
17
) have also found that certain proteins 
get adsorbed to both aluminum salt adjuvants through mechanisms other than electrostatics such 
as ligand exchange, hydrogen bonding, van der Waals forces and attractive hydrophobic 
interactions. 
To probe if the adsorption of the VLPs to Alhydrogel® affects the structural integrity and 
stability of adsorbed VLPs, fluorescence spectroscopy was used to measure the thermal stability 
both in the presence and absence of the adjuvant in base buffer and lead candidate formulation 
buffer F6. Overall, adjuvanted and non-adjuvanted VLPs in the candidate formulation buffer had 




VLP mixture which showed similar stability in both buffers). In general, the aluminum adjuvated 
EEV VLPs showed decreased thermal stability in formulation buffer compared to the non-
adjuvanted VLPs. Our findings are in agreement with the work of multiple research groups, 
where adsorption of antigen to Alhydrogel® caused structural alterations in the antigen and/or 
detrimentally affected the physical stability profile of vaccine antigen.
17,66-68
 
Desorption of the antigen from the adjuvant is desirable to better characterize the final 
vaccine drug product for total antigen content, amount of antigen adsorbed, conformational 
integrity and bioactivity by in vivo animal models.
69
. Common desorption methods using 
surfactants employing sodium dodecyl sulfate (SDS) or cetylpyridinium chloride (CPC) can be 
quite effective in eluting the antigen from aluminum adjuvant
70
. These surfactants, however, may 
denature the antigens or alter their functional epitopes. In this study, phosphate buffer was found 
to the most efficient desorption media for all three VLPs and their mixture with varying degree 
of desorption observed for the three VLPs. A number of previous studies have shown that 
phosphate ions can affect desorption of antigens from Alhydrogel® primarily through 
replacement of the hydroxyl ions of Alhydrogel® with phosphate ions and subsequent decrease 
of the adjuvant pI from ~11 to ~4 (depending on phosphate concentration) 
71-73
. This disrupts the 
electrostatic interactions between the bound antigen and aluminum adjuvant. We also observed 
that the strength of interaction between the aluminum adjuvant and the VLPs differed since 
different amounts of phosphate could elute the VLP from the surface. EEE, WEE and VEE VLPs 
required the highest, intermediate and lowest amounts of phosphate, respectively indicating the 
highest, intermediate and weakest strength of adsorption to Alhydrogel®. We also noted a 








This work provides a set of analytical characterization tools to monitor the structural and 
conformational integrity of three different EEV VLPs. Stability indicating methods were 
developed and used to identify stabilizing excipients for a stable candidate formulation for bulk 
storage of the three VLP vaccine candidates. The set of analytical methods developed in this 
study will be very useful for comparability assessments to monitor the effect of both process and 
product related changes to the physical quality of these VLPs as they further advance into 
clinical development. It also lays the groundwork for future pharmaceutical development of 
monovalent and trivalent aluminum adsorbed drug product equine encephalitis VLP vaccine 
candidates using common buffer and excipient conditions. In further work, we are correlating the 
physicochemical data from this work with immunogenicity assays (in vitro binding and animal 













Table 4.1. Concentration optimization of lead stabilizing excipients for their stabilizing effect on the 
overall tertiary structure of VEE VLPs (0.1 mg/mL) as measured by intrinsic tryptophan fluorescence 
spectroscopy as a function of temperature.  Excipients were formulated at indicated excipient 
concentration in 10 mM sodium phosphate, 100 mM NaCl, pH 7.5. Delta Tonset and delta Tm values are 
shown for different excipients where delta values represent the difference between VEE VLP formulated 
in 10 mM sodium phosphate, 100 mM NaCl, pH 7.5 with added excipient and VEE VLP formulated in 
same buffer without additive (control) Data represent mean and range of duplicate replicates. The results 
for EEE and WEE VLPs are shown in Supplemental Table 4.2. 






Mean Range Mean Range 
Sorbitol 
5 % w/v 9.2 9.0, 9.4 2.3 2.1, 2.5 
10 % w/v 9.6 9.4, 9.8 1.8 1.5, 2.1 
15 % w/v 9.7 9.6, 9.8 2.9 2.6, 3.2 
20 % w/v 13.8 13.5, 14.1 3.5 3.5, 3.6 
Trehalose 
5 % w/v 7.3 7.2, 7.4 1.3 1.2, 1.4 
10 % w/v 7.8 7.6, 8.0 1.3 1.1, 1.5 
15 % w/v 10.0 9.8, 10.1 1.8 1.5, 2.1 
20 % w/v 10.5 10.3, 10.6 2.2 2.1, 2.4 
Sucrose 
 
5 % w/v 8.4 7.8, 9.0 1.9 1.7, 2.1 
10 % w/v 9.8 9.6, 10.0 0.7 0.6, 0.8 
15 % w/v 9.9 9.5, 10.3 1.6 1.5, 1.8 
20 % w/v 10.8 10.6, 10.9 2.4 2.3, 2.5 
Pluronic F-68 
0.025 % w/v 8.0 7.6, 8.4 1.9 1.7, 2.1 
0.05 % w/v 8.5 8.5, 8.5 1.2 0.9, 1.6 
0.1 % w/v 10.4 10.0, 10.8 -1.5 -1.4, 1.6 
Glycine 
0.05 M 0.7 0.5, 0.9 1.2 0.5, 1.8 
0.1 M 2.0 1.0, 2.9 1.6 1.1, 2.2 
0.15 M 2.9 2.5, 3.3 0.8 0.5, 1.2 




2.5 % w/v 2.1 1.5, 2.7 2.3 2.1, 2.5 
5 % w/v 2.8 2.5, 3.1 2.0 1.1, 2.9 
7.5 % w/v 4.3 3.8, 4.8 2.4 2.2, 2.6 





Table 4.2. Effect of lead excipient combinations on the overall tertiary structure stability of 
VEEV (0.1 mg/mL) as measured by intrinsic tryptophan fluorescence as a function of 
temperature and the corresponding osmolality values of the formulations. Excipients were 
formulated at indicated levels in 10 mM sodium phosphate, 50 mM NaCl, pH 7.5. Delta Tonset 
and delta Tm values are shown for different excipients where delta values represent the difference 
between VEE VLP formulated in 10 mM sodium phosphate, 100 mM NaCl, pH 7.5 with added 
excipient and VEE VLP formulated in same buffer without additive (control) Data represent 
mean and range of duplicate replicates for thermal melt analysis. Data from osmolality 
measurements represent the mean and standard deviation for triplicate measurements. The results 
for EEE and WEE VLPs are shown in Supplemental Table 4.3.  
Excipient Combination  
(% w/v) 









Mean Range Mean Range Mean SD 
5 % Sorbitol 
9.2 9.0, 9.3 2.4 2.4, 2.4 358 6 
 
7.5 % Sorbitol 
10.2 10.0,10.3 3.5 3.5, 3.5 483 7 
 
10 % Sorbitol 
10.6 10.3,10.8 4.7 4.7, 4.7 677 5 
 
10 % Sucrose 
8.0 7.9, 8.1 0.7 0.2, 1.0 394 1 
 
15 % Sucrose 
9.1 8.9, 9.2 2.1 2.1, 2.1 601 7 
 
5 % Sorbitol + 5 % Sucrose 
9.6 9.5, 9.6 1.9 1.9, 1.9 501 4 
 
5 % Sorbitol +  
0.05 % Pluronic F-68 
8.7 8.7, 8.7 2.4 2.3, 2.5 364 5 
 
7.5 % Sorbitol +  
0.05 % Pluronic F-68 
9.5 9.5, 9.5 2.5 2.5, 2.5 486 3 
 
10 % Sorbitol +  
0.05 % Pluronic F-68 
9.7 9.7, 9.7 3.2 3.0, 3.3 668 11 
 
10 % Sucrose +  
0.05 % Pluronic F-68 
7.8 7.7, 7.8 2.2 2.1, 2.2 405 2 
 
15 % Sucrose +  
0.05 % Pluronic F-68 
9.1 9.0, 9.2 2.7 2.6, 2.7 620 3 
 
5 % Sorbitol + 5 % Sucrose + 
0.05 % Pluronic F-68 












Figure 4.1. Size analysis of three equine encephalitis virus-like particles (EEE, VEE and WEE 
VLP). (A, B, C) Representative transmission electron microscopy (TEM) images of each VLP 
with size bar of 100 nm displayed below the images, and (D) Comparison of hydrodynamic 
diameter values as reported previously
2,19,20
 and as measured by dynamic light scattering (DLS) 
and TEM. The polydispersity values from DLS measurements are also shown. The values 






Figure 4.2. Structural characterization of three equine encephalitis virus-like particles (EEE, 
VEE and WEE VLPs). (A) Representative SDS-PAGE analysis of VLPs under non-reducing and 
reducing conditions (in presence of DTT), (B) UV-Visible absorption spectroscopy of VLPs. The 
inset shows the A260/280 ratios for each of the VLP, indicating presence of ~10 % nucleic acid, 
(C) Far-UV circular dichroism spectra at 10 °C, and (D) Intrinsic tryptophan fluorescence spectra 












Figure 4.3. Three-index empirical phase diagrams of biophysical stability profile (vs. 
temperature and pH) of three equine encephalitis virus-like particles in 20 mM phosphate, 100 
mM NaCl buffer. (A) EEE, (B) WEE, and (C) VEE VLP. EPDs were generated using the 
biophysical datasets obtained from circular dichroism, intrinsic Trp fluorescence peak position, 
and turbidity analyses. Refer to Supplemental Figure 4.1 for biophysical data sets from circular 
dichroism, intrinsic Trp fluorescence peak position, and turbidity measurements, and the 





Figure 4.4. Effect of excipients on the thermal stability of VEE VLP as measured by intrinsic 
tryptophan fluorescence spectroscopy. Delta Tonset and delta Tm values are shown for different 
excipients where delta values represent the difference between VEE VLP formulated in 10 mM 
sodium phosphate, 100 mM NaCl, pH 7.5 with added excipient and VEE VLP formulated in 
same buffer without additive (control). Samples were formulated at 0.1 mg/mL and the data 
represents the mean values and error bars of range values from duplicate experiments. The 





Figure 4.5. Effect of different candidate formulations on freeze-thaw stability (0, 1 and 5 freeze-
thaw cycles) of VEE VLPs at -20
o
C. (A) % Absorbance at 280 nm showing protein loss with 
increasing freeze thaw cycles, (B) hydrodynamic diameter as a function of freeze-thaw cycles as 
measured by DLS, and (C) conformational stability of VEE VLP as measured by DSC. The VEE 
VLP protein concentration was 0.15 mg/mL in all six formulations: (F1) 10 mM sodium 
phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % sorbitol; (F3) F1 buffer + 7.5 % sorbitol; 
(F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; (F5) F1 buffer + 5% sorbitol, 5% sucrose 
and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68. Data represent average and 
standard deviation from triplicate measurements. *VEE VLP formulated in F1 aggregated after 5 
FT cycles and hence there is no DLS data point for 5 FT cycles. The dotted line represents the 
average Tm values at prior to FT (0 FT) for better visualization of the deviation in Tm values 









Figure 4.6. Effect of different candidate formulations on freeze-thaw stability (0, 1 and 5 freeze-
thaw cycles) of VEE VLPs at -80
o
C. (A) % Absorbance at 280 nm showing protein loss with 
increasing freeze thaw cycles, (B) hydrodynamic diameter as a function of freeze-thaw cycles as 
measured by DLS, and (C) conformational stability of VEE VLP as measured by DSC. The VEE 
VLP protein concentration was 0.15 mg/mL in all six formulations: (F1) 10 mM sodium 
phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % sorbitol; (F3) F1 buffer + 7.5 % sorbitol; 
(F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; (F5) F1 buffer + 5% sorbitol, 5% sucrose 
and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68. Data represent average and 
standard deviation from triplicate measurements. The dotted line represents the average Tm 







Figure 4.7. Accelerated stability studies of particle size of VEE VLPs in six different candidate 
formulations when stored at different temperatures (4, 25, 40, -20 and -80
o
C) for 28 days as 
measured by DLS. The VEE VLP protein concentration was 0.15 mg/mL in the six formulations: 
(F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % sorbitol; (F3) F1 
buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; (F5) F1 buffer + 
5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68. 











Figure 4.8. Adsorption studies of three equine encephalitis virus-like particles (EEE, VEE and 
WEE VLPs) onto aluminum adjuvant. (A) Percent adsorption of the three virus-like particles on 
two different aluminum salt adjuvants, Alhydrogel® and Adjuphos®. Fifty micrograms of 
protein was adsorbed onto 200 µg of adjuvant in a 25 mM Tris, 100 mM sodium citrate, pH 8.5, 
(B, C) Binding isotherms of the three VLPs with 50 µg Alhydrogel
®
 in the base buffer (B) or the 
formulation buffer (C), (D) Binding isotherms of a mixture of different concentrations of mixed 
EEE, WEE and VEE VLPs (1:1:1 ratio) with 50 µg Alhydrogel
®
 in the base buffer (BB) or the 
formulation buffer (FB), and (E,F) Thermal onset temperature (Tonset) and thermal melting 
temperatures (Tm) of individual VLPs +/- Alhydrogel and the 1:1:1 trivalent mixture +/-
Alhydrogel in base buffer (BB) and formulation buffer (BB) as measured by intrinsic Trp 
fluorescence spectroscopy. The non-adjuvanted samples contained 0.12 mg/ml VLPs, and the 
adjuvanted samples contained 0.12 mg/ml VLPs and 0.5 mg/ml Alhydrogel. Base buffer (BB) 
was 10 mM NaPO4, 50 mM NaCl, pH 7.8 and the formulation buffer (FB) was 10 mM NaPO4, 
50 mM NaCl, 5% sucrose, 5% sorbitol, 0.05% Pluronic F-68, pH 7.8. Data represents mean and 







Figure 4.9. Desorption studies of three equine encephalitis virus-like particles (EEE, VEE and 
WEE) from Alhydrogel® adjuvant. (A) Desorption of individual VLPs and a mixture of the three 
VLPs from Alhydrogel
®
 in the presence of increasing concentrations of sodium phosphate (pH 
7.8), (B) Time course profiles for the desorption of individual EEV VLPs and a mixture of the 
three VLPs from Alhydrogel
®
 in the presence of 0.5 M sodium phosphate (pH 7.8), (C, D, E, F) 
Changes in the extent of VLP desorption from Alhydrogel
®
 measured over eight weeks of 
storage time in formulation buffer at 4
o
C (10 mM NaPO4, 50 mM NaCl, 5% sucrose, 5% 
sorbitol, 0.05% Pluronic F-68, pH 7.8). The orange, blue and black traces are for 30 minutes, 4 
hours, and 24 hours of sample incubation with the 0.5 M sodium phosphate desorption buffer 









Supplemental Table 4.1. Summary of thermal onset temperature values (Tonset) for the EEE, 
WEE and VEE VLPs at 0.15 mg/mL in 20 mM citrate-phosphate, 100 mM NaCl under different 
pH conditions (pH 6.5, 7.0, 7.5, 8.0 and 8.5) measured by circular dichroism at 214 nm, intrinsic 
fluorescence MSM peak position and turbidity (OD350 nm) analysis. Data represent mean 
duplicate replicates. ND indicates that no transition was detected and as a result Tonset values 
could not be determined. 
pH Circular dichroism MSM Peak Position Turbidity (OD350) 
EEE WEE VEE EEE WEE VEE EEE WEE VEE 
6.5 50.2 52.6 ND 40.2 45.2 39.5 45.2 47.8 46.7 
7.0 52.6 54.9 ND 43.8 47.3 40.5 47.8 50.6 49.2 
7.5 55.4 55.1 ND 46.8 47.3 40.8 51.2 52.3 56.7 
8.0 56.3 55.3 ND 49.3 47.4 40.8 52.0 52.5 ND 





















Supplemental Table 4.2. Effect of excipients on the thermal stability of EEE and WEE VLPs as 
measured by intrinsic tryptophan fluorescence spectroscopy vs temperature measurements. Delta 
Tonset and delta Tm values of VLPs are shown for in presence of different excipients where delta 
values represent the difference between EEE/WEE VLPs formulated in 10 mM sodium 
phosphate, 100 mM NaCl, pH 7.5 with added excipient and EEE/WEE VLPs formulated in only 
10 mM sodium phosphate, 100 mM NaCl, pH 7.5. All samples were formulated at 0.1 mg/mL 
and the data represent mean and range of duplicate replicates. 
Excipient EEE WEE 














 Mean Range Mean Range Mean Range Mean Range 
20 % Sorbitol 14.4 14.3,14.5 2.9 2.9,2.9 5.0 4.8,5.1 3.1 3.0,3.1 
20 % Trehalose 15.7 13.3,18.0 4.1 2.6,5.5 2.5 2.4,2.5 2.5 2.3,2.6 
10 % Mannitol 11.5 11.4.11.5 1.1 0.7,1.4 3.8 3.4,4.2 3.0 2.9,3.0 
20% Sucrose 12.8 12.2,13.3 2.6 2.6,2.6 2.2 2.2,2.2 0.4 0.4,0.5 
0.1 % Pluronic F-68 3.3 -0.2,6.8 0.8 0.2,1.4 2.3 2.1,2.3 1.0 1.0,1.0 
0.3 M Glycine 4.7 4.1,5.2 1.0 0.2,1.7 2.4 2.4,2.4 2.1 2.0,2.1 
10 % 2-OH propyl γ-
CD 11.1 9.0,13.1 3.0 2.9,3.1 -2.9 -2.9,-3.1 -1.3 
-1.3,-
1.3 
10 % 2-OH propylα-
CD 10.3 9.7,10.9 3.4 2.6,4.1 -2.3 -2.3,-2.4 -0.1 
-0.1,-
0.2 
10 % 2-OH propylβ-
CD 3.7 3.6,3.8 0.8 0.2,1.4 -5.5 -5.1,-5.5 -4.6 
-4.3,-
4.8 
0.075 M Aspartic 
Acid -5.5 -4.2,-6.7 0.7 0.2,1.2 1.5 1.3,1.5 0.3 0.2,0.3 
0.15 M Malic Acid -0.5 -0.4,-0.6 2.6 2.6,2.6 0.7 0.5,0.7 0.1 0.0,0.1 
15 % Lactose 3.3 3.2,3.3 2.9 2.9,2.9 2.5 2.3,2.5 2.1 2.0,2.1 
0.15 M Lactic Acid 3.6 3.3,3.9 0.8 0.2,1.4 2.2 1.9,2.2 0.3 0.3,0.3 













Supplemental Table 4.3. Concentration optimization of lead stabilizing excipients for their 
stabilizing effect on the overall tertiary structure of EEE and WEE VLPs (0.1 mg/mL) as 
measured by intrinsic tryptophan fluorescence spectroscopy vs. temperature.  Delta Tonset and 
delta Tm values of VLPs are shown for in presence of different excipients where delta values 
represent the difference between EEE/WEE VLPs formulated in 10 mM sodium phosphate, 100 
mM NaCl, pH 7.5 with added excipient and EEE/WEE VLPs formulated in only 10 mM sodium 
phosphate, 100 mM NaCl, pH 7.5. Data represent mean and range of duplicate replicates. 
Excipient Concentration EEE WEE 
















  Mean Range Mean Range Mean Range Mean Range 
Sorbitol 
2.5 % w/v 1.8 1.5,2.0 0.1 0.0,0.2 0.5 0.4,0.6 0.6 0.4,0.8 
5 % w/v 1.5 1.3,1.6 -0.3 -0.2,-0.4 2.7 2.6,2.8 0.2 0.0,0.4 
7.5 % w/v 3.7 3.4,4.0 0.1 -0.1,0.3 2.8 2.6,3.0 1.5 0.4,2.5 
10 % w/v 3.3 3.2,3.3 -0.2 -0.1,-0.3 2.7 2.6,2.7 0.1 0.0,0.2 
Trehalose 
2.5 % w/v 1.8 1.5,2.0 0.2 0.0,0.4 1.3 1.1,1.5 0.1 0.0,0.2 
5 % w/v 1.4 1.2,1.5 0.0 0.0,0.0 1.3 1.2,1.4 0.2 0.2,0.2 
7.5 % w/v 2.5 2.4,2.6 0.0 -0.2,0.3 2.0 1.9,2.1 1.3 1.2,1.3 
10 % w/v 1.1 0.3,1.9 -0.2 -0.1,-0.3 2.2 2.0,2.3 0.1 0.0,0.2 
Sucrose 
2.5 % w/v 0.4 0.2,0.6 -1.2 -0.4,-2.0 0.3 0.2,0.4 0.2 0.2,0.2 
5 % w/v 1.2 0.3,2.0 0.0 -0.1,0.1 0.9 0.8,1.0 1.3 0.4,2.1 
7.5 % w/v 2.0 1.8,2.1 -0.6 -0.4,-0.8 0.9 0.9,1.0 0.1 0.0,0.2 
10 % w/v 2.5 2.0,3.0 -0.1 0.0,-0.3 2.4 2.3,2.5 1.3 1.0,1.5 
Pluronic F-68 
0.01 % w/v 1.9 1.8,2.0 0.1 -0.1,0.4 0.1 0.0,0.2 0.0 0.0,0.0 
0.05 % w/v 0.4 0.0,0.9 -0.9 -0.3,-1.5 1.6 1.4,1.7 0.1 0.0,0.2 














Supplemental Table 4.4. Effect of lead excipient combinations on the overall tertiary structure 
stability of EEE and WEE VLPs (0.1 mg/mL) as measured by intrinsic tryptophan fluorescence 
vs. temperature. Delta Tonset and delta Tm values of VLPs are shown for in presence of different 
excipients where delta values represent the difference between EEE/WEE VLPs formulated in 10 
mM sodium phosphate, 100 mM NaCl, pH 7.5 with added excipient and EEE/WEE VLPs 
formulated in only 10 mM sodium phosphate, 100 mM NaCl, pH 7.5. Data represent mean and 
range of duplicate replicates. 
 

















 Mean Range Mean Range Mean Range Mean Range 
7.5% Sorbitol  3.2 3.1,3.3 0.5 0.4,0.6 3.9 3.7,4.1 1.5 1.3,1.7 
7.5% Sorbitol 0.05% Pluronic -F68  3.2 3.1,3.3 0.4 0.4,0.5 3.9 3.8,4.0 1.4 1.1,1.7 
10% Sucrose  1.3 1.2,1.4 0.1 0.0,0.2 4.0 3.6,4.4 2.0 1.3,2.7 
10% Sucrose 0.05% Pluronic -F68 1.6 1.4,1.8 0.1 0.0,0.1 3.9 3.8,3.9 2.0 1.5,2.5 
5% Sucrose 5% Sorbitol  3.1 3.1,3.1 0.4 0.2,0.5 4.5 4.2,4.8 2.3 1.9,2.7 
5% Sucrose 5% Sorbitol 0.05% 
Pluronic -F68 3.2 3.1,3.2 1.4 1.3,1.4 3.9 3.6,4.2 1.2 0.9,1.5 
7.5% Sucrose 5% Sorbitol 0.05% 
Pluronic -F68 3.1 2.9,3.3 1.2 1.0,1.3 3.9 3.4,4.4 2.5 1.7,3.3 
2.5% Sucrose 7.5% Sorbitol 0.05% 
Pluronic -F68  3.3 3.2,3.3 1.6 1.4,1.7 3.4 3.0,3.8 1.2 0.9,1.5 
5% Sucrose 7.5% Sorbitol 0.05% 
Pluronic -F68 3.3 3.3,3.3 1.1 1.0,1.1 3.7 3.6,3.7 3.0 2.7,3.3 
10% Trehalose  1.3 1.1,1.5 0.5 0.3,0.7 2.5 2.4,2.5 0.1 0.1,0.1 
10% Trehalose 0.05% Pluronic -
F68 1.8 1.8,1.8 0.4 0.2,0.5 4.1 4.0,4.2 0.1 0.1,0.1 
5% Trehalose 5% Sorbitol  2.8 2.7,2.9 1.1 0.8,1.4 4.0 3.8,4.2 1.3 1.2,1.3 
5% Trehalose 5% Sorbitol 0.05% 
Pluronic -F68 2.5 2.4,2.5 0.9 0.7,1.0 3.9 3.6,4.2 1.8 1.1,2.5 
7.5% Trehalose 5% Sorbitol 0.05% 
Pluronic -F68 3.0 2.9,3.1 1.3 1.1,1.4 3.0 2.6,3.4 1.9 1.1,2.7 
2.5% Trehalose 7.5% Sorbitol 
0.05% Pluronic -F68 2.6 2.5,2.7 0.9 0.8,1.0 4.0 3.8,4.2 1.9 1.2,2.5 
5% Trehalose 7.5% Sorbitol 0.05% 












Supplemental Figure 4.1. Biophysical characterization of three equine encephalitis virus-
like particles (0.15 mg/mL) as a function of temperature across the pH range 6.5-8.5 in 20 
mM sodium phosphate, 150 mM NaCl buffer. Biophysical measurements include (A) circular 
dichroism at 214 nm, (B) intrinsic fluorescence MSM peak position, (C) turbidity (OD350 nm). 








Supplemental Figure 4.2. Effect of different candidate formulations on freeze-thaw 
stability (0, 1 and 5 freeze-thaw cycles) of EEE VLPs at -20
o
C. (A) % Absorbance at 280 nm 
showing protein loss with increasing freeze thaw cycles, (B) hydrodynamic diameter as a 
function of freeze-thaw cycles as measured by DLS, and (C) conformational stability of EEE 
VLPs as measured by DSC. The EEE protein concentration was 0.15 mg/mL in all six 
formulations namely: (F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 
% sorbitol; (F3) F1 buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-
68; (F5) F1 buffer + 5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 
% Pluronic F-68. Data represent average and standard deviation from triplicate 
measurements.*EEE formulated in F1 aggregated after 5 FT cycles and hence there is no DLS 
data point for 5 FT cycles. The dotted line represents the average Tm at 0 FT for better 






Supplemental Figure 4.3. Effect of different candidate formulations on freeze-thaw 
stability (0, 1 and 5 freeze-thaw cycles) of EEE VLPs at -80
o
C. (A) % Absorbance at 280 nm 
showing protein loss with increasing freeze thaw cycles, (B) hydrodynamic diameter as a 
function of freeze-thaw cycles as measured by DLS, and (C) conformational stability of EEE 
VLPs as measured by DSC. The EEE protein concentration was 0.15 mg/mL in all six 
formulations: (F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % 
sorbitol; (F3) F1 buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; 
(F5) F1 buffer + 5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % 
Pluronic F-68. Data represent average and standard deviation from triplicate measurements. The 
dotted line represents the average Tm value at 0 FT for better visualization of the deviation in 







Supplemental Figure 4.4. Effect of different candidate formulations on freeze-thaw 
stability (0, 1 and 5 freeze-thaw cycles) of WEE VLPs at -20
o
C. (A) % Absorbance at 280 nm 
showing protein loss with increasing freeze thaw cycles, (B) hydrodynamic diameter as a 
function of freeze-thaw cycles as measured by DLS, and (C) conformational stability of WEE 
VLPs as measured by DSC. The WEE protein concentration was 0.15 mg/mL in all six 
formulations: (F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % 
sorbitol; (F3) F1 buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; 
(F5) F1 buffer + 5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % 
Pluronic F-68. Data represent average and standard deviation from triplicate measurements. 
*WEEV formulated in F1 aggregated after 5 FT cycles and hence there is no DLS data point for 
5 FT cycles. The dotted line represents the average Tm value at 0 FT for better visualization of 






Supplemental Figure 4.5. Effect of different candidate formulations on freeze-thaw 
stability (0, 1 and 5 freeze-thaw cycles) of WEE VLPs at -80
o
C. (A) % Absorbance at 280 nm 
showing protein loss with increasing freeze thaw cycles, (B) hydrodynamic diameter as a 
function of freeze-thaw cycles as measured by DLS, and (C) conformational stability of WEE 
VLPs as measured by DSC. The WEE protein concentration was 0.15 mg/mL in all six 
formulations: (F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % 
sorbitol; (F3) F1 buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; 
(F5) F1 buffer + 5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % 
Pluronic F-68. Data represent average and standard deviation from triplicate measurements. The 
dotted line represents the average Tm at 0 FT for better visualization of the deviation in Tm after 






Supplemental Figure 4.6. Accelerated stability studies of size of EEE VLPs in different 
candidate formulations at different temperatures (4, 25, 40, -20 and -80
o
C) for 28 days as 
measured by DLS. The EEE protein concentration was 0.15 mg/mL in the six formulations: (F1) 
10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % sorbitol; (F3) F1 buffer + 
7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; (F5) F1 buffer + 5% 
sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68. Data 











Supplemental Figure 4.7. Accelerated stability studies of size of WEE VLPs in different 
candidate formulations at different temperatures (4, 25, 40, -20 and -80
o
C) for 28 days as 
measured by DLS. The WEE protein concentration was 0.15 mg/mL in the six formulations: 
(F1) 10 mM sodium phosphate, 50 mM NaCl, pH 7.5; (F2) F1 buffer + 5 % sorbitol; (F3) F1 
buffer + 7.5 % sorbitol; (F4) F1 buffer + 7.5 % sorbitol, 0.05 % pluronic F-68; (F5) F1 buffer + 
5% sorbitol, 5% sucrose and (F6) F1 buffer + 5% sorbitol, 5% sucrose, 0.05 % Pluronic F-68. 











Supplemental Figure 4.8. Conformational stability of three equine encephalitis virus-like 
particles VLPs (and a trivalent mixture) with and without adsorption to Alhydrogel® as 
measured by intrinsic Trp fluorescence spectroscopy vs. temperature.  Peak position (mean 
spectral mass method) versus temperature graphs of the three VLPs and adjuvanted mixtures, in 
base buffer (with and without adjuvant) and formulation buffer (with and without adjuvant). 
Base buffer (BB) was 10 mM NaPO4, 50 mM NaCl, pH 7.8 and the formulation buffer (FB) was 
10 mM NaPO4, 50 mM NaCl, 5% sucrose, 5% sorbitol, 0.05% Pluronic F-68, pH 7.8. The 












Supplemental Figure 4.9. Desorption studies of three equine encephalitis virus-like 
particles (EEE, VEE and WEE) and their mixture from Alhydrogel® adjuvant.  (A) 
Desorption of EEV VLPs from Alhydrogel
®
 in various desorption media. All the desorption 
media shown above, except 20 mM sodium citrate (pH 6.0), contained 20 mM sodium phosphate 
and had a pH value of 7.8. The formulation buffer (10 mM NaPO4, 50 mM NaCl, 5% sucrose, 
5% sorbitol, 0.05% Pluronic F-68, pH 7.8) was included here as a negative control Desorption 
was measured after incubating VLP-Alhydrogel
®
 mixtures with desorption media for 1 hr at 4
o
C, 
(B) Desorption of EEV VLPs as a function of both time and temperature with various desorption 
media for 1 hr at 4°C, or for either 3 hr and 16 hr at room temperature (RT), and (C) Desorption 
of individual EEV VLPs and a "mixture" of the three VLPs from Alhydrogel
®
 in the presence of 
500 mM sodium phosphate (pH 7.8) after incubating the samples with sodium phosphate for 3 hr 





1. Zacks MA, Paessler S 2010. Encephalitic alphaviruses. Veterinary Microbiology  
140(3):281-286. 
2. Long MT 2014. West Nile Virus and Equine Encephalitis Viruses. Veterinary Clinics of 
North America: Equine Practice  30(3):523-542. 
3. Weaver SC, Powers AM. 2014. Alphaviruses: equine encephalitis and others.  Viral 
Infections of Humans, ed.: Springer. p 123-145. 
4. Acha P, Szyfres B. 2003. Zoonoses and communicable diseases common to man and 
animals. Volume 2.Chlamydioses, rickettsioses, and viroses. 3rd ed.Washington DC: PAHO; 
2003. Scientific and Technical Publication No. 580. Eastern equine encephalitis; p. 110-115. ed. 
5. Acha P, Szyfres B. 2003. Zoonoses and communicable diseases common to man and 
animals. Volume 2.Chlamydioses, rickettsioses, and viroses. 3rd ed.Washington DC: PAHO; 
2003. Scientific and Technical Publication No. 580. Venezuelan equine encephalitis; p. 333-345. 
ed. 
6. Acha P, Szyfres B. 2003. Zoonoses and communicable diseases common to man and 
animals. Volume 2.Chlamydioses, rickettsioses, and viroses. 3rd ed.Washington DC: PAHO; 
2003. Scientific and Technical Publication No. 580. Western equine encephalitis; p. 365-372. ed. 
7. Giltner L, Shahan M 1933. The 1933 outbreak of infectious equine encephalomyelitis in 
the eastern states. North Am Vet  14:25. 
8. Broeck GT, Merrill MH 1933. A serological difference between eastern and western 
equine encephalomyelitis virus. Proceedings of the Society for Experimental Biology and 
Medicine  31(2):217-220. 
9. Prevention CfDCa 2016. Eastern Equine Encephalitis 
https://www.cdc.gov/easternequineencephalitis/ Accessed July 22, 2014. 
10. Wolfe DN, Heppner DG, Gardner SN, Jaing C, Dupuy LC, Schmaljohn CS, Carlton K 
2014. Current strategic thinking for the development of a trivalent alphavirus vaccine for human 
use. The American journal of tropical medicine and hygiene  91(3):442-450. 
11. Sherman MB, Weaver SC 2010. Structure of the Recombinant Alphavirus Western 





12. Paessler S, Weaver SC 2009. Vaccines for Venezuelan equine encephalitis. Vaccine  
27S4:D80-D85. 
13. Taylor K, Kolokoltsova O, Ronca SE, Estes M, Paessler S 2017. Live, Attenuated 
Venezuelan Equine Encephalitis Virus Vaccine (TC83) Causes Persistent Brain Infection in 
Mice with Non-functional αβ T-Cells. Frontiers in Microbiology  8:81. 
14. Chang L-J, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov 
G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, 
Mascola JR, Pierson TC, Graham BS, Ledgerwood JE 2014. Safety and tolerability of 
chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. The 
Lancet  384(9959):2046-2052. 
15. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR 2012. Improved data visualization 
techniques for analyzing macromolecule structural changes. Protein Science  21(10):1540-1553. 
16. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR 2011. Multidimensional 
methods for the formulation of biopharmaceuticals and vaccines. Journal of Pharmaceutical 
Sciences  100(10):4171-4197. 
17. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR 2005. Effects of 
Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein 
Antigens. Journal of Biological Chemistry  280(14):13406-13414. 
18. Estey T, Vessely C, Randolph TW, Henderson I, Braun LJ, Nayar R, Carpenter JF 
Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum 
neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. Journal of 
Pharmaceutical Sciences  98(9):2994-3012. 
19. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro J-C 2003. VENEZUELAN EQUINE 
ENCEPHALITIS. Annual Review of Entomology  49(1):141-174. 
20. 2009. APPENDIX 2. Transfusion  49:45S-233S. 
21. Schmid F-X. 2001. Biological Macromolecules: UV-visible Spectrophotometry.  eLS, 
ed.: John Wiley & Sons, Ltd. 
22. Porterfield JZ, Zlotnick A 2010. A Simple and General Method for Determining the 
Protein and Nucleic Acid Content of Viruses by UV Absorbance. Virology  407(2):281-288. 
23. Sambrook J, Russell DW. 2001. Molecular Cloning: A Laboratory Manual. ed.: Cold 




24. Warburg O 1941. Isolierung und kristallisation des garungsferments enolase. Biochem z  
310:384-421. 
25. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR 2012. Improved data visualization 
techniques for analyzing macromolecule structural changes. Protein Sci  21(10):1540-1553. 
26. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR 2011. Multidimensional 
methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci  100(10):4171-
4197. 
27. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ 2014. 
Bioengineering virus-like particles as vaccines. Biotechnology and bioengineering  111(3):425-
440. 
28. Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM 2010. Virus-like 
particles in vaccine development. Expert review of vaccines  9(10):1149-1176. 
29. Zeltins A 2013. Construction and Characterization of Virus-Like Particles: A Review. 
Molecular Biotechnology  53(1):92-107. 
30. Chirino AJ, Mire-Sluis A 2004. Characterizing biological products and assessing 
comparability following manufacturing changes. Nature Biotechnology  22:1383. 
31. Federici M, Lubiniecki A, Manikwar P, Volkin DB 2013. Analytical lessons learned from 
selected therapeutic protein drug comparability studies. Biologicals  41(3):131-147. 
32. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta 
P, Bruner M, Burman S, DalMonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, 
Siegel R 2011. Comparability assessments of process and product changes made during 
development of two different monoclonal antibodies. Biologicals  39(1):9-22. 
33. Zhao Q, Potter CS, Carragher B, Lander G, Sworen J, Towne V, Abraham D, Duncan P, 
Washabaugh MW, Sitrin RD 2014. Characterization of virus-like particles in GARDASIL® by 
cryo transmission electron microscopy. Human Vaccines & Immunotherapeutics  10(3):734-739. 
34. Wang JW, Roden RBS 2013. Virus-like particles for the prevention of human 
papillomavirus-associated malignancies. Expert review of vaccines  
12(2):10.1586/erv.1512.1151. 
35. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC 1991. Structures 
of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-




36. Diminsky D, Schirmbeck R, Reimann J, Barenholz Y 1997. Comparison between 
hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast 
cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine  15(6):637-
647. 
37. Gilbert RJC, Beales L, Blond D, Simon MN, Lin BY, Chisari FV, Stuart DI, Rowlands 
DJ 2005. Hepatitis B small surface antigen particles are octahedral. Proceedings of the National 
Academy of Sciences of the United States of America  102(41):14783-14788. 
38. Toprani VM, Hickey JM, Sahni N, Toth RT, Robertson GA, Middaugh CR, Joshi SB, 
Volkin DB 2017. Structural characterization and physicochemical stability profile of a double 
mutant heat labile toxin (dmLT) protein based adjuvant. Journal of Pharmaceutical Sciences. 
39. Qi W, Zeng Y, Orgel S, Francon A, Kim JH, Randolph TW, Carpenter JF, Russell 
Middaugh C 2014. Preformulation Study of Highly Purified Inactivated Polio Vaccine, Serotype 
3. Journal of Pharmaceutical Sciences  103(1):140-151. 
40. Jain NK, Sahni N, Kumru OS, Joshi SB, Volkin DB, Russell Middaugh C 2015. 
Formulation and stabilization of recombinant protein based virus-like particle vaccines. 
Advanced Drug Delivery Reviews  93:42-55. 
41. Alsenaidy M, Jain NK, Kim J, Middaugh C, Volkin D 2014. Protein comparability 
assessments and potential applicability of high throughput biophysical methods and data 
visualization tools to compare physical stability profiles. Frontiers in Pharmacology  5(39). 
42. More AS, Toprani VM, Okbazghi SZ, Kim JH, Joshi SB, Middaugh CR, Tolbert TJ, 
Volkin DB 2016. Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical 
Stability Profiles of IgG1-Fc Glycoforms. Journal of Pharmaceutical Sciences  105(2):588-601. 
43. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu 
D-M, Shiver JW, Volkin DB 2004. Development of stable liquid formulations for adenovirus-
based vaccines. Journal of Pharmaceutical Sciences  93(10):2458-2475. 
44. Peek LJ, Brey RN, Middaugh CR 2007. A Rapid, Three-Step Process for the 
Preformulation of aRecombinant Ricin Toxin A-Chain Vaccine. Journal of Pharmaceutical 
Sciences  96(1):44-60. 
45. Pastorino B, Baronti C, Gould EA, Charrel RN, de Lamballerie X 2015. Effect of 
Chemical Stabilizers on the Thermostability and Infectivity of a Representative Panel of Freeze 
Dried Viruses. PloS one  10(4):e0118963. 
46. Adebayo AA, Sim-Brandenburg JW, Emmel H, Olaleye DO, Niedrig M 1998. Stability 




47. Wiggan ON, Livengood JA, Silengo SJ, Kinney RM, Osorio JE, Huang CYH, 
Stinchcomb DT 2011. Novel formulations enhance the thermal stability of live-attenuated 
flavivirus vaccines. Vaccine  29(43):7456-7462. 
48. Ohtake S, Martin RA, Saxena A, Lechuga-Ballesteros D, Santiago AE, Barry EM, 
Truong-Le VU 2011. Formulation and Stabilization of Francisella tularensis Live Vaccine 
Strain. Journal of Pharmaceutical Sciences  100(8):3076-3087. 
49. Bhatnagar BS, Bogner RH, Pikal MJ 2007. Protein Stability During Freezing: Separation 
of Stresses and Mechanisms of Protein Stabilization. Pharmaceutical Development and 
Technology  12(5):505-523. 
50. Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB 2014. Vaccine 
instability in the cold chain: Mechanisms, analysis and formulation strategies. Biologicals  
42(5):237-259. 
51. Diminsky D Physical, chemical and immunological stability of CHO-derived hepatitis B 
surface antigen (HBsAg) particles. Vaccine  18(1-2):3-17. 
52. Kerwin BA, Heller MC, Levin SH, Randolph TW 1998. Effects of tween 80 and sucrose 
on acute short-term stability and long-term storage at −20 °C of a recombinant hemoglobin. 
Journal of Pharmaceutical Sciences  87(9):1062-1068. 
53. Piedmonte DM, Summers C, McAuley A, Karamujic L, Ratnaswamy G 2007. Sorbitol 
Crystallization Can Lead to Protein Aggregation in Frozen Protein Formulations. Pharmaceutical 
Research  24(1):136-146. 
54. Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M 2011. Frozen State Storage 
Instability of a Monoclonal Antibody: Aggregation as a Consequence of Trehalose 
Crystallization and Protein Unfolding. Pharmaceutical Research  28(4):873-885. 
55. Miller MA, Rodrigues MA, Glass MA, Singh SK, Johnston KP, Maynard JA 2013. 
Frozen-State Storage Stability of a Monoclonal Antibody: Aggregation is Impacted by Freezing 
Rate and Solute Distribution. Journal of Pharmaceutical Sciences  102(4):1194-1208. 
56. Cavatur RK, Cavatur R 2002. Crystallization Behavior of Mannitol in Frozen Aqueous 
Solutions. Pharmaceutical research  19(6):894-900. 
57. Wen J, Arthur K, Chemmalil L, Muzammil S, Gabrielson J, Jiang Y 2012. Applications 
of Differential Scanning Calorimetry for Thermal Stability Analysis of Proteins: Qualification of 




58. Johnson CM 2013. Differential scanning calorimetry as a tool for protein folding and 
stability. Archives of Biochemistry and Biophysics  531(1):100-109. 
59. Kushnir N, Streatfield SJ, Yusibov V 2012. Virus-like particles as a highly efficient 
vaccine platform: Diversity of targets and production systems and advances in clinical 
development. Vaccine  31(1):58-83. 
60. Thrane S, Janitzek CM, Agerbæk MØ, Ditlev SB, Resende M, Nielsen MA, Theander 
TG, Salanti A, Sander AF 2015. A Novel Virus-Like Particle Based Vaccine Platform 
Displaying the Placental Malaria Antigen VAR2CSA. PloS one  10(11):e0143071. 
61. Caulfield MJ, Shi L, Wang S, Wang B, Tobery TW, Mach H, Ahl PL, Cannon JL, Cook 
JC, Heinrichs JH, Sitrin RD 2007. Effect of Alternative Aluminum Adjuvants on the Absorption 
and Immunogenicity of HPV16 L1 VLPs in Mice. Human Vaccines  3(4):139-145. 
62. Deng Z-H, Hao Y-X, Yao L-H, Xie Z-P, Gao H-C, Xie L-Y, Zhong L-l, Zhang B, Cao 
Y-D, Duan Z-J 2014. Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like 
particles in mice. Immunology  142(1):58-66. 
63. Fox CB, Kramer RM, Barnes V L, Dowling QM, Vedvick TS 2013. Working together: 
interactions between vaccine antigens and adjuvants. Therapeutic Advances in Vaccines  1(1):7-
20. 
64. Gupta RK 1998. Aluminum compounds as vaccine adjuvants. Advanced drug delivery 
reviews  32(3):155-172. 
65. Al-Shakhshir RH, Regnier FE, White JL, Hem SL 1995. Contribution of electrostatic and 
hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. 
Vaccine  13(1):41-44. 
66. Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR 2007. Effects of 
Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants. 
Journal of Pharmaceutical Sciences  96(3):547-557. 
67. Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter 
JF 2009. Stability of a Trivalent Recombinant Protein Vaccine Formulation Against Botulinum 
Neurotoxin during Storage in Aqueous Solution. Journal of pharmaceutical sciences  98(9):2970-
2993. 
68. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL 
2012. Structural and Immunological Analysis of Anthrax Recombinant Protective Antigen 





69. Dey AK, Malyala P, Singh M 2014. Physicochemical and functional characterization of 
vaccine antigens and adjuvants. Expert review of vaccines  13(5):671-685. 
70. Rinella JV, Workman RF, Hermodson MA, White JL, Hem SL 1998. Elutability of 
Proteins from Aluminum-Containing Vaccine Adjuvants by Treatment with Surfactants. Journal 
of Colloid and Interface Science  197(1):48-56. 
71. Iyer S, HogenEsch H, Hem SL 2003. Effect of the Degree of Phosphate Substitution in 
Aluminum Hydroxide Adjuvant on the Adsorption of Phosphorylated Proteins. Pharmaceutical 
development and technology  8(1):81-86. 
72. Iyer S, Robinett RSR, HogenEsch H, Hem SL 2004. Mechanism of adsorption of 
hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine  22(11):1475-1479. 
73. Hem SL, HogenEsch H 2007. Relationship between physical and chemical properties of 
aluminum-containing adjuvants and immunopotentiation. Expert review of vaccines  6(5):685-
698. 
74. Shi Y, HogenEsch H, Hem SL 2001. Change in the degree of adsorption of proteins by 
aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and 













Chapter 5 Analytical Comparability Assessments of Five Recombinant CRM197 Proteins 

























Polysaccharide vaccines have been used effectively since the 1970s to mitigate bacterially-
associated diseases, such as pneumonia and meningitis, in adults
1
. The transient immune 
response elicited by polysaccharide vaccines limit efficacy in individuals with an immature (< 2 
yrs) immune system
2
. Subsequently, conjugate vaccines, composed of bacterial polysaccharides 
chemically linked to a carrier protein, were developed to stimulate a more robust and sustained 
(T cell-dependent) immune response. While commercially available polysaccharide-protein 






) have substantially decreased incident 
rates of bacterially associated diseases 
3,4
, their complex nature leads to costly production which 
currently is one major hurdle limiting vaccine coverage in developing countries
5,6
.  
Three carrier proteins have been used in a majority of commercial conjugate vaccines
7
. 
These immunogens consist of tetanus toxoid (TT), diphtheria toxoid (DT), and a single amino 
acid substitution of diphtheria toxin (G52E), termed cross-reactive material 197 or CRM197. 
Conjugate vaccines employing these three proteins have proven to be safe and effective, and 
from the limited literature available, induce comparable immune responses to similar 
polysaccharide antigens. While the clinical efficacy of these proteins appears similar, inherent 
manufacturing requirements and challenges differentiate these three immunogens. TT and DT 
require detoxification prior to polysaccharide conjugation using formaldehyde treatment. 
Conversely, the amino acid substitution in CRM197 renders the protein non-toxic and therefore is 
more advantageous to manufacture than TT or DT since CRM197 does not require formaldehyde 
treatment (resulting in more lysine groups available in the carrier protein as potential 
polysaccharide conjugation sites. Production of CRM197 is hindered, however, by the strict 




yields compared to other expression systems
8
. Given these challenges, evaluation of recombinant 
CRM197 expressed in multiple heterologous organisms (e.g. E. coli, P. fluorescens, Bacillus 
subtilis) is being pursued as alternative source of carrier protein
9
.   
Given the complex process of manufacturing conjugate vaccines
10
, delineating the 
physicochemical properties of recombinant CRM197, expressed in C. diphtheriae or a 
heterologous system, is essential to mitigate risk during manufacturing, including subsequent 
polysaccharide conjugation, to ensure the immunogenicity of the final drug product. CRM197 has 
a similar overall conformation to diphtheria toxin, however the crystal structure of CRM197 (PDB 
ID: 4AE0) elucidated subtle but functionally-important (i.e., lack of toxicity in CRM197) 
differences between the two proteins
11
. CRM197 is translated as a 58 kDa polypeptide in C. 
diphtheriae, which can be cleaved by a trypsin-like protease into two subunits (fragments A and 
B) linked through a disulfide bond. During manufacturing of CRM197, cleavage of the 
polypeptide, also known as “nicking”, is controlled and generally limited to <5% of total 
CRM197
12
. Following purification of CRM197, polysaccharides are generally conjugated to 
primary amines on the carrier protein through either direct or indirect (linker molecule) methods 
13
. In addition to multiple factors that can affect the immunogenicity of a vaccine during 
conjugation (e.g., polysaccharide composition, linker length, conjugation chemistry), the 
accessibility of specific side-chains in the carrier protein can affect polysaccharide conjugation 
14
. Therefore ensuring the carrier protein is consistently manufactured and well-characterized 
prior to conjugation is critical. 
In this study, five different recombinant CRM197 molecules from the traditional expression 
system (C. diptheriae) as well as two heterologous systems (E. coli and P. fluorescens) were 




solubility and conformational stability using a wide variety of biochemical, biophysical and in 
vitro antigen binding assays. The results from this study provide baseline data sets of the key 
structural attributes of CRM197 to enable future comparisons of the physicochemical and 
immune-reactivity properties of recombinant CRM197 irrespective of expression system and/or 
production process.  
5.2 Materials and Methods 
5.2.1 Materials 
The sample information for the five different CRM197 molecules examined in this study 
are summarized in Table 5.1. EcoCRM
™
 (Fina Biosolutions LLC, Rockville, MD), rCRM 
(Biological E. Limited, Hyderabad, Telangana, India), Pfenex CRM (Reagent Proteins, San 
Diego, CA), C7 CRM (List Biological Laboratories Inc., Campbell, CA) and VaxForm CRM 
(VaxForm LLC, Lehigh Valley, PA) were diluted to 2.0 mg/mL with their respective formulation 
buffers and then dialyzed against 10 mM sodium phosphate, 150 mM NaCl, pH 7.2 (PBS buffer) 
using 10 kDa molecular weight cutoff (MWCO) Slide-A-Lyzer Mini Dialysis devices (Thermo 
Scientific, Rockford, IL). The samples were dialyzed overnight at 4°C with three buffer changes 
at three hour intervals, and the concentration of each CRM197 sample was determined both pre 
and post centrifugation (13,000 rpm for 5 min). Each of the CRM197 samples were further diluted 
to 1.0 mg/mL with PBS buffer for all subsequent analyses. All other chemical and reagents were 
purchased from commercial sources.   
5.2.2 Methods 
5.2.2.1 UV-Visible Absorbance Spectroscopy 
The UV-Visible absorption spectra of each CRM197 sample at 1.0 mg/ml was recorded 




with Deuterium (D2) and Tungsten (W) lamps. In addition, samples were centrifuged at 13,000 × 
g for 5 min and the UV-Visible absorption spectra of the resulting supernatant were recorded. 
The Beer-Lambert law was used to calculate the actual concentration given an extinction 




) (calculated using 
http://web.expasy.org/protparam/). Spectra were collected from 190-1100 nm using a 0.5 s 
integration time and 1 cm path length quartz cuvettes. The instrument was first blanked using the 
buffer for each sample prior to measuring solutions containing protein. All UV-Visible 
absorbance spectra were mathematically corrected for light scattering using a technique included 
in the manufacturer’s data analysis software (Chemstation UV-Vis analysis software, Agilent 
Technologies).  
5.2.2.2 SDS-PAGE 
For the reduced samples, 2.5 g of each CRM197 sample was mixed with 4X LDS loading 
dye (Life Technologies, Grand Island, NY) containing 50 mM dithiothreitol (DTT, Invitrogen, 
Carlsbad, CA) and 100 mM iodoacetamide (Life Technologies), and incubated at room 
temperature for 30 min. The reduced CRM197 samples were then separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis using NuPAGE 4-12% Bis-Tris (Life Technologies) 
gels and MES running buffer (Life Technologies). A similar procedure was followed for non-
reduced CRM197 samples except the DTT was omitted during the incubation at room temperature 
for 30 min step. The NuPAGE gels were run for 60 min at 120 V. Protein bands were visualized 
by staining with Coomassie blue R250 (Teknova, Hollister, CA) and destained with a mixture of 
40% methanol, 10% acetic acid, and 50% ultrapure water. Gels were digitized using an 




5.2.2.3 Intact Mass Spectroscopy 
Each CRM sample in PBS (50 pmol) was injected into an 1200 series LC system (Agilent 
Technologies), bound to a C8 micro-trap (Michrom Bioresources Inc., Auburn, CA), desalted, 
and then subjected to electrospray ionization time-of-flight mass spectrometry (model 6220, 
Agilent Technologies).  Mass spectra were acquired from 400 to 2000 m/z at a scan rate of one 
spectrum per sec. Protein MS spectra were deconvoluted using MassHunter Quantitative 
Analysis software (v B.07.00, Agilent Technologies). 
5.2.2.4 LC-MS Peptide Mapping 
 Each CRM sample was incubated overnight at 37°C with 2 μg of trypsin. Trifluoroacetic 
acid (0.05%) was added to quench proteolysis and ~20 g of each digested sample was subjected 
to LC-MS. The peptides from the digested protein solution were separated by a liquid 
chromatography system (Thermo Scientific, Waltham, MA) prior to analysis. Peptides were 
injected onto a C18 column (1.7µm, 2.1 x 150 mm, Waters) and a 55 min 5-50% B gradient (A: 
H2O and 0.05% trifluoroacetic acid; B: ACN and 0.05% trifluoroacetic acid; 200 μl/min flow 
rate) for separation. MS was performed using a LTQ-XL ion trap (Thermo Scientific) and the 
Xcalibur 2.0 software (Thermo Scientific). The instrument was also tuned using a standard 
calibration peptide (Angiotensin II, Sigma, St. Louis, MO) for maximal sensitivity before 
running any experiments. The mass spectra were acquired in the LTQ over a mass range of m/z 
350-1900. The ion selection threshold was 10,000 counts and the dynamic exclusion duration 
was 5 sec.   
Raw experimental files were initially evaluated manually to determine if the ion counts 
and fragmentation of each peptide were sufficient for further analysis. The raw data files were 




experiment consisted of the primary sequences of CRM and trypsin. Potential common post-
translational modifications (e.g. Asn deamidation, Met oxidation, mixed disulfide bonds) were 
included during the analysis. Peptide assignments of MS/MS spectra were validated using a 
confidence score of ≥ 95% and disulfide-bonded peptide assignments were also manually 
verified. 
5.2.2.5 Capillary Isoelectric Focusing (cIEF) 
Electrophoretic separation by isoelectric point was performed using an ICE280 system 
(Protein Simple, Santa Carla, CA) equipped with a D2 lamp (280 nm), a PrinCE micro-injector, 
and an auto-sampler.  The FC coated cartridge was rinsed with ultrapure water before and after 
daily experiments. Separation efficiency and transfer time were determined by separation of a 
hemoglobin analytical standard. CRM samples were analyzed under the following conditions 
adapted from Rustandi et.al. (2014)
15
 and Loughney et.al.(2017)
16
: Ampholytes: a mixture of pH 
4-6.5 and pH 3-10 in a 2:1 ratio (GE Healthcare, Pittsburgh, PA), IEF markers (4.65, 7.05), 
additives (20% glycerol) and 1.0% methylcellulose (Protein Simple). The sample was resolved 
using the pre-focusing conditions of 1 min at 1500 V and a focusing condition of 8 min at 3000 
V. Data analysis and peak integrations were performed using ChromPerfect software (Protein 
Simple). 
5.2.2.6 Anion Exchange Chromatography (AEX) 
AEX was performed on a Shimadzu Prominence UFLC HPLC system equipped with a 
diode array detector using a TSKgel BioAssist Q (4.6 mm × 5 cm, 10 µm) column (TOSOH 
Biosciences, King of Prussia, PA). 20 µg of each CRM197 sample was injected onto the column 
for each run, and the experiment was performed in triplicate. The column and auto-sampler 




sodium phosphate, pH 7.4; (B) 20 mM sodium phosphate, 1 M sodium chloride, pH 7.4. The 
flow rate was 0.7 mL/min and the gradient consisted of 0% B (5 min), 0-100% B (10 min), 100% 
B (3 min), 100-0% B (2 min), and 0% B (5 min). Protein peaks were monitored using the 
absorbance signal at 214 nm. In addition, the samples were subjected to AEX without the 
column attached to better determine if any fraction of the sample binds or cannot pass through 
the column (i.e., sample recovery). Data analysis was performed using LC solutions software 
(Shimadzu, Kyoto, Japan). 
5.2.2.7 Far-UV Circular Dichrosim 
Far-UV circular dichroism spectroscopy was performed using a Chirascan-plus CD 
spectrometer (Applied Photophysics Ltd, Leatherhead, UK) equipped with a 6-cuvette position 
Peltier temperature controller (Quantum Northwest, Liberty Lake, WA) and a high performance 
solid-state detector. The lamp (150 W air-cooled Xe arc) housing, monochromator and sample 
compartment were continuously purged with N2 gas. The CD spectra of the protein samples at 
0.2 mg/mL were collected in the range of 260-200 nm using 1 nm step size and a 0.5 sec 
sampling time. Quartz cuvettes (0.1 cm path length) sealed with a teflon stopper (Starna Cells 
Inc., Atascadero, CA) were used. The CD signal at 222 nm was monitored as a function of 
temperature from 10-90°C in 1.25°C intervals. The heating rate was 1°C/min, and the 
equilibration time at each temperature was 2 min. All data were subjected to a 5-point Savitzky-
Golay smoothing filter using the Chirascan software (Applied Photophysics) and PBS buffer 
alone was subtracted from all measurements.   
5.2.2.8 Intrinsic Tryptophan Fluorescence & Static Light Scattering 
The intrinsic tryptophan fluorescence spectra of each CRM197 sample was measured in 




International (PTI), Inc., Birmingham, NJ) equipped with a 4-position cell holder Peltier 
temperature control device, a high power continuous 75 W short-arc Xe lamp (Ushio), and a 
Hamamatsu R1527 photomultiplier tube. Data were collected using FelixGX software (PTI). 
Fluorescence emission spectra of 0.2 mg/mL CRM were recorded as a function of temperature 
(10-90°C) using an excitation wavelength of 295 nm (>95% Trp). Emission spectra were 
collected from 305-405 nm with a step size of 1 nm and an integration time of 1 sec. Static light 
scattering data were acquired concurrently with the fluorescence spectra by employing a second 
detector (90° to the incident light and 180° to the fluorescence detector) that collected light 
scattered signal at the excitation wavelength (295 nm) as a function of increasing temperature. 
The excitation and emission slits were both set such that the initial signal at 10°C had an 
emission maximum of ~800,000 counts per sec for fluorescence spectra and an emission 
maximum of ~20,000 counts per sec for light scattering spectra. The spectra were collected at 
1.25°C intervals with a 2 min equilibration time at each temperature with samples in quartz 
cuvettes (1 cm path length). The position of the emission wavelength maximum was determined 
using a mean spectral center of mass method (MSM) executed using in-house software 
(MiddaughSuite) after formulation buffer subtraction. This analysis algorithm increases the 
signal to noise ratio, but the peak positions are generally red shifted by 5-10 nm from their 
experimental positions. 
5.2.2.9 Extrinsic ANS Fluorescence 
8-Anilino-1-naphthalene sulfonate (ANS) was used as an extrinsic fluorescence probe in 
the presence of CRM197 with the same instrument as described above. A dye to protein molar 
ratio of 25:1 was used for sample preparation. ANS was excited at 372 nm, and emission spectra 






C. The corresponding ANS in buffer spectrum was subtracted from ANS in the presence of 
protein spectrum prior to data analysis. The emission peak intensity was determined using a 
mean spectral center of mass method (MSM) executed in the in-house software. The Tonset values 
were determined by identifying the point at which the baseline deviated from linearity using 
Origin 8.0 software. 
5.2.2.10 Differential Scanning Calorimetry 
CRM197 samples were loaded in the autosampler tray held at 4°C and DSC was 
performed in triplicate using an Auto-VP capillary differential scanning calorimeter 
(MicroCal/GE Health Sciences, Pittsburgh, PA) equipped with Tantalum sample and reference 
cells. Scans were completed from 10-90°C using a scanning rate of 60°C/h. Reference 
subtraction and concentration normalization were performed using Origin (OriginLab, 
Northampton, MA). Data analysis was performed using the MicroCal LLC DSC plug-in for the 
Origin 7.0 software package. The results were fitted to a multistate model with two transitions to 
calculate the melting temperature (Tm) values. The onset melting temperature (Tonset) was 
determined by identifying the point where the heat capacity (Cp) value for the first thermal 
transition reached ≥500 cal mol–1 ˚C–1. 
5.2.2.11 Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) 
SV-AUC experiments were performed on a Proteome Lab XL-I (Beckman Coulter, 
Fullerton, CA) analytical ultracentrifuge equipped with a scanning ultraviolet-visible optical 
system. All experiments were conducted at 20°C after ≥1 h of equilibration after the rotor 
reached the set temperature, at a rotor speed of 40,000 rpm and with detection at 280 nm. 
CRM197 samples and PBS alone were each loaded into Beckman charcoal-epon two sector cells 




The data were analyzed using Sedfit (Dr. Peter Schuck, NIH). A partial specific volume 
of 0.73 mL/g was calculated using Sednterp (Professor Thomas Laue, University of New 
Hampshire and BITC) based on amino acid sequence, and used in the analysis. The buffer 
density and viscosity used in the analysis, 1.0058 g/mL and 0.010195 Poise respectively, were 
calculated using Sednterp based on buffer composition. A continuous c(s) distribution was used 
with 200 scans. A range of 0 to 15 svedbergs was used, with a resolution of 300 points per 
distribution and a confidence level of 0.95. Baseline, radial independent noise, and time 
independent noise were fit, while the meniscus and bottom positions were set manually. 
Distributions were imported into Origin (OriginLab, Northampton, MA) before reporting.  
5.2.2.12 Size Exclusion Chromatography (SEC) 
A Shimadzu Prominence UFLC HPLC system equipped with a diode array detector (with 
absorbance detection at 214 nm) was used. Twenty micrograms of each CRM197 sample was 
injected onto a TSK-Gel BioAssist G2SWxl column (7.8 x 300 mm, TOSOH Biosciences) and 
the corresponding guard column (TOSOH Biosciences). The columns were operated at 30°C and 
equilibrated with at least 10 column volumes of mobile phase (10 mM sodium phosphate, 150 
mM NaCl, pH 7.2) prior to sample injection. A flow rate of 0.7 mL/min was used with a 30 min 
run time. A gel filtration standard (Bio-Rad, Hercules, CA) was subjected to SEC before and 
after the CRM sample to ensure integrity of the column and HPLC system. In addition, the 
samples were subjected to SEC without the column attached to better determine if insoluble 
aggregates are present in the samples or if the sample binds to the column (i.e., sample recovery). 




5.2.2.13 Resonant Mass Measurement (RMM) 
An Archimedes Particle Metrology System (Malvern Instruments Ltd, United Kingdom) 
was used to quantify sub-micron sized particles (0.2-2μm).  A Hi-Q micro-H sensor, calibrated 
using 1 µm polystyrene beads (Thermo Scientific), and a reference solution of 1:20 D2O:H2O 
was used for all measurements. Prior to daily measurements, the accuracy of the sensor was 
assessed by analysis of 1 µm polystyrene beads (Thermo Scientific). To achieve a clean baseline, 
the sensor and the tubing were rinsed with 20% Contrad-20 followed by ultrapure water.  The 
sensor was then loaded with particle free water and two “sneeze” operations were performed. 
Each CRM197 sample at 1.0 mg/mL was loaded for 30 sec and a stop trigger of 300 particles was 
used. The total number and size distribution of sub-micron particles were analyzed in triplicate. 
The limit of detection was determined empirically (0.030 Hz) and used throughout the study. 
Data analysis was performed using ParticleLab software 1.9.30 (Malvern, UK).  
5.2.2.14 Micro-Flow Imaging (MFI) 
The concentration and size range of sub-visible particles (2-100 μm) were measured and 
quantified using a DPA-4200 flow microscope (Protein Simple) that was previously calibrated 
using 10 µm polystyrene particle standards (Thermo Scientific). The instrument was flushed with 
particle free water until a clean baseline was achieved. Each CRM197 sample at 0.2 mg/mL (1:5 
dilution) was analyzed in triplicate experiments. The samples were carefully drawn up in a low 
protein binding, filter-tip pipette (Neptune Scientific, San Diego, CA) and analyzed using a flow 
rate of 0.2 mL/min. Data analysis was performed using MVSS software (Protein Simple) 
5.2.2.15 PEG-Precipitation Assay  
The protocol for the high throughput version of the PEG assay for assessing apparent 
solubility of CRM molecules was adopted from Gibson et al. (2011)
17





. Stock solutions of PBS pH 7.2 and PBS containing 40% w/v PEG-10,000 at pH 7.2 were 
mixed to prepare various concentrations of PEG solutions ranging from 0 to 40% w/v PEG. A 
volume of 200 µL of the various PEG-10,000 solutions was added to wells of a 96-well 
polystyrene filter plate (Corning Life Sciences, Corning, NY). Fifty microliters of each CRM 
sample in PBS pH 7.2 (1 mg/mL) was then added to each well to a final protein concentration of 
0.2 mg/mL. The plates were incubated overnight at room temperature and then centrifuged at 
3,500 rpm (1,233 rcf) for 15 min and the filtrate was collected in a clear 96 well collection plate 
(Greiner Bio-One North America Inc., Monroe, NC). Subsequently, 200 µL of filtrate was 
transferred into a 96 well UV Star microplate and the protein concentration in each filtrate was 
determined using a SpectraMax M5 UV-Visible plate reader. The % PEGmidpt and apparent 
solubility values (thermodynamic activity) were calculated as described previously 
17
.  
5.2.2.16 Empirical Phase Diagrams/Radar Charts 
Each of the five CRM197 samples were dialyzed against 10 mM sodium phosphate buffer 
containing sodium chloride at an ionic strength of 0.15 at pH 5.8, 6.3, 6.8, 7.2, 7.6, and 8.0 using 
Slide-A-Lyzer dialysis devices (10 kDa MWCO, Thermo Scientific). After four rounds of buffer 
exchange overnight at 4°C, each CRM197 sample was collected from the dialysis device and 
centrifuged at 13,000 × g at 4°C for 5 min. The biophysical stability of CRM197 molecules was 
determined using far-UV circular dichroism spectroscopy, intrinsic tryptophan fluorescence 
spectroscopy, static light scattering, and differential scanning calorimetry (as described above) 
for each protein sample at each pH as a function of temperature. EPDs and radar charts were 
constructed as data visualization tools to summarize the effect of pH and temperature on the 
physical stability profile of the CRM197 samples (using the biophysical stability data sets) as 






5.2.2.17 Enzyme-Linked Immunosorbent Assay (ELISA) using Polyclonal Antibodies 
One hundred microliters of 0.5 µg/ml heparin-binding EGF-like growth factor (HB-EGF, 
Sigma) in PBS was added to each well of a 96-well plate. The plate was then incubated overnight 
at 4°C. The following day, the plate was washed three times with PBST (PBS with 0.05% 
Tween-20) and 200 µl of blocking buffer was added (PBS + 5% w/v fat-free milk). The plate 
was incubated for 1 hr at room temperature, and then the blocking solution was removed and the 
plate was washed three times with PBST. Each CRM sample in PBS pH 7.2 (at 2 mg/ml) was 
then diluted with PBST + 1% fat-free milk to 100 µg/ml. A 1:2 dilution series was performed 
with each CRM molecule in triplicate and 100 µl of each CRM solution was added to each well 
in the 96-well plate. The plate was incubated for 1 hr at 37°C, and then the CRM solutions were 
removed and the plate was washed three times with PBST. One hundred microliters of a rabbit 
anti-CRM polyclonal antibody (at 0.5 µg/ml in PBST, AIC LLC, Rockville, MD) was added to 
each well and the plate was incubated for 1 hr at 37°C. The primary antibody solution was 
removed and the plate was washed three times with PBST. One hundred microliters of a goat 
anti-rabbit antibody (at 0.25 µg/ml in PBST, Jackson ImmunoResearch, West Grove, PA) was 
added to each well and the plate was incubated for 1 hr at 37°C. The secondary antibody solution 
was removed and the plate was washed three times with PBST. One hundred microliters of 
SureBlue TMB peroxidase (SeraCare Life, Milford, MA) was added to each well and the plate 
was incubated for 1 hr at room temperature in the dark. One hundred microliters of 1N HCl was 
added to quench the reaction and the absorbance at 450 nm of each well was measured using a 
SpectralMax M5 plate reader (Molecular Devices, Sunnyvale, CA). Statistical analysis of the 
ELISA results was performed using Prism software (GraphPad Software Inc, La Jolla, CA). A 






(1) LogXb = LogEC50 + (1/HillSlope)*Log((2^(1/S))-1) 
5.2.2.18 Enzyme-Linked Immunosorbent Assay (ELISA) using Monoclonal Antibodies 
One hundred microliters of C7 CRM in PBS (1:1 serial dilutions from 10 to 0.005 mg/ml) 
was added to each well of a 96-well plate. The plate was then incubated overnight at 4°C. The 
following day, the plate was washed three times with PBST (PBS with 0.05% Tween-20) and 
200 µl of blocking buffer was added (PBS + 5% w/v fat-free milk). The plate was incubated for 
1 hr at room temperature, and then the blocking solution was removed and the plate was washed 
three times with PBST. The five monoclonal mouse CRM197 antibodies (AB8306, AB8307, 
AB8308, AB8310, and AB53827, Abcam, Cambridge, MA) were diluted 1:1000 with PBST + 
0.1% w/v BSA and 100 µl of each antibody was added (individually) to the CRM197-containing 
96-well plate. The plate was incubated for 2 hr at room temperature, and then the antibody 
solutions were removed and the plate was washed three times with PBST. The goat anti-mouse 
antibody (Thermo Fisher) was diluted 1:4000 with PBST + 0.1% w/v BSA and 100 µl of the 
antibody was added to each well. The plate was incubated for 1 hr at room temperature and then, 
the secondary antibody solution was removed and the plate was washed five times with PBST. 
One hundred microliters of p-nitrophenyl phosphate-liquid substrate (Sigma) was added to each 
well and the plate was incubated for 1 hr at room temperature in the dark. One hundred 
microliters of 2N NaOH was added to quench the reaction and the absorbance at 405 and 490 nm 
of each well was measured using a SpectraMax M5 plate reader (Molecular Devices). The 
absorbance value at 490 nm was then subtracted from the 405 nm value. 
5.2.2.19 BioLayer Inferometry 
The binding kinetics of CRM with mAbs was evaluated using Octet Red 96 system (Pall 




hydrated for ~15-20 min in kinetics buffer (PBS pH 7.2 + 0.1% BSA), followed by 
preconditioning comprising of three rounds of 20 sec exposure each to regeneration buffer (10 
mM glycine, pH 1.7) alternating with kinetics buffer. After the biosensor preconditioning, the 
kinetic assay comprised of five steps: (1) 300 sec equilibration with kinetics buffer; (2) 450 sec 
of antibody loading to capture CRM197-mAb onto the biosensor; (3) 200 sec equilibration with 
kinetics buffer to obtain a stable baseline after Fc mAb immobilization; (4) 600 sec association 
with each of the five CRM197 samples individually; and (5) 600 sec dissociation with kinetics 
buffer. The biosensors were regenerated for up to 5 times by subjecting to alternating cycles of 
regeneration and kinetics buffer for 5 sec each. Kinetics assay were performed using 8 nM of 
each mAb and a range of CRM197 concentrations (0-200 nM). Data analysis were performed 
using Octet Data Analysis (v 8.2) software. After data processing, including reference 
subtraction using the 0 nM CRM197 concentration (buffer blank) trace, baseline alignment, and 
inter-step correction, the association and dissociation traces of the five CRM197 samples with 
each of the five mAbs individually were fit to a 1:1 binding model. KD, ka and kdis values were 
extracted from the curve fitting analysis of the kinetic data. 
5.3 Results 
5.3.1 Protein Purity, Primary Structure and Post-translational Modification Analysis of 
Five CRM197 Molecules 
Under non-reducing or reducing SDS-PAGE conditions, one band was primarily 
observed in each CRM197 sample (Figure 5.1A). The migration of the main band (between the 49 
and 62 kDa molecular weight (MW) protein markers) was consistent with the theoretical MW of 




and C7 CRM. Independent analysis of LC-MS peptide mapping confirmed these lower MW 
species were the A (~21 kDa) and B (~38 kDa) subunits of CRM197 (data not shown).  
Intact mass spectrometry was used to elucidate and compare the molecular composition 
of the five CRM197 proteins. As shown in Figure 5.1B, a single species was observed in the 
deconvoluted mass spectra of rCRM, Pfenex CRM, and Vaxform CRM (58,541 ± 1 Da), which 
was consistent with the expected mass of an unmodified and non-reduced CRM197 monomer 
(Table 5.2). EcoCRM™ contained two species that differed in mass by ~131 Da. LC-MS peptide 
mapping confirmed these two species were the unmodified CRM197 monomer without (58,410 ± 
1 Da) and with (58,541 ± 1 Da) an N-terminal Met residue (Figure 1C). In addition to the 
unmodified CRM197 monomer in C7 CRM, two additional higher MW species were observed 
(CRM197 MW + ~324 Da and CRM197 MW + ~648 Da), which may represent post-translational 
modifications involving disaccharides (e.g., potentially lactose glycations in the lyophilized 
samples).   
The five different CRM197 molecules were also subjected to peptide mapping analysis to 
confirm their primary amino acid sequence. As shown in Figure 5.1C, the trypsin-digested 
reversed phase UPLC chromatograms of the five CRM197 samples were similar. MS/MS analysis 
of individual trypsin or GluC digests confirmed a similar amino acid composition of the five 
CRM197 proteins (Supplemental Figure 5.1). The two native disulfide bonds in CRM197 (Cys187-
Cys201 & Cys462-Cys472) were identified in each CRM197 molecule, and no non-native 
disulfide bonds or free Cys residues were observed in any sample. Multiple smaller peaks were 
observed in C7 CRM, and while the identities of these peaks are unknown, they could potentially 




5.3.2 Charge Heterogeneity Analysis of Five CRM197 Molecules 
Capillary isoelectric focusing (cIEF) and anion exchange chromatography (AEX) were 
utilized to assess the overall charge heterogeneity of each CRM197 protein. As shown in Figure 
5.2A, the pI of the major peak in each CRM197 sample was ~5.7 as measured by cIEF, which was 
consistent with previously reported pI of CRM197
15
. The EcoCRM™ and Vaxform CRM samples 
contained a small amount (4-7%) of a more acidic species (pI 5.5-5.6) relative to the main peak 
(Table 5.2), while the relative area of this species was more prominent in C7 CRM sample 
(~21%). The elution profile of each CRM197 protein through AEX was overall similar to their 
cIEF electropherograms profiles in which the retention time of the major peak was consistent 
across all five samples. In addition, EcoCRM™ and C7 CRM contained measurable acidic 
species, 8% and 24%, respectively, as measured by AEX. For Vaxform CRM sample, ~4% of 
the relatively more acidic species were observed through cIEF, but this species was found to be 
more prominent through AEX analysis (~17%).  
5.3.3 Higher Order Structure (HOS) Analysis of Five CRM197 Molecules 
Far-UV circular dichroism (CD) spectroscopy was used to assess the overall secondary 
structure of each CRM197 protein. As shown in Figure 5.3A, double minima at 208 and 222 nm 
were observed at 10˚C indicating a primarily α-helical secondary structure, consistent with the 
X-ray crystal structure of CRM197 (PDB ID:4AE0)
11
. Second derivative UV spectroscopy, 
intrinsic Trp fluorescence spectroscopy, and extrinsic ANS fluorescence spectroscopy analyses 
were performed to evaluate and compare the overall tertiary structures of the five CRM197 
molecules at 10°C. Six major peaks were observed for each CRM197 sample by second derivative 
UV spectroscopy, which correspond to different local polarity environments of the three 




300 nm) in each protein (Figure 5.3B). The similar positions of these peaks between the five 
CRM197 proteins suggest a similar overall tertiary structure via a similar environment around the 
average aromatic acid residues. The intrinsic Trp and extrinsic ANS fluorescence spectra further 
support an overall similar tertiary structure across the five samples. As shown in Figure 5.3C, the 
intrinsic Trp fluorescence wavelength of maximum intensity (λmax) was ~330 nm at 10˚C, which 
indicated a similar hydrophobic environment for the average Trp residue in each CRM197 
molecule. Finally, the extrinsic ANS fluorescence emission peak maximum and peak intensity at 
10˚C was not notably different between the five proteins (Figure 5.3D), which suggested a 
comparable overall surface hydrophobicity across the five proteins.  
5.3.4 Size and Aggregate/Particle Analysis of Five CRM197 Molecules 
The size analysis of monomer, aggregate and fragment species in each CRM197 sample was 
assessed under non-denaturing solution conditions by sedimentation velocity analytical 
ultracentrifugation (SV-AUC) and size exclusion chromatography (SEC). The sedimentation 
coefficient value of the major species in each CRM197 sample was 3.9 ± 0.1 S, consistent with a 
CRM197 monomer (Figure 5.4A). The relative area of this monomeric peak ranged from 68-99% 
of each sample’s total peak area (Table 5.2). Furthermore, some larger species (e.g., dimer, 
trimer) with higher sedimentation values (~5-8 S) were observed in EcoCRM
™
, Vaxform CRM, 
and C7 CRM while smaller species (e.g., fragments), at ~1-3 S sedimentation values, were 
present in rCRM and C7 CRM samples. SEC analysis showed comparable size distributions of 
monomer, aggregate and fragment species in which EcoCRM
™
, rCRM, and Pfenex CRM were 
primarily monomeric (~97-100%) while Vaxform CRM and C7 CRM contained more abundant 
smaller fragment (1% and 14 %, respectively) and larger aggregate (28 % and 13 %, 




In addition to size analysis by SV-AUC and SEC, the presence of larger aggregates/particles 
were assessed through resonant mass measurements (RMM) and micro-flow imaging (MFI). 
RMM measures the concentration and size distribution of sub-micron (0.2-2 µm) particles, while 
MFI measures the same parameters for sub-visible (2-100 µm) particles. As reported in Table 
5.2, a slightly higher number of sub-micron particles were present in Vaxform CRM and C7 
CRM (~5 × 10
5 
particles/mL) compared to EcoCRM
™
, rCRM and Pfenex CRM (~2 × 10
5
 
particles/mL). The majority of sub-micron particles were in the size range of 0.2-1.0 μm. MFI 
analysis indicated a low number of sub-visible particles in EcoCRM
™
, rCRM, Pfenex CRM, and 
Vaxform CRM (~100 particles/mL), while a slightly higher number of sub-visible particles were 
measured in C7 CRM (~450 particles/mL). The majority of sub-micron and sub-visible particles 
in all the five CRM197 samples were 0.2-1.0 μm and 2-5 μm, respectively. 
5.3.5 Conformational Stability, Aggregation Propensity and Relative Solubility of Five 
CRM197 Molecules 
The conformational stability of each CRM197 proteins’ overall secondary structure was 
assessed through monitoring their molar ellipticity values at 222 nm as a function of temperature 
(10-90˚C) in PBS buffer, pH 7.2. As shown in Figure 5.5A, each of the CRM197 molecules 
(except C7 CRM) showed a sharp transition. The C7 CRM sample showed a biphasic transition 
between 55-75°C, which may be due to heterogeneity in the protein sample (as observed by 
SDS-PAGE and intact mass analysis; see Figures 5.1 and 5.2). The calculated apparent thermal 
melting temperature values (Tm) of EcoCRM
™
, rCRM, Pfenex CRM, and Vaxform CRM were 
~58°C (Table 5.2). For C7 CRM, the broad and slightly biphasic nature of the transition 




The conformational stability of each CRM197 proteins’ overall tertiary structure vs. 
temperature was evaluated through both intrinsic and extrinsic fluorescence spectroscopy in PBS 
buffer, pH 7.2. A single transition (red shift) was observed in the intrinsic tryptophan 
fluorescence spectra peak position vs. temperature in all five samples with Tm values at ~42°C. 
The Tm values calculated from changes in ANS fluorescence emission peak intensity vs. 
temperature in the presence of the protein were also similar between the five CRM197 molecules 
(~41˚C). These results indicated a relative overall similar tertiary structure stability in terms of 
the average Trp residue and average surface hydrophobicity of the proteins, respectively. 
Furthermore, DSC was used to assess the overall conformational stability of each of the five 
CRM197 samples as a function of temperature in PBS buffer, pH 7.2. As shown in Figure 5.5D, 
one major and one minor endothermic peak was observed for all CRM197 molecules at ~40˚C 
and 50˚C, respectively. Overall, the DSC thermograms of rCRM, Pfenex CRM, and Vaxform 
CRM samples appeared similar but subtle differences were observed in EcoCRM
™
 (slightly 
lower stability of Tm1) and C7 CRM (slightly higher stability of Tm1)(Table 5.2).  
The aggregation propensity and relative solubility of the five CRM197 samples was also 
studied by static light scattering vs temperature and PEG precipitation curves, respectively. The 
light scattered from each CRM197 sample was measured a function of temperature (10-65°C) in 
PBS buffer. As shown in Figure 5.5E, one sharp transition was observed in all samples that 
began (Tonset) at ~45°C. The relative apparent solubility (thermodynamic activity) profiles of the 
five CRM197 molecules were assessed using PEG precipitation assay as described previously
18
. 
As shown in Figure 5.5F, the shape of the PEG curves (concentration of protein, (mg/mL) vs. 
percentage (w/v) PEG-6,000 of Vaxform CRM appeared to have a shifted profile compared to 
the four other CRM197 samples (C7 CRM, rCRM, EcoCRM
™




reason for the more rapid precipitation of Vaxform CRM as a function of PEG concentration is 
the relatively higher levels of aggregates present in the sample as observed by size exclusion 
chromatography and SV-AUC.  From the PEG vs. protein concentration curves, two different 
relative solubility parameters (PEGmidpt and apparent solubility) were calculated. PEGmidpt value 
is a parameter to quickly and reliably compare datasets while the apparent solubility value is 
extrapolated from each precipitation curve and assumes no interaction between the PEG and 
protein, which is not necessarily the case for all proteins
17
. The PEGmidpt value was lowest for 
Vaxform CRM (~21.5%) while rCRM, EcoCRM
™
, Pfenex CRM and C7 CRM had similar 
PEGmidpt values (~23%)(Table 5.2). A comparison of the apparent solubility values of each of the 
proteins showed a similar trend as seen in the PEGmidpt values, in which Vaxform appeared to 
have a lower apparent solubility (~16 mg/mL) compared to C7 CRM, rCRM, EcoCRM
™
, and 
Pfenex CRM (~27-34 mg/mL) in PBS buffer, pH 7.2. 
5.3.6 Physical Stability Profiles of Five CRM197 Molecules during pH/Temperature 
Stresses 
The physical stability profiles of the five CRM197 molecules were evaluated in PBS buffer 
under a wide range of pH (pH 5.8-8.0) and temperature (10-90
o
C) conditions. For each pH and 
temperature, the overall secondary and tertiary structural integrity, overall conformational 
stability and aggregation propensity of each CRM197 sample were measured using circular 
dichroism, intrinsic tryptophan fluorescence spectroscopy, differential scanning calorimetry and 
static light scattering, respectively. Representative data sets for C7 CRM in PBS buffer at 
different pH values from these different biophysical techniques are shown in Figure 5.6A (see 
Supplemental Figures 5.2-5.5 for the corresponding biophysical data sets for each of the five 




dramatic pH dependence with a single thermal transition event at pH values of s 5.8-7.2 (with 
Tm values ranging between ~37-62°C). At pH 7.6 and 8.0, however, a distinct thermal transition 
was not observed, which prevented accurate calculation of a Tm. Clear differences in the stability 
of the overall secondary structure were observed in the CRM197 samples (i.e., more stable pH ≥ 
7.2 and less stable at pH 5.8-6.8). An increase in Trp fluorescence peak position of C7 CRM 
spectra was observed with increases in temperature for each pH, indicating a pH dependent 
alteration of the protein’s overall tertiary structure. The observed Tm values were highest at pH 
6.8-7.2 (42-44°C), slightly lower at pH 6.3, 7.6, or 8.0 (41-42°C), and distinctly lower at pH 5.8 
(34°C) (Table 5.2). DSC results indicated the highest overall conformational stability of C7 
CRM occurred at pH 6.8-7.2 and was slightly lower at the other solution pH conditions tested. 
Finally, the temperature at which C7 CRM began (Tonset) to scatter more light (i.e., aggregate) 
was lowest at pH 5.8 (29°C) and increased with an increasing solution pH (Tonset was 47°C at pH 
8.0) as measured by static light scattering. Similar pH-dependent physical stability profiles were 
observed with EcoCRM
™
, rCRM, Pfenex CRM, and Vaxform CRM (See Supplementary Figures 
5.2-5.5 and Supplemental Table 5.1). 
Using the large biophysical datasets from the above four techniques, two data visualization 
tools were utilized, an empirical phase diagram (EPD) and a radar chart to better compare the 
overall physical stability profiles of each CRM197 protein as a function of pH and temperature 
19,20
. The EPD displayed changes in the structural characteristics of each CRM as measured by 
the four different biophysical techniques (circular dichroism, intrinsic tryptophan fluorescence, 
static light scattering, and differential scanning calorimetry), as a function of temperature and 
pH. The EPD plots for all five CRM197 molecules indicated the presence of six distinct colored 




represented regions with similar structural characteristics and changes in color reflected 
structural alterations in each CRM197 protein as measured by the biophysical measurements. In 
addition to the native-like region at low temperatures (Region I), five structurally altered protein 
states were observed both with EPD. Region II denotes an overall altered conformation of 
CRM197 molecule, Region III represents a structurally altered state beginning to aggregate, 
Region IV corresponds to an aggregated state of protein, Region V represents more extensively 
aggregated and structurally altered state, and Region VI shows substantial secondary structure 
alterations.  
Radar plots were also constructed to visualize the same physical stability data sets for each 
of the five CRM197 proteins as a function of solution pH and temperature. A Radar plot displays 
the results of the different biophysical analyses in a polygon, in which each vertex is mapped to a 
particular biophysical technique and concentric circles represent the signal variation/strength. As 
shown in Figure 5.6C, the signals for each of the biophysical techniques (CD molar ellipticity, 
intrinsic tryptophan fluorescence, DSC, and static light scattering) were minimal in Region I, 
representing the native-like state for the CRM197 molecule. Region II represents CRM197 in an 
overall structurally altered conformation as indicated by increase in the DSC signal and 
alterations in the intrinsic tryptophan fluorescence peak position. Region III was assigned based 
on the loss of tertiary structure as monitored by intrinsic tryptophan fluorescence. Region IV 
represents CRM197 in aggregated state as indicated by increase in the light scattering signal. 
Region V corresponds to a more aggregated and structurally altered state as seen from notable 
changes in the signals from light scattering and CD, and lastly, Region VI reflects loss of 
secondary structure as measured by circular dichroism. Overall, a comparison of EPD and radar 




vs. pH and temperature. Additionally, the total area for the native-like state as a function of pH 
and temperature, Region I, was similar (35-37%) for all five CRM197 molecules.   
5.3.7 In vitro Antigenicity Assessment of Five CRM197 Molecules 
For comparing of the in vitro antigenicity of each CRM molecule, the steady-state and 
pre-steady state kinetics were measured through an ELISA (polyclonal anti-CRM197 antibodies) 
and bio-layer interferometry (individual measurements with five different monoclonal CRM197 
antibodies), respectively. While a visual comparison of the binding curves of the CRM 
molecules to commercially available polyclonal CRM197 antibodies suggested subtle differences 
in antigenicity between the five CRM197 molecules (Figure 5.7A), a statistical analysis indicated, 
however, that the steady-state interactions of each CRM197 molecule with the polyclonal 
antibodies were not significantly (p > 0.05) different from each other (Table 5.2).  
The pre-steady state kinetics of between each CRM197 and five monoclonal antibodies 
(mAbs) were measured using bio-layer interferometry (BLI). Prior to the BLI assay, the 
concentrations of each of the five mAbs required to monitor binding to C7 CRM was optimized 
with an ELISA. As shown in Figure 5.7B, affinity differences were observed between the five 
antibodies and C7 CRM as measured by the ELISA. The five mAbs were categorized into three 
groups, one higher-affinity mAb (AB53827), two intermediate affinity mAbs (AB8308 and 
AB8310), and two lower-affinity mAbs (AB8307 and AB8306). The pre-steady state kinetics 
(ka, kdis, and KD) were then measured between each CRM197 molecule and mAb using BLI. A 
representative association and dissociation binding curve for C7 CRM and a lower-affinity mAb 
(AB8306) as measured by BLI is shown in Figure 4.7C. Similar to the ELISA results with C7 















comparable between all the five CRM197 molecules (Table 5.2). For the three other mAbs 
(AB8308, AB8310, and AB53827), pre-steady state kinetics could not be accurately measured 
by this technique due to their strong affinity (KD < nM) for each of the five CRM197 molecules.  
5.4 Discussion 
In this study, the physicochemical and immunological binding properties of recombinant 
CRM197 from the traditional expression system (C. diptheriae) as well as two heterologous 
systems (E. coli and P. fluorescens) were evaluated and compared as part of an analytical 
comparability assessment. A comprehensive suite of analytical techniques assessed numerous 
structural attributes including primary structure and post translational modifications, higher order 
structures, overall surface hydrophobicity and charge heterogeneity, and aggregate/particle 
formation from small multimers to larger sub-visible particles. Overall, the five CRM197 
molecules exhibited overall highly similar physicochemical characteristics (with some 
exceptions in terms of subtle physicochemical differences as described below) in a common 
buffer (PBS, pH 7.2). These similarities were also conserved in terms of conformational stability 
under different stress conditions (pH/temperature changes) as well as for relative solubility (in 
the presence of molecular crowding agent, PEG). Finally, each CRM197 displayed essentially 
equivalent in vitro antigenicity in terms of binding to a series of antibodies (polyclonal and 
monoclonal mAbs specific for CRM197). Together, these observations indicate the various 
expression systems produced generally comparable CRM197 molecules. 
The largest differences noted between the CRM197 proteins were the presence of product-
related variants/impurities. The nature of these species in some cases was determined, and in 
other cases, will require additional analysis. For example, N-terminal heterogeneity with a Met 




vs. without N-terminal Met) and was not necessarily unexpected given a lower catalytic 
efficiency of methionyl-aminopeptidase in some strains of E. coli 
22,23
. Two low-abundant 
species in C7 CRM contained post-translational modifications with +324 and +648 Da, which 
were possibly caused by non-enzymatic glycation between a reducing sugar (lactose) within the 
formulation buffer and the protein, especially upon lyophilization, as has been observed with 
other freeze-dried proteins 
24-26
. The C7 CRM sample also contained lower and higher molecular 
weight species that were observed by two different orthogonal sizing techniques (SV-AUC and 
SEC). The presence of these fragment and soluble aggregate species may have arisen during the 
bulk manufacturing process, lyophilization and/or subsequent storage. Analysis of material from 
each downstream processing step would be needed to identify the mechanism(s) that induced the 
formation of these species. In addition, the Vaxform CRM sample contained relatively elevated 
levels (~29% by SV-AUC) of higher molecular weight species, which could potentially be a 
consequence of the material’s age and long-term storage (~11 yrs.). Furthermore, although 
speculative, the higher MW species in this sample may possibly be comprised of the observed 
acidic peak through AEX since the cIEF results indicated  the levels of the acidic species in 
Vaxform CRM was greatly reduced. Unlike AEX, cIEF assess the overall charge (pI) of a 
generally unfolded molecule following migration through a pH gradient, therefore the larger 
(non-covalently associated) species in Vaxform CRM would likely dissociate during analysis. 
The more acidic species in C7 CRM however, were observed at a similar amount (21-24%) by 
both AEX and cIEF. This acidic peak in C7 CRM may represent CRM197 containing the lactose 
glycan(s) variants that were observed by intact mass analysis. Finally, the composition of the low 
abundant acidic species (7-8%) observed in EcoCRM™ through AEX and cIEF could represent 






and determination of these species is suggested for future work. In addition, potential differences 
in process-related impurities (e.g. residual host cell proteins, residual DNA) between CRM197 
from different manufacturers should also be examined as part of future comparability work. 
In this work, we have implemented state-of-the-art analytical methods to 
comprehensively characterize the structural integrity, conformational stability and relative 
solubility of CRM197 bulk materials. Mass spectrometry analysis can rigorously define the 
primary structure and post translational of proteins ensuring the structural integrity and defining 
the presence of structural variants. A current technical challenge is the use of analytical tools to 
rigorously characterize the higher order structure of protein. This work did not utilize higher 
resolution methods such as X-ray crystallography or hydrogen deuterium exchange mass 
spectrometry since such methods are not commonly available, expensive and are relatively time 
consuming. Instead, the key structural attributes of the CRM197 molecule were monitored using 
commonly available analytical instruments. In addition, the biophysical techniques utilized in 
this work, combined with data visualization tools, can monitor the conformational stability of the 
CRM197 in a comprehensive manner as a function of stress conditions such as pH and 
temperature. The stability of protein structure can be a sensitive probe for the overall higher 
order structural integrity of proteins and it has been suggested such an approach is an important 
part of protein comparability studies and biosimilarity analyses 
27-29
. In this work, the resulting 
empirical phase diagrams were similar overall for the five CRM197 molecules, indicating a 
similar structural integrity and conformational stability. Not surprisingly, all of the CRM197 
molecules showed a notable decrease in the overall conformational stability profile as the 








Interestingly, despite the noted structural heterogeneity differences noted between the five 
CRM197 samples, their binding reactivity to polyclonal or multiple individual monoclonal 
antibodies was equivalent. This result could be due to the low levels of these variants in the 
preparations and an associated lack of sensitivity to detect small differences in these types of 
binding assays. Future work would need to focus on the isolation of the variants and then a more 
direct comparison of their in vitro binding properties. Furthermore, the specific epitopes 
recognized by the five anti-CRM197 monoclonal antibodies described in this study are currently 
unknown, but in general, in vitro immunological binding assays are a critical probe of the overall 
structural integrity of biologicals. Due to the challenges in rigorously defining all aspects of 
higher order structure of proteins with current analytical technology (as described above), 
functional or potency assays are required to ensure to the overall structure/function of protein 
vaccine or drug candidates are maintained during development. To this end, biological potency 
assays (either in vitro assays or in vivo animal studies depending on the nature of the vaccine 
antigen) remain a cornerstone of the overall analytical strategy to ensure comparability and 
biosimilarity 
31
. In the case of the carrier protein CRM197 for use in  as polysaccharide conjugate 
vaccines, in vitro binding assays are a useful tool for probing the overall conformational integrity 
of the molecule as part of comparability assessments (especially using mAbs with known 
binding to specific epitopes to a reference with known in vivo activity as part of future work). 
Nonetheless, to directly compare the ability of the different CRM197 molecules to generate 
immune responses, an in vivo biological potency assay would be more suited for the final 




These findings lead to question if some or any of these subtle physiochemical 
differences/impurities observed in the bulk CRM197 have an effect (if any) on the preparation of 
the final drug product of conjugate vaccine. From the limited literature available, conjugate 
vaccines containing CRM197 from different expression systems elicit similar immune responses 
in animal models 
5,31
. It is currently unknown which analytical readout(s) performed in this work 
could predict detrimental effects on subsequent conjugation of the protein to various 
polysaccharides and its effects on the safety and efficacy of the conjugate vaccine drug product. 
Furthermore, for industrial use of CRM197 as carrier protein in conjugate vaccines, the critical to 
quality (CTQ) parameters have to be established with prospective acceptance criteria to ensure 
that the carrier protein meets the quality requirements for robust and sustainable manufacturing. 
Typically this information would be available to the manufacturer in a pharmacopeia/WHO 
technical review series (TRS) monograph. Unfortunately, such a monograph does not currently 
exist for CRM197 carrier protein. It is also important for the industry to have this CTQ parameters 
quantified, so that these could be used for in-depth characterization, lot release and stability 
analysis. While additional studies are needed to determine if the observed subtle differences 
between different sources of commercially available CRM197 influence the development of 
conjugate vaccines, the presented results provide a basis to develop and establish specifications 
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Table 5.2. Summary of the key structural attributes (physicochemical and in vitro antigenicity) 
of recombinant CRM197 proteins (in PBS pH 7.2) produced from three different expression 















Intact Protein Mass (Da) 
58410 ± 1 
58541 ± 1* 
58410 ± 1 58410 ± 1 58410 ± 1 
58410 ±1 
58734 ± 1* 
















(pI 5.6-5.7) (%) 
92 ± 0 99 ± 0 99 ± 0 95 ± 0 79 ± 1 
Acidic species 
(pI 5.5-5.6) (%) 
7 ± 0 0 ± 0 0 ± 0 4 ± 0 21 ± 1 
Basic species 
(pI 5.7-5.8) (%) 
1 ± 0 1 ± 0 1 ± 0 1 ± 0 0 ± 1 
Anion Exchange 
Chromatography 
Main Peak (%) 92 ± 0 100 ± 0 100 ± 0 83 ± 0 75 ± 1 












208 & 222 
58.2 ± 1.0 
208 & 222 
57.9 ± 0.7 
208 & 222 
57.9 ± 0.3 
208 & 222 
59.6 ± 0.6 











328 ± 1 
41.2 ± 0.3 
329 ± 1 
42. 3± 0.3 
329 ± 1 
42.3 ± 0.3 
330 ± 1 
42.2 ± 0.6 
331 ± 1 




C) 43.0 ± 0.6 43.4 ± 0.2 43.6 ± 0.3 44.6 ± 0.5 45.2 ± 0.7 
Extrinsic ANS 
Fluorescence 







441 ± 7 
40.8 ± 0.5 
441 ± 9 
41.5 ± 0.3 
437 ± 8 
41.4 ± 0.5 
443 ± 11 
41.3 ± 0.6 
411 ± 16 













32.7 ± 0.3 
42.0 ± 0.0 
51.3 ± 0.2 
35.0 ± 0.2 
42.9 ± 0.0 
51.3 ± 0.1 
34.8 ± 0.2 
42.8 ± 0.0 
51.1 ± 0.2 
33.5 ± 0.2 
42.8 ± 0.2 
51.1 ± 0.3 
35.2 ± 0.6 
44.0 ± 0.1 





Monomer (%) 98 ± 0 99 ± 0 100 ± 0 71 ± 0 73 ± 1 
Aggregates (%) 1 ± 0 0 ± 0 0 ± 0 28 ± 0 13 ± 1 





Monomer (%) 99 ± 0 99 ± 0 100 ± 0 70 ± 0 68 ± 1 
Aggregates (%) 1 ± 0 0 ± 0 0 ± 0 30 ± 0 11 ± 1 












Total particles after dilution 
(number/mL) 





PEGmidpt (%) 23.3 ± 0.2 23.0 ± 0.2 23.5 ± 0.1 21.5 ± 0.2 24.0 ± 0.2 
Apparent Solubility in 
PBS pH 7.2 (mg/mL) 
























) 1.3 ± 0.3 1.4 ± 0.5 1.5 ± 0.4 1.6 ± 0.9 1.7 ± 0.4 
K
D


























) 1.4 ± 0.4 1.3 ± 0.6 1.4 ± 0.4 1.6 ± 0.4 1.6 ± 1.0 
K
D





Figure 5.1. Primary Structure Analysis of Five CRM197 Molecules. (A) SDS-PAGE analysis of 
CRM197 molecules under non-reducing and reducing conditions. (B) Representative intact mass 
spectrometry analysis of the non-reduced CRM197 molecules.  (C) Representative LC peptide 
mapping chromatograms of non-reduced trypsin-digested CRM197 samples. The red and blue 








 bonded peptides, 





Figure 5.2. Charge Heterogeneity Analysis of Five CRM197 Molecules. The overall charge 
heterogeneity of the CRM197 samples were compared through both (A) capillary isoelectric 
focusing, and (B) anion-exchange chromatography. The migration of two pI markers (4.7 and 











Figure 5.3. Higher Order Structure Analysis of Five CRM197 Molecules. (A) The overall 
secondary structures were evaluated by Far-UV circular dichroism spectra, (B) the overall 
tertiary structures were monitored by both (B) Second derivative UV absorbance spectra, and (C) 
Intrinsic tryptophan fluorescence emission spectra.  (D) The overall surface hydrophobicity of 
the samples were determined by Extrinsic ANS fluorescence emission spectra.  The five CRM197 









Figure 5.4. Size Analysis of Five CRM197 Molecules. The size and distribution of monomer, 
aggregate and fragment species in each of the CRM197 samples were compared through (A) 
sedimentation velocity analytical ultracentrifugation (SV-AUC), and (B) size exclusion 
chromatography (SEC). The elution times and molecular weight values of gel filtration standard 








Figure 5.5. Conformational Stability, Aggregation Propensity, and Relative Solubility Analysis 
Five CRM197 Molecules. The conformational stability profiles of the CRM197 samples in PBS 
buffer (pH 7.2) were compared as a function of temperature (10-90˚C) through (A) far-UV 
circular dichroism, (B) intrinsic tryptophan fluorescence spectroscopy (MSM peak position), (C) 
extrinsic ANS peak intensity in the presence of each protein, and (D) differential scanning 
calorimetry. (E) The aggregation propensity of the CRM197 samples were compared through 
static light scattering as a function of temperature (10-90˚C). (F) The relative apparent solubility 
of the CRM197 samples were compared as a function of an increasing concentration (0-33% w/v) 










Figure 5.6. Physical Stability Analysis of the Five CRM197 Molecules as a Function of pH and 
Temperature.  (A) The molar ellipticity at 222 nm, intrinsic Trp fluorescence MSM peak 
position, differential scanning calorimetry, and static light scattering at 295 nm for C7 CRM in 
PBS buffer at six different pH s (5.8, 6.3, 6.8, 7.2, 7.6, and 8.0) were measured as a function of 
temperature (10-90˚C).  (B) An empirical phase diagram and radar chart for C7 CRM were 
generated from the data in panel A. Six distinct biophysical states of C7 CRM (regions I-VI) 
were observed as a function of pH and temperature (see Results section for more details). (C) 
Summary of calculated radar charts of each of the five CRM197 molecules. The contributions of 
each biophysical technique towards the different structural states of each CRM197 are indicated 







Figure 5.7. In vitro Antigenicity Analysis of the Five CRM197 Molecules. (A) ELISA reactivity 
of each CRM197 protein as a function of protein concentration (0.005-100 µg/mL) to a polyclonal 
CRM197 antibody. (B) ELISA reactivity of C7 CRM as a function of protein concentration 
(0.005-10 µg/mL) to five different monoclonal CRM197 antibodies. (C) Representative 
association and dissociation binding curves of six concentrations (4-200 nM) of C7 CRM to a 



















Supplemental Table 5.1. Thermal melting temperature (Tm) values of each CRM197 protein 
calculated from each biophysical technique in PBS buffer at pH 5.8, 6.3, 6.8, 7.2, 7.6, or 8.0 vs. 
temperature. 






Circular Dichroism at 222 
nm (Tm) 
5.8 33.8 ± 0.1 37.4 ± 0.0 37.4 ± 0.1 37.5 ± 0.1 36.5 ± 0.4 
6.3 41.1 ± 0.5 41.8 ± 0.6 41.7 ± 0.5 41.4 ± 0.4 42.9 ± 0.7 
6.8 45.8 ± 0.8 52.6 ± 0.2 49.1 ± 0.8 49.0 ± 0.2 47.9 ± 0.5 
7.2 59.6 ± 0.6 62.2 ± 0.4 61.9 ± 0.6 61.3 ± 0.1 59.0 ± 0.5 
7.6 * * * * * 
8.0 * * * * * 
Intrinsic Tryptophan 
Fluorescence Peak Position 
(Tm) 
5.8 32.3 ± 0.4 35.5 ± 0.7 36.0 ± 0.4 36.2 ± 0.3 34.4 ± 0.3 
6.3 39.4 ± 0.5 39.9 ± 0.2 39.9 ± 0.1 39.6 ± 0.5 41.0 ± 0.5 
6.8 41.3 ± 0.1 42.4 ± 0.2 42.3 ± 0.3 42.3 ± 0.2 42.7 ± 0.3 
7.2 41.5 ± 0.1 42.2 ± 0.2 42.5 ± 0.4 42.2 ± 0.2 43.5 ± 0.1 
7.6 40.1 ± 0.2 41.4 ± 0.0 41.3 ± 0.1 41.4 ± 0.0 42.2 ± 0.6 




5.8 36.7 ± 0.1 39.4 ± 0.0 39.3 ± 0.0 39.8 ± 0.0 38.9 ± 0.1 
6.3 41.7 ± 0.0 42.7 ± 0.0 42.6 ± 0.0 42.5 ± 0.0 43.6 ± 0.0 
6.8 42.3 ± 0.0 43.1 ± 0.0 43.1 ± 0.0 43.1 ± 0.0 44.2 ± 0.0 
7.2 42.2 ± 0.0 42.8 ± 0.1 42.9 ± 0.1 42.8 ± 0.0 44.1 ± 0.0 
7.6 41.3 ± 0.0 42.4 ± 0.0 42.4 ± 0.0 42.4 ± 0.0 43.4 ± 0.1 
8.0 41.2 ± 0.0 41.8 ± 0.0 41.9 ± 0.0 42.0 ± 0.0 43.0 ± 0.0 
Static Light Scattering 
(Tonset) 
5.8 26.4 ± 0.1 28.2 ± 0.6 27.6 ± 0.2 27.8 ± 0.2 28.9 ± 0.2 
6.3 37.0 ± 0.1 35.0 ± 0.4 35.1 ± 0.2 34.1 ± 0.4 38.5 ± 0.1 
6.8 41.6 ± 0.1 40.4 ± 0.0 40.1 ± 0.0 40.2 ± 0.2 42.5 ± 0.2 
7.2 44.1 ± 0.1 42.5 ± 0.4 43.0 ± 0.1 42.1 ± 0.1 44.8 ± 0.6 
7.6 47.2 ± 0.2 43.3 ± 0.1 44.4 ± 0.1 43.9 ± 0.1 46.4 ± 0.6 
8.0 48.1 ± 0.1 43.6 ± 0.2 44.6 ± 0.1 44.2 ± 0.2 47.2 ± 0.1 











Supplemental Figure 5.1. Sequence coverage of the five CRM197 molecules from a non-
reduced, A) trypsin-digestion or B) GluC-digested peptide mapping method. Black, red, blue, 
green, and orange bars indicate one or more peptides that were identified covering each region 
for EcoCRM
TM
, rCRM, Pfenex CRM, Vaxform CRM, and C7 CRM, respectively. The two 













Supplemental Figure 5.2. Molar ellipticity values at 222 nm of each CRM197 protein in 
PBS buffer at pH 5.8, 6.3, 6.8, 7.2, 7.6, and 8.0 as a function of temperature (10-90˚C) as 











Supplemental Figure 5.3. Intrinsic Trp fluorescence spectroscopy MSM peak position 
values of each CRM197 protein in PBS buffer at pH 5.8, 6.3, 6.8, 7.2, 7.6, and 8.0 as a function 







Supplemental Figure 5.4. Differential scanning calorimetry thermograms of each CRM197 












Supplemental Figure 5.5. Static light scattering signal of each CRM197 protein in PBS 










Supplemental Figure 5.6. Empirical phase diagram of each CRM197 protein in PBS buffer 
as a function of pH (5.8, 6.3, 6.8, 7.2, 7.6, and 8.0) and temperature (10-90˚C) as measured by 
circular dichroism, intrinsic tryptophan fluorescence, differential scanning calorimetry, and static 
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The clinical development of a vaccine candidate includes several activities such as 
preclinical animal and human clinical testing, CMC (Chemistry, Manufacturing and Control) 
development and regulatory filings
1,2
. All of these activities result in a long, complex and costly 
process with an overall low chance of getting a regulatory approval
3,4
. Vaccines are considered 
the most complex products of biopharmaceutical industry (e.g., macromolecular antigens, 
adjuvants, excipients) and are among the most difficult to stabilize
5
. Proteins are structurally 
complex with fragile structures, and protein based vaccines are very sensitive to environmental 
stresses that can lead to physical or chemical instabilities which in turn can affect potency and 
efficacy
6
. Thus, it is critical to ensure that the protein maintains its stability during all stages of 
CMC development including manufacturing, long term storage, transportation and eventual 
administration to patients
5,7
. There is an ongoing need for better and more sensitive analytical 
tools and robust formulation development approaches to monitor a protein’s key structural and 
biological properties to ensure the stability and potency of the final drug product over the desired 
shelf life
8
. In an effort to better understand the interrelationships between physicochemical 
stability of a protein vaccine with critical functional attributes (such as potency), key focus areas 
of this thesis work included the development of analytical stability-indicating tools and 
formulation development strategies for different protein-based subunit vaccine candidates. 
This dissertation further demonstrated the importance of developing analytics and its utility 
in characterizing the structural integrity and stability profiles for dmLT, a protein-based adjuvant 
(Chapter 3) and three equine encephalitis virus-like particle (EEV VLPs) vaccine antigens 
(Chapter 4). Furthermore, analytical stability indicating methods were developed and used to 
identify stabilizing excipients for a development of stable candidate formulations for the bulk 
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storage of VLPs antigens and dmLT adjuvant candidate. Additionally, a micro-PEG precipitation 
assay was developed to determine the apparent solubility of multiple proteins using less than a 
milligram of material (Chapter 2) and also used in determining the apparent solubility profiles of 
CRM197 molecules (Chapter 5). In addition to analytical characterization and formulation 
development, comparability assessment exercises are also essential to determine the structural 
integrity and stability of a protein containing vaccine candidate due to both product and process 
related manufacturing changes
9,10
. An extensive set of analytical tools was utilized to compare 
the physicochemical properties, physical stability profiles and in vitro antigenic properties of five 
recombinant CRM197 molecules from different expression systems and manufacturers (Chapter 
5). 
6.2 Chapter summaries and future work 
6.2.1 Chapter 2 
A micro PEG assay was successfully developed to estimate the apparent solubility of 
various mAbs against HIV-1 virus. The optimized assay utilizes only about 1 mg of protein, as 
developed using the VRC01-WT mAb including determining the assay’s accuracy and precision 
for various readouts. Relative protein apparent solubility profiles of a series of broadly 
neutralizing mAbs to HIV-1 envelope were determined using micro PEG assay including 
evaluating the curve shape (%PEG vs. protein concentrations), %PEG midpoint numbers, and 
extrapolated apparent solubility values. 
The PEG-assay was then successfully utilized to a) rank ordering via evaluation of 
PEGcurves, PEGmidpt, and apparent solubility values of different mAbs compared to VRC01-WT 
and b) screen numerous formulation conditions (buffers, salt, pH and arginine) to evaluate the 
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relative protein apparent solubility profiles of VRC01-WT.  The PEGmidpt values were found to 
decrease as the solution pH increased over the range of pH 5.0 - 8.0 using phosphate buffer. The 
apparent solubility values also decrease as the pH increased from 5.0 to 8.0. The relative 
apparent solubility profiles of VRC01-WT mAb varied under different formulation conditions. 
Both salt and arginine increased the relative apparent solubility of VRC01-WT as is evident by 
their effect on the PEGcurves, PEGmidpt and apparent solubility values. A final optimization of the 
micro-PEG assay established that protein amounts as low as 0.1-0.2 mg can be used. Thus, this 
high throughput assay developed in this study can be very useful in early candidate selection and 
assessing apparent solubility of mAbs where only limited amounts of material are available. 
Further, it can also be used to screen various solution conditions as a part of preformulation 
studies. 
As part of future work, experiments to study the effect of different combinations and 
concentrations of commonly used pharmaceutical excipients (such as polysorbate-80 and 
sucrose) in presence of PEG and their effect on the apparent solubility of various mAbs and/or 
model proteins can be explored. Such studies would provide a data base of excipient effects on 
protein solubility and correlations to other physical properties (such as protein-protein 
interaction) could be established from a formulation development point of view. It would also be 
interesting to examine the utility of micro-PEG assay to determine the relative apparent 
solubility of combination protein drug products (e.g., multiple mAbs coformulated). This work 
will help in better understanding the utility of this tool during protein formulation development 





6.2.2 Chapter 3 
This chapter employed a wide variety of analytical techniques to comprehensively 
evaluate the physicochemical properties of a lyophilized sample of dmLT (a protein based 
adjuvant) and develop a stable frozen liquid formulation for its bulk storage and subsequent use 
with a wide variety of vaccine antigens in a drug product. LC-MS peptide mapping confirmed 
with primary amino acid sequence of the protein and a glycated Lys84 residue was identified as a 
post- translational modification. A combination of size analysis by SV-AUC and HIC 
determinations showed the dmLT sample consists of a mixture of free B chain and AB5 complex. 
The physicochemical degradation pathways of dmLT included protein aggregation, glycation 
and oxidation By identifying the physicochemical degradation pathways of dmLT using newly 
developed stability-indicating analytical methods, a more stable candidate bulk formulation 
of dmLT was developed that protected dmLT against conformational destabilization, freeze-thaw 
stress, aggregation/particle formation and chemical degradation. By developing a new frozen 
liquid stable bulk formulation, lyophilization and reconstitution of dmLT for use in preclinical 
and clinical studies will no longer be required. Removing the lyophilization unit operation should 
not only reduce costs, but also simplify future patient administration procedures with dmLT 
adjuvant. HIC was able to separate out free B chain from AB5 complex and can potentially be 
used in the future as a process control and/or QC assay for dmLT.  
As a part of future work, the isolation of degradants (e.g., forced oxidation or 
deamidation products) and determining their potency as an adjuvant will be useful to identify 
CMC challenges and potential CQA’s of dmLT. For further pharmaceutical development of 
dmLT adjuvant stored in the candidate bulk formulation, compatibility testing with different 
vaccine antigens in a final drug product, and finally immunogenicity studies to evaluate adjuvant 
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activity will be needed. Another part of future work includes analytical comparability studies of 
physicochemical properties of two dmLT molecules made by different host organisms using the 
analytical stability indicating assays developed from this work. For such a study, freeze-thaw 
stability of dmLT at two protein concentrations (1 and 10 mg/mL) and real-time/accelerated 
stability of the same samples at different temperatures (-80,-20, 4 and 37 
o
C) could be evaluated. 
Furthermore the storage stability comparisons of dmLT material from different host systems at 1 
mg/mL and stored at 4, 15, 25, 30, 37 and 45˚C will be executed to develop Arrhenius plot. Such 
plots will be useful to predict the degradation rates at storage temperatures and estimate the shelf 
life of the protein. 
6.2.3 Chapter 4 
Chapter 4 of this dissertation examined the structural integrity of three equine 
encephalitis virus-like particles (VLP) based vaccine candidates (EEE, WEE and VEE) using 
various biophysical methods. Initial characterization studies showed the VLPs were uniform in 
size, ~70 nm and contained some nucleic acid impurities. The physical stability profile of the 
three VLPs was assessed over a wide range of pH (6.5-8.5 with 0.5 unit increments) and 
temperature conditions (from 10°C-90°C with 2.5°C increments). We observed that the physical 
stability of EEE and WEE VLPs was higher than VEE VLP. Various stabilizing excipients were 
identified for developing six monovalent candidate bulk formulations. The final candidate 
formulation showed a good maintenance of stability at all storage stability conditions except 
when stored at minus 20
o
C. Both the monovalent and trivalent VLPs formulated in the candidate 
formulation were also found to be stable and compatible with Alhydrogel® adjuvant, and this 




For future work, some additional steps or improvements to the existing steps during the 
downstream processing of these VLPs can be implemented to remove the nucleic acid impurity 
from the VLPs. The possible ways include adding DNAase and RNAase enzymes during 
purification or using ion exchange chromatography to remove the nucleic acids. Additionally, by 
correlating the physicochemical data from this work with immunological potency assays to 
monitor key protective epitopes (e.g., in vitro binding or animal potency assays); a structure-
function relationship can be established. Such studies will help to identify CQA’s of the three 
VLPs and help in better understanding of product and processes parameters as these VLPs 
further advance into clinical development. Furthermore, long term storage stability studies of 
both the adjuvanted monovalent and trivalent drug products along with immunogenicity studies 
in animal models should be performed.  
6.2.4 Chapter 5 
In this chapter, an analytical comparison of recombinant CRM197 expressed in the natural 
host source (C. diptheriae) as well as in non-natural sources (i.e., E. coli and P. fluorescens) was 
executed. A wide variety of analytical techniques were employed to: analytically compare the 
physicochemical properties of the five CRM197 molecules; evaluate the relative solubility of the 
five CRM197 molecules using polyethylene glycol (PEG) and compare the physical stability 
profile of each CRM molecule as a function of pH and temperature using data visualization tools 
(Empirical Phase Diagram (EPD) and Radar Chart). Finally, in vitro antigenic reactivity of each 
CRM197 molecule were assessed through two methods, ELISA containing polyclonal anti-CRM 
antibodies; and bio-layer interferometry measuring association/dissociation rates with five 
monoclonal anti-CRM antibodies.  
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Overall, this work indicated that recombinant CRM197 molecules expressed in non-
natural systems were very similar (if not better) to those expressed in the natural host system in 
terms of primary sequence, higher-order structural conformation, apparent solubility, physical 
stability profile as a function of pH and temperature, as well as in vitro immune-reactivity. 
Therefore, the analytical similarity between the tested CRM197 molecules suggest that 
recombinant CRM197 expressed in the non-natural sources (i.e., E. coli and P. fluorescens) could 
be used instead of CRM197 expressed in the natural host (C. diphtheria) to develop lost cost 
CRM bulk protein and eventually low-cost conjugate vaccines.  
In terms of future work, these physicochemical assays could complement standard QC 
and potency assays and should be useful for future formulation development work, comparability 
assessments, stability analyses, and process validation studies (e.g., consistency of 
manufacturing). Future analytical comparison of these five CRMs from different manufacturers 
and expression systems should focus on measuring the extent of polysaccharide conjugation with 
each protein. Furthermore, the immunological activity of conjugate vaccines composed of these 
CRM197 proteins from these different sources should be tested in an animal model to evaluate if 
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